var title_f14_40_14976="Seldinger cricothyrotomy step 2";
var content_f14_40_14976=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=EM%2F75433&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=EM%2F75433&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Seldinger cricothyrotomy technique: Step 2",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 428px; height: 509px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Apply a small amount of negative pressure on the syringe and insert the needle carefully into the cricothyroid membrane at a 45 degree angle with the needle oriented caudad.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f14_40_14976=[""].join("\n");
var outline_f14_40_14976=null;
var title_f14_40_14977="Dermoscopy melanoma 3";
var content_f14_40_14977=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=DERM%2F73202&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=DERM%2F73202&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 560px\">",
"   <div class=\"ttl\">",
"    Dermoscopic image of thick melanoma",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 540px; height: 292px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Melanoma 3.8 mm. Atypical network (solid arrow), negative network (solid square) and atypical globules (dashed square) are observed.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Drs. Ashfaq Marghoob and Natalia Jaimes.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f14_40_14977=[""].join("\n");
var outline_f14_40_14977=null;
var title_f14_40_14978="Inversions and recombinations";
var content_f14_40_14978=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=OBGYN%2F65339&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=OBGYN%2F65339&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 548px\">",
"   <div class=\"ttl\">",
"    Effects of chromosomal inversions on recombination",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 528px; height: 426px; background-image: url(data:image/jpeg;base64,/9j/4AAQSkZJRgABAQAAAQABAAD/2wBDAAYEBQYFBAYGBQYHBwYIChAKCgkJChQODwwQFxQYGBcUFhYaHSUfGhsjHBYWICwgIyYnKSopGR8tMC0oMCUoKSj/2wBDAQcHBwoIChMKChMoGhYaKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCj/wAARCAGqAhADASIAAhEBAxEB/8QAHwAAAQUBAQEBAQEAAAAAAAAAAAECAwQFBgcICQoL/8QAtRAAAgEDAwIEAwUFBAQAAAF9AQIDAAQRBRIhMUEGE1FhByJxFDKBkaEII0KxwRVS0fAkM2JyggkKFhcYGRolJicoKSo0NTY3ODk6Q0RFRkdISUpTVFVWV1hZWmNkZWZnaGlqc3R1dnd4eXqDhIWGh4iJipKTlJWWl5iZmqKjpKWmp6ipqrKztLW2t7i5usLDxMXGx8jJytLT1NXW19jZ2uHi4+Tl5ufo6erx8vP09fb3+Pn6/8QAHwEAAwEBAQEBAQEBAQAAAAAAAAECAwQFBgcICQoL/8QAtREAAgECBAQDBAcFBAQAAQJ3AAECAxEEBSExBhJBUQdhcRMiMoEIFEKRobHBCSMzUvAVYnLRChYkNOEl8RcYGRomJygpKjU2Nzg5OkNERUZHSElKU1RVVldYWVpjZGVmZ2hpanN0dXZ3eHl6goOEhYaHiImKkpOUlZaXmJmaoqOkpaanqKmqsrO0tba3uLm6wsPExcbHyMnK0tPU1dbX2Nna4uPk5ebn6Onq8vP09fb3+Pn6/9oADAMBAAIRAxEAPwD6pooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKAIru5gs7Wa6vJooLaFGklllcIkaKMlmJ4AABJJqDRtTtNZ0mz1PTZvPsbyJZ4JNpXejDIOCARwehGa8R/bPuri3+FNlHBNJHHcatFFMqMQJEEUrhWHcblU4PdQe1dJ+y7d3F58E9Ae7nlndDNErSMWKokrKqgnsAAAOwAFAHpupX1pplhcX2o3EVtZwIZJZpWCqijqSTXKfDz4m+FviALhfDeoGS5t8tLbTRmOVV3FQ+D1U4ByM43AHBOK8+/bA8Qf2V8MY9NjmuYrjVLlYx5XCtGvzOrnPQ8cd/pmvIP2Kf8Akqeq/wDYFl/9HwUAfalIWUMFLAM3QZ5NLXm/iu11q58YDW7TTzLbaE8KQ5dxI6tzcmKMIfMDRuqjkfNGepGAAekUUUUAFFFFABRRRQAUUUUAFRTXMEEkEc80Uclw5jhV2AMjhWbaoPU7VZsDspPY1LXwtrvivVfFH7TOlf2ncytbWXiaG3tbbzGaKBUuI4yUUkhS3lqWxjJoA+6axZ/FegweJY/D8+r2UWtSIJEs3lCyMDnGAep4JwOcc4xVjxNqyaD4c1XWJommj0+0lu2jQgFxGhYgZ7nFfm74y8V6h4p8Y3/iO7leK9uZ/OTZIcwAH5FU9QFAAB9qAP00rD8TeJLTw9JpyXccshvbhYR5YB8tSQDI2TwgLKCf9oUeBbme88EeHrq7lea5n063llkfku7RKSx9yTVPxL4OtPEd/cT6ncXPktYtZRRQSyQ+WHYmRiVYb92IvlIwPL754AOooqGyjmhs4I7qYT3CRqskoTYHYDltuTjJ5xk1NQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFef6j4pu4PiLFbpJcDR4JYtOnQWzmMzSqWDmXbtBDNboF3D/WNweK72KWOUExOrgMVJU5wQcEfUHigB9FeVeFNf19fDOl6ndT3bx32n2gV76FJPOvJNp/dJGVbaVLH5io+7yMNWxpHi/VtRudMtPsVnBNIL43jTOVEa2s8UZKhSwywkzjcQP7xxyAd7RXm8PjzUd7I1rBIt3HbS2Fy0ZhjKzziJWZd7MVG5TkhCemBnNXNZ8T69p+pyaZa2NvqF7a2gvJjBGVWdWd1VF3SDyziM5YlwNy8c0Ad5RXC3PinVBftGkdmltJf3OmRfKxkV47eSZZCc4x+6K7cd857UeG9f167TwxazDT55b7TVv7m4bch2AxA7VAILHzD6DP5UAd1RXC+BvEep6/Zae8bWscUVlZS3P2jLSzNNCrkqQQFxuwDtO5tw+XFd1QAUUUUAeN/ta6VBqHwW1G6nMgk025t7qEKQAXMghIbjkbZW9OcfSl/ZMu7ef4L6ZBBPHJNbT3CTIrZMbGVmAYdiVIP0Nep+IdKg17QNT0i7eVLbULWW0laIgOqSIVJUkEZwTjINfKH7K/i6HwN4k8TeE/F9/BpSLIzYupoo4YriNtkimQtyxwoABIO0n6gHTftwMv8Awj3hddw3fapjjPONi1m/sSeGWD+IfFM8Thdq6bbPvGG5EkoK9eMQ4PuR645r9pG9i+JfxY0fSPA+3WbqK1W38y0kSWKRmYvkOrEbVDfMTgDB+tfVPwy8LjwX4D0Xw+JTK9nBiR924GRiXfacD5dzNjgHGKAOnriNb8bvpniWfTjDZtFDNaxESTskr+cwG5flK4XOeSM46iu3rlNc8O6bcajdSX2r3NvFqflpPZ+ZCsdwEGAvzJv56HawoA6uiiigAooooAKKKKACiiigAr87fG0l74L+OupX13aq11p+uf2isBkBDr5omQFlzjcpX3GeeRiv0Sr4V/a28PzaR8W7nUHMj2+rwR3KOYiqqyqI2QNnDEbFY9Mbxx3IB9XfHHWYtH+Dniq9uI5HSXT3tQseMhp8QqeewaQE+wNfnhpsAutRtbdg5WWVUIT72CQOPevt3436ufEH7LV5rBg+zm/srC68ndu2b54GxnAzjPXAr57/AGVvDL6/8V7K6ZZfs2lKbx3jdV2sOEBB5IJ4IH6UAfc+kafBpOk2WnWm77NZwJbxbzk7EUKMnucAVxfiS50lfHNxDr+pmygGlwvAPtz253mWUEptYEtgL0yeld/WLqWtSQ6t/ZmnWL316sIuJR5ixpFGzMqkse7FHAAB+6c4oAf4RkvpvDOmSatv+3NApkMi7XPoWXsxGCRxg56Vr1FayPNawyywvBI6BmicgtGSMlTgkZHTgkVLQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAY89xokMN/HeCyt7eK4H2j7QqxxtLtSTcd3DH5lOfUeoq3aNp1tBKbRrSGEsZpDEVVS0h3FzjuxOc985rnB4Wuj4rfU5GtWtjqxvwpJLBPsEduBjGN29CevTHOeKzNP8C3tuugQvcWwtIbeCHVIlLETm3bfBs4HAYkNnGVAFAHWONAms5tHcaXJa2caiWxPllII1wV3R9FUYGMgAYplofDun3NpBZnSbW4PmR20cXlo5ywMioBzyyLuA7qM9K4u48Aag+lavYhreWWe0v4La7kvpetwG+9DswvLDcQx+7kDnA27/wrcReIrS70CGy061UwLOUkwJI43ZinkeWVzhm2uGUgtnnaAQC/Z2nhSOJI4rHSLX+0g0YheCOJrgZ5XaQC3I6c1IdM8LXUkOlmx0SZ7YM8dp5MTGIFvmKpj5eepA61y8PgfVIbGW0D6fIt5axW00zSMHttk0sm6IbDuOJAQCVwy5yc8bGneF7m11Oyui1qPJ1W9vpCpO5o5hIFHTkjcmc8cdTgUAdOLCzWRHFpbh0mNwrCMZWUqVLg4+8VZgT1wSO9R2Gk6dp5Q2Gn2lqUVlXyYVTaGIJAwOhIBP0FXaKAM4aFpCy2ko0qwElmix2zi3TMCL91UOPlA7AdK0aKKACiiigCjrmr2Gg6RdaprF1HaWFqhkmmkOAo/mSTgADkkgDJNfC/ib4p/wBufHOz8ZaB4eiItnSOG0KHzbxVDLuk25/eFWwMZ2hVHzbcn1z9tPxe9ro+keFLO4UG9Y3d6isQ/loQI1YdCrNuP1iFa/7HfhO1svAD+IZ7e0lvtQuXMM+zMsUafu9mT0+YOeOzDPoADx3wL8YNOs/jddeK7vwxZ21rqZ8lo7Ub5bYtgGRDwGdud3A3ZPTnP3LX5u/GONIviv4uSJFRBqlwAqgAD94ewr7e/Z/8Tr4r+FGhXjPG11bRfYrlUcuVeL5RuJ53Muxzn+/360AeiVw1zFa2viLxG+v6Rc6gl6Yzaulg90rQCFFMOVUhf3gkbDYB359cdzXJ3/iPU4L3XTbadbXFlpBXzR55WaRTEsjFBtK5AbgEjOOooA6yiorWeO6tobiBt0UqCRGxjKkZBqWgAooooAKKKKACiiigAryf9pTwTpni34eT3OoX9rpdzpObqC+uB8i8YMbHBba/yjC8lgnB6H1ivkX9s3xwt5qmn+DrGUNFZkXl7twf3pBEadMghSzEdDvX0oA4ifQtf1D9nDTdRfxZp7eGrPUcf2S8KK9tKZHTcZFBdm/eb9h/gbI6CvrT4KeDtI8HeA9Pt9HezunuYlmuL+1O5btyPvhsnK+nb6V8x+Jvgvpmkfs/23jaHVbyS/e3tr14CgER84xKExn+Hex3d89BXX/sg/Eq/ubtvBGrytPbxwtLpzlSWjC8tGW/u45GenIzjAAB9VVh6ho12dcOq6RfQ2tzJbrazpcW5mjkRGZkOA6EMDI/OSMN0rcry34oXLp4heEalbWLHSJGga4vpLbEu/AZNp+ZxxigD021SWO1hS4lE0yoA8gXbvbHLY7ZPOKlqtpc7XOmWk8kUsLywo7RzDDoSoOG9x3qzQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUVBfMVsrhlJDCNiCOoOKAPgD9pHxD/wkXxg1ySK6e4tbJlsYNybfLEYw6AYBwJDJz3z6Yr7R+C+ir4f+FnhmwFlJYzLZRyTwShg6zON0m4NyCWLHHbpgdK/Pnw/YzeKPF+m6fc3bi41W+jgkupcyMGlkCl2ycsctk88+tfpzGuxFXOcACgD82vi1d29/8T/FV3ZTxXFtNqU7xyxMGR1LnBBHBHvX0Z+w9qk82heKtJYR/ZbW5guoyB82+VXVsn0xCmPxr5MvP+Puf/ro386+pP2GP+Z2/wC3H/24oA+qq5bUvDtlPqGotNrN7bxamUN1ZpLEiSgII8Z2eYAVUA7WHeuprzzVLJT8RL+4uo7tInt7RYZE0lrpHKtLuG/y2CYyueR1zQB6EiqiKiKFRRgKBgAUtFFABRRRQAUUUUAFFFFABX5sfFm/utS+Jvim4vpmmn/tGeLewGdqOUQceiqo/Cv0nr8+LD/k5a3/AOxuX/0soA+qv2kreC0/Z6122tIYoLeKKzSOKJAiIouYQFVRwAB2FfGXwu1xfDfxC0DVpBcGK2u0aRYG2uyk4KjkZyD0Jwelfevxq0IeJPhT4n03bcPI1k88SW43SPLFiWNQMHOXRRgDJBIGDzX5yQPJHPG8ORKrBlwM8g8cUAfqhXO+IfFEWjara2DW/mTTwvOGaeOFQqsqkZcjJy44HvVzwjcXl34U0W41QONQmsoZLkSR+W3mmNS+VwNpznjAxVTXNBur3XrXU7K6sonhtpLYx3dmbhWDsjZGJEwRsx360Ab0L+ZCj4A3KGwCD19x1p9NiVliRXKlgACVXAz7DnAp1ABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABUdzGZraWMHBdCufTIqSigD4A+EnhEx/tEaR4dv5nVtO1ORjKibd7WweRSAegYxj8DX3/WCnhLRl8ZzeKvscZ1qS1S088qPlRSxyOPvHcAT1wqjgdd6gD86vjV4FvfA/j3ULFrKWHTbmZ5dOfcZFlhLfKA3UsMgEHkH1yCfsX9nPwNd+AvhvBZaqpj1S9ne9uotwbymYKqoCPRUXPX5i3OK9HvbCzvxGL60t7kRtvQTRh9reoyODVmgArlda8TT2fiqPRoRYputo5w9zKyly7um1Qqn+7+tdVVFNMhTW5dUDSfaJbdLYrkbdqszAgYznLnv6UAXqKKKACiiigAooooAKKKKACvAPGXwR1HUvjvo/jPS7yAacb2C9vUkGGiaHYQFA+8H2AZ7EknNe/0UAFfKGufsx30XxGtZ9AvEHhaS4SaQyS/6RbLuyyDIO/H8JPPPOcZP1fRQAVxXjWC5vfFPh+0ttrq8F27xSXEkSNt8nBJTkkZOPqa7WigBkEYigjjUYCKFAyT0HqeTT6KKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACuR1zxe+leJrrTZLNWtotPS6W48zGZn88rGRjgEW7/ADZ6kDHIrrqwNc8KWGtHVjePcA6jaQ2khjYAxiJ5HR044cNKTk5Hyrx1yAQWnjCzm+zCSC4Ac28U06qDDBNMqMkTHOcnzE5AI+ZckZFMh8bWNzHA1pZanObmVoLdRb7POdQxbaXIGAEbkkD3qSLwdYxTxlLm8FsJLeaS13J5c0sCoI5G+XduHlx9CAdi8VZsvDVnZx6OkUtwRpckksO5l+Yurqd3HIw5xjHagCrYeM7C+hMsFte7GtPtsO9FTz4sgErlhjBYA7tvXPTmodL8ZW+sahpcemKrQ3EtxBPuZWaN4kDYDIxU/eHIJHNE3gTTJdOs7Np7wJaWq2sTbkJAWWOVWOVwSGiTgjaRkEEGrWmeE7Ww1BL03l7c3S3EtyXmKfM8kaRnIVQMYQYAx/SgDoqKKKACiiigAooooAK8d8Mz6ppPgfSNbuLma0t7vTbKEyG884yTSbD9ocygpCMEgn5s7+Qdq59iooA818N+I9b1e60i2+32wQpqMlxNDEJ/tC29xAibGAUZKyHLBcHso4xmWXjnU5hcmG/hktJYLebz5GjlksFknCSGRY0VUKo2SrF9uMscZFeu0UAeW694q1K0u0g0zXbCa1W18+2v7uaGKK8l8xwYmYIVYKFTIj2t8+e1X59a1l9T2penyrjVbvSkgSJfkVLWaVXBxuL7owOuMHpnmvQ6KAPOPBuq6pqA8LWkGuR3MUmmfa7yV4llkd0aEGMsD8p+dgScn8aj8C+Iri/t9Dj1HV49OY6fYSQWjBSb7zIVZ2y+Wb5iVG05BUls5Fel0UAcL401m+03WpVsJFjf7HBtZgWAL3aRk7c4PDGqV34p1bQ0u5rl21G1s76bTj+6AllkaKOS3J2gAZdjFwACZFPY16PRQB5sfEGv2/imHTL2/wBPhlhltIPLmkSEXquiebKiFSzHc0iqFYAFMHOap3vibXLbw5Y6teazbRxXLTO0UKwwzBUJCrH5pKOem4ZBPG3HNeq0UAeayeI7hNY1GKfUhpGntqG176VVBjIsbWRYyJMqhYu5xj+Ejqc1GnifXprdLyaYWrW9vpc0tqIABI1xKUkDbssox0AIIPUnpXp1FABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRWZ4m1dNB0C+1OWJ5hbRlhEhwZG6KoPbJIGe2abo7a55zDWY9NERTcptJHJRs8qQw+YY/i4/3RQBq0Vyd98SPBdhezWl74q0WC5gcxyxPeIGRhwQRngioP+Fp+A/+hw0L/wADU/xoA7OiuM/4Wn4D/wChw0L/AMDU/wAa3fD3iPRfElvLPoGq2WpRRNske1mWQK2M4OOnFAGtRXD23jDURbNqd5p1qNGGqzaY0kVwxmj2XbWqyFCuCC6gkBsgHPOK7igAooooAKKKKACiiigAooooAKKKKACiiigAork/iP4jm8O6NCbCWyj1G7m8q3N64WLKq0jbiSOqoVHPVl69DqnWEu/CR1rTmVo5bI3cBYZBBTcuf0oA16K4j4KeJ9Q8ZfDLRde1gQC+uxN5nkoVT5ZnQYBJ7KPxrt6ACquqzPbaXeTxECSOF3UkZ5CkirVUde/5Aeo/9e0n/oJoA5H4F+JNS8XfCvQ9b1uVJdRuRMJXRAgbZPIgOBwOFHSu8ryr9lz/AJIT4Z/7ev8A0qlr1U8daAOV8C+JpvEtotzILFEaISGKGVnkjJPAbKgevSuqrM8O2tlpuk2um6fcefDaRiNSXVmwO5x/hWnQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUV542pay3i/Wvs8979jsNTiSUuIvssVr9kgkkDZ+cvl2I29yvbNRQ+M9TlVorqEJuk0uaCeOPyfMiuLtYiNpdzjGeTtJBPyr1oA9IorgofFGqz/ANlXVxDbRWtzqdzaxJDISzLFDdkmTK9zChwPz7VDaeNNVeO0juILEXGoW9jPbMqvsh+0uy4fJy23bkEbdxOOOtAHodFc9oeuST6BqF9qjW8ZsZ7mGWSNWCYhdlL4ySOFzjJ/Guct/Gmrl7m1ms4Bch7AwSSRmJWS6leMEoJHPy+WTyVJz0XqQD0SivO7zxVq11p9zZW5tLfUIoNReW5KNsItpBH+7XdkFt4OSx2/7Wa7Xw9K8+gabLM5eSS2iZmY5LEoCSaAL9FFFABRRRQBT1jTbXWNKu9O1CMyWl1G0UihipKkY4I5B9CORXn9mt/4jvrzS9G1/W5tKgkks9R1K5VIWRo3Kvb222NCXypDTHIUcIS5LJ6ZXGfCr/kCax/2H9V/9LZqAOp0vT7TSdOt7DTbaK1srdBHFDEu1UUdABUGt65pOg2yXGuapY6bbu/lpLeXCQqzYJ2gsQCcAnHtWR4m8Qzx6zbeHNCCSa9dRfaC0gzHZ2+7aZ3H8XPCqOrdcDJrNs9K8NeGdVk+z6VNqfiBoPMvL1bb7RdOjMTulkx/EUOEHZcKuFAAB2tpcwXlpDdWc0U9tMiyRSxOGSRCMhlI4IIIIIrn/FPh6e7uoda0GaKz8R2ibIpZM+VdRZybecDkoSSQw+ZGO5c5ZW5TUH0XRNTv9T8IWq6bqUMw/tA/Y5IbW8Z0SXy7lwuEO2QESkZjZsnKl0erpfxo0zTrCI+PwmiXDl0jkRXlSZo3McoMahmiZZFYFTuUZGJH5wAaPgyz0nVpZLSXU9UjubW+l1G58O3jwq1tcPO024hEDvGJXLI25kOFOTjj0mvI/DernXfjul//AGbdafC/hmQQfatoknT7Wnz7VJ2r6ZPIPQcivXKACiiigAooooAKKKKACiiigAoqNZ4muHt1ljM6KsjRhhuVWJAYjqASrYPsfSpKACiiigDG1m70XTtSsr3VriGC7WOWO3aWQj5SUMmB0/hTnGR6jJzDdQWFv4Jvl0gxtYNaTyRGOTehDBmypyeMk4xwBwOMVD4iivovE2i6jZ6bcX8FvBcxSrbvErKX8rb/AKx1BHyN0NV7TTrjTvBOti7jWGS5F3dfZ1bcsAk3MEyOM85OONxOM9aAOZ/Ze/5IV4Y+lz/6Uy16nXln7L3/ACQrwx9Ln/0plr1OgAqjr3/ID1H/AK9pP/QTV6qOvf8AID1H/r2k/wDQTQB5x+y5/wAkJ8M/9vX/AKVS16bqKs+n3SoCzGJgAOSTg15l+y5/yQnwz/29f+lUteja/fnStC1HUFjEhtLaScITjdsUtjPbOKAOT+FVnHZ6NZxlLqO5SyhSWOfSmtNjBRkbzGu8g+59a7uud0zW73+0rKy1e0t4mvoWmtpbaZnUlQpZGBUFThsg8g4PTAz0VABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFAFHz9NtJbs+bZwSsTNcncqklUUFn+iBBk9Bt7YrKgt/COn2Ed3BDoNrY3Dx7JkWFI5GRtyYYcEhhkehGRzWRrHgqS+PiOeP7Il7f6jbXkEvKsY4Y7ceU7gblBeF+mcbgcE5FMsfC2paffw6jb2enyzYuVltrm/llUmbysyCQxZ3HysFdgBDdeuQDqVGiGcWS/2aZrQtceQNm6EuGDSbf4ch3y3fc3qazNRj8NajYNYR3ulwCXy7BTD9nY/IQywBXVlP+4VOMnAB5rHk8H6k+bfNgkEVzfXcdwrt5sjXCSqI3XZgIvmjkMeIk44pZ/BN01vepCbJHl0rT7GM8jbJBLK7n7vAIdMY5yvIGBQBp+EbnQbDS7rTNNnUm0luTPDIU81isjeY/lrgbS2cYUDoAB0q1p9p4WtJILeytNHtZ7jy3jgSKKORynzp8uAcruLD0yTxmuffwhqk0s0cg0+KBL2/vYpo5nMkpnjlRUddgCgCUE4ZuUWpbXwbeQqxZ7PzTe6fcBwWzst0iVxnb1Ox8D35xk0Aaup3PhBtPu5r46LcWllKXnykcwhkdsEsADhmY8nqea1E1bS7e2lP2m3t7O2VAZWYJCqsPlw33cY9K4JvAuu3cdw2oXFnLcvp7Wpla6ldZ5RLHIreWUCwqdh+VM4z/FWvceGdVbW11iKLTTLHPDOlm07CI7beSJhv8vIIMmQdp6EYGcgA62fVLC3aFZ761iM5URB5lXzN33duTzntjrVyvOW8B3v9mahAstkZrjShZxEkgRSGaWUgfLwg8xQMc/KOOK9GoAKKK4jRvGgv/iDf6KZ7JrRfMit1RwZhLCE8zeM8Al2A4/5Ysc8igCt4B8fyeJ9QtLWaCxQ3Vi96Ps9wzNDtdF8t1ZRknfnKk42nOMjN34Vf8gTWP+w/qv8A6WzVZ8O+C7XRJdOf+0tRvU02F4LOO6MW2BWwCRsjUscADLE8VW+FHzeHL64XmC61jUbmCQfdliku5XSRT/ErKQwYcEEEUAYNpfx2/wAT/iFrmpRuzaDptvBbKnyl7YxG4fgnDHzMjd26etXPD2ralqHinWrnSNPt98ttaSTxXl0FCkiQIyyRCQHIXlCFK4B5DCs/4waWNPvZPFTSCLTpdLm0XV5dvmPBbSElJkTIzskbLAEkrwATXU+EfCTaHqU99NcWTSyW0dqI7Cy+yxlUJO513vuf5uuRgduTQBTuvD+uzr4nstumCz12UNJc+c5eFGtYYJMRbME/u2Iy+ORnoRWX8NtE0m08UfEKyt7C1kgTVATK8YkeQzQRTSKzHOQHY/L2wO/Nd14j1iDQdIlv7lJJArRxRxR43SyyOsccYyQAWdlXJIAzkkAE1Q8B6Lc6F4bit9RkSTUZ5Zb28MTZj+0TSNLKI8gHZvdtoPOMZyeaAOM0XRtP0D462+n6Papa2Y8NTzCJCcB3vELEZ9T26V6pXncn/Jw0H/YrSf8ApWlaXgvWdX1e4eW9EgtvOuI122qrHhJXRcPvJJwv93rmgDsqKKKACiuQ8EaxqWsyXE17K3lLLcRqgsjGmEmZFxISdxwvPHrXX0AFeU6/pPxgl1u+k0TxJ4Zh0tpmNtHPav5iR5+VW+U5IGATnmvVqKAPG/7F+OP/AENPhP8A8BX/APiKP7F+OP8A0NPhP/wFf/4ivZKKAPhL4+x+O9P+JukJr+pw3niJ7GH7JJoyPGdvnSbFAABL7wx49RX0R8Bz8V5LeGX4gG1XSfJxGl0uL4ngqzbRgdcEPhuOnr62dOsjqY1I2dsdREP2cXXlL5oizu2b8Z255xnGatUAFFFFAHP69fXp13S9G0+ZLV7uGe5kuWjDlUiMalVB43EyqcnOArcek2qR3MPhHUkvrhLm4W1nzKkflhhtbHy5POMA+pycDoLeraRZasIftsbl4GLxSxSvFJGSMHa6EMMjg4PPes7xAljofgnVQ8wt7OG1mZpLmctgsGJLO5JOSe570AcZ+y9/yQrwx9Ln/wBKZa9Tryb9le6guPgfoEcE0Uklu1xFMqMCY38+RtrDsdrKcHswPevWaACqOvf8gPUf+vaT/wBBNXqiu4EubWaCUkRyoUbBwcEYNAHl/wCy5/yQnwz/ANvX/pVLXperWMeqaVeWFwzrDdQvA7IQGCspUkZzzg15N+y75lt4J17SBPJLZ6Pr95YWfmYLJCuxsEgDJ3O5z6t6YFeoeKbe9u/DOr2+lSGLUZrOaO2cNt2ylCEOe2DigCjoel2cWo+cdXn1W8tIjboJpIibdTjICxqoBO0ckE8YzjNdDXM+Fn0hnto9P0S50+eG2KZl094PKXK5j8xlAbJAPykg7c+ldNQBxGk+M7s6Noeq61Y28Fhq1us0UltM0jRMYTMEdSo/hVhuB6gDHOa17rxbptvG7N57lYrObakeSRdStFCAPUspBHaqWn+ENP02z0uxvdTvb20s4fsdlBePEqp+6MfGxELP5e4ZOSAWxjJqpfeBXGnyR2OrXkl27abH590Y8xQ2lz5w2BY8bsM+NwIJ257mgB2q+OVtUklitjGtvaX811FcjDwyW6o207SwwQ+cjdkEEVtr4ihkubyO3sr2eG1MiSXEaL5fmIuWjBLAk9s4254znNZ134F068s7mC5ur6SS5gu4J5yyCSX7Qqq7nC4DBUULgADHQ1Pe+D7W6i1K2N/fx2F+zvLaI0flh3+84yhbr82CSueo5IoAox+P7O5ksE0+yuLp59QbT5o45I3aFxbvNnKMyNwg4DcZPOV2mb/hYOhfaJ4jLIBGJPLcbWE5RgrKigls7iANwG7+HI5qVPBtus32g6nqLXovFvVuT5IZXWEwYCiPZt8tiMbe+eDTD4HsfIuLZLy9SylZnS3XygIXL7wyts3/ACt8wBYgccYAAAI7fxTdz2uuE2Bt7u11GLT7W3nwWLSQwMC+xmGAZiTtP3V+tO1TxjFa6xYW0UD/AGFr2W1ur6QARJ5dtNKwU7txYGIAnbj7wzkVYsPC4tNZF617Pdhrh72U3ATe1wYI4FYbFUBRGjjGOr57Yptz4L0+5vBJPcXj2n2mW7+xFk8kySwyRSfw78MJXON3U8Y6UAUh48s7yOIaYh843VpGyTbSTDPLsDjaxweG4OGGOQMiorr4k6V/Z91cafDLePHELiGNXQfaYvMSMuuCSoBkU/MFJBGB3rTtfCFvDbwwSahfzwwywTRLIIQVMThlGVjBbOACWJPHUHJqKDwPYwaZPpsd7fDTnh8iK3/dAW65BXYwTedu0Y3swx1zQBJL420qDVotPnE0U7SRQSb9g8mWXHlxsN24k7k+6CBuGSKTR/FX9r+Iba1tLWVdOuLGS8huZQB54DxqrJhidpDk/MAehHBqaPwrFFqp1CPUb1Z5HjkuRthIuXRVUM2Y8qSqqDsKjAFLoPhS10W8tpre7vZUtbVrK2glKFIYSykIuFDHGxQCSTj1oA6GiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAivCq2kzPP9nUIxM2QPLGPvfMCOOvPHrXjdu/hCC3soY/jJEBZztcwMb/S9ySMHDNnyuc+Y+c5zuNe0MAykMAQeCD3ql/Y+mf8AQOsv+/C/4UAea/2t4SuSYdZ+Ldpqumuf31hcahpyRTr12OY41cpnqu7DDKsCpKnrR8RvA4GB4x8NAD/qKQf/ABVbv9j6Z/0DrL/vwv8AhR/Y+mf9A6y/78L/AIUAc/cfEPwJLbyxzeLfDU0TqVeP+0YH3gjkbdxznpjHNcXos3itbmCz+G8VxF4ayAj+JrIiC3hDYK2oV0uOMnEcy4wgCsigA+rJpWnowZLC0VhyCIVH9KuUAeVaXq9/pmqw3vxSt7uK7gbEN3bwq2j2sjDG6IqTKpMed0s42p+9AdFbDdX/AMLH8D/9Dl4b/wDBpB/8VXUuiyIyOoZGGGVhkEehql/Y+mf9A6y/78L/AIUAcR4o8TeANet4D/wm/h+z1G0fzrK/g1S3822kxjK5bBBHDKcqwJBBFctpWtWelO0lj8Tfh/G7O7lGuJ3hBdizYia/KgliTwO/Fewf2Ppn/QOsv+/C/wCFcT4Fsp9Rke71C1aW2M9zGpaG0EOEmdFACxiTgKByfrQBk/8ACdT/APRT/hl/35P/AMm0f8J1P/0U/wCGX/fk/wDybXpn9j6Z/wBA6y/78L/hR/Y+mf8AQOsv+/C/4UAcp8M9Ws54bnT7fxP4W1l4y06xaKSDGGcs7ODPKSCzdeAM49MdzXCfDgXVw1zeTpeIhmuYlbybSO3YLOyqF8sCXICj73oevFd3QAUUUUAFFFFABRRRQAUUUUAFeffFGGe31jwprtzDJc+HtHupbjUoY1MpXMZEU/lfx+W/z5GWXqoJrX8aaxf6bqGj2unsy/a2m8wx2puH+RMjCgjv3p1tqcusfDh9QuBGtzNp8jTLGCqpIEIdcHkYYEYPQjGTQBheA9VtPG3iy68X+HjJHoSWzaaJWieI6lIGRxLtYA7IvnRScnMkoAXB3ei15Z+y9/yQrwx9Ln/0plr1OgAry/4jSQL450seLbK5vfBa6fKwhWyku4XvvMUL5kUasWxHvI3qVB5HzAV6hRQB5X8FToV3rXjHUvBMf2bwxJcQWyWqxvAi3caEzukLAeWCskCnhSTGcjgE+lardGx0y8uwm8wQvLtJxnapOP0ryj9mjnR/HH/Y2X3/AKDFXrV/bJeWNxazFljmjaNipwQGBBx+dAHMeCfFr+Ibme3ljtA0drDdB7aYuP3m75CGUHI29Rkc9u/UXpnFnObQKbkRt5QboXxxn2zisPw5odnYXSTx6pcalcQ2wtImneImKIEHaBGijkquScngV0VAHmMVlNqdn4eRj4ia6F7BJqDXSzRmN/ImDlGIAUbjgmM7RlcYyDUunQ+JrjYv2nU4ntbG5MCyjak0yXDrCJWZctlAh68g5Oa9JooA8zjfWZLGdNNk14W7yaWjvdRyCdZWugLopvXO3yiCxHyDnb3pl7b+JbOF30eTVZbxb+9tbdbh3kjEAtZ3hLbuCPOEQEjZPIXJBxXp9FAHmVy2pva3g06412PSw1qyfa7e6M8kn73zkyq+ciEeSdyggNuA4yKRbnX5RavJBrVtemGzNjCDJJECXPnCd9oGdvXzMHbjADZr06igDzuxsNXvNRtDe3OtJFdXupx3IWWSNVhSd/s+MY2DaFIYYLA9SOKy9Ln8V3Muiy6rPqNpObSwkXFnO6sxRDcLIqfIrFt6nzANoIIxgmvWKKAOI8AyamNT1CHUBqFwgRX+2XKzxLI5dvlEUqgIQMf6slMY6cZ7eiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigArMk1u0j1ttLk81blYPtLM0ZEYjzjJfp1rTrkPEmg6pqeq6q9utktrdaPLp6O87BxI2SCVCEbcn+9n2oA6S11KxuyRa3ttORIYj5cqt84GSvB6gAnHWkm1OwgeFJ761jaaQxRB5lBkcHBVcnkg8YFclf+Eb4veXOnPZRXkcVk9huLBEng8wMHwOEZX2EjJ2seOlZ+ofD64CRR27x3sEmnLY3KS3klrufe7vLlFbcXaQlhxyoINAHe3Oq6farK11f2kKxDMhkmVQgzjJyeOSBTDrFgBMz3USwRQR3LTswEXluWCtv6fwHv6etcpdeDXMOoTQ21k+oz6o19FOs7QSIuMKfMEbHcPQqy4qunhDWlube9nuLC6u4LewGxiY45pIHuS4bamAMXCkMF+8udo6UAdpPq+mwQwzT6hZxwzYMTvMoWTPTaSec57Uup6lBp32T7QHP2m4S2TaM/M2cZ9uK4lvA97Ja3YkaxEtxp+pQBASUilupfMAU7fuAZBOAT1xzgdLrejXGoWOkQRyoj2lzDNK5YgkKCDtODzzxmgDSj1TT5UunjvrV0tSROyzKRCR1D8/L+NZVrD4Y0tBq1u+mWsUu5xdLKqo+45Yhs4OSf1rmIfBOqfYbGOT+zI5NNtrW2hSJ2Md55M0cmZfk+TPl4AG/aXJy3Qvm0TV7PW9JuYtPs7m5mu7y6kh81xb2++JVA8zyyecE5KjJZqAPRFYMoZSCCMgjvS1meF9MbRfDel6Y8olazto4C4GASqgcDsOOB2GK06AIbS2gtIRDaxJFEGZtiDAyxLE/iST+NTUUUAFFFFABRRRQAUUUUAFFFFAGJ4ps9Hkt4b/XZ2tYrNvkuVvJLbyy+E++jL1JA5Pel1Syt9O8IX9pZRCK3is5Qqgk/wAJJJJ5JJySTySc1m+O9DvfEkmnadD9nTTgZZrp7iPzUchNiRlA6sc+Yz5BwDGM9QDNEmoRfDuaHWR/xMIbCSGZsg+YyoV8zgnhsbsdRuweaAOS/Ze/5IV4Y+lz/wClMtep15Z+y9/yQrwx9Ln/ANKZa9ToAKKKKAPHv2aP+QN44/7Gy+/9Bir1nUVZ9PulQFmMTAAcknBryb9mj/kDeOP+xsvv/QYq9hoA4T4VWcdno1nGUuo7lLKFJY59Ka02MFGRvMa7yD7n1ru65XwL4mm8S2i3MgsURohIYoZWeSMk8BsqB69K6qgAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKiuoI7q2mt513RSoY3GcZUjBGRUtFAGT4U8O6Z4U0C10XQrc2+nWu7yojIzldzFz8zEk/MxPWtaiigAooooA5jwF4NsvBdrq0Gn3FzOupajNqUpnKkrJIFBVcAfKNo966eiigCjoemQ6NpFpp1q0jwW0YiRpCCxA9cADP4VeoooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAoornfiNrFz4f8BeINXsVja6srGWeISAldyqSM4IOPoRQBtpeW0l7NZpcRNdwoskkIcF0ViwViOoBKtg99p9Knr40/Y81C81T4w6zeand3F5eS6NIZJ7iRpJHxNbgZZiSeAB+Fe5ftO+MNQ8G/C6afRpJYL7ULlLBLmJ9r24ZXdnHB5KxsoxgjdkEECgD0TTvEWi6nqd3p2natYXd/aEi4toLhXkhIODuUHIweOe9atfAn7MPiAaH8X9JWaW6EGobrNkhPDu4wm8ZGQGwe+PSvva7uIrS1mubhwkMKNJI56KoGSfyFAEtFcJ8MvEOoarJqFvrJuftMix6hCk9s0BiilB/cjco3eWykbhn7w5Nd3QAUUUUAFFFFABRRRQAE4GT0qvp19aanZQ3mnXMN1aTLvjmhcOjj1BHBFfO/wC2j4m1TSdA8PaRptzJbW2pvctdNDIyPIqIi+WSCAUYTNuUg5wvpzofsY6tPe/Dm/0+VIhDp96ViZQdzBxvO7nnk9sUAe8ahe2unWU15qFxDbWkKl5ZpnCIijqSTwBUekapYazp8V/pF7b31lLnZPbyCRGwSDhhwcEEfhXyl+2V42vpNZtfBsUfk2EUaXk0iyNmdmztUr02jGec84PGK1P2GridrXxlbNNIbaN7SRIix2KzCYMwHQEhEBPfaPQUAfUtIGUsyhgWXqAelKeOa838FWutWvik6xqGnmGHX0kech3aSNlYtbiVCg8orCShyT8wUcHAoA9IooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACua+Jml3Ot/D3xHpliEN1d2E0MW9tq7ihAye1dLSOiujI4BVhgg9xQB8F/soajdWXxt0eC2l2RX0Nxb3C7Qd8YiaQDkcfPGhyMHjHQkV6Z+3OTt8FLk7T9tOP+/FeZpEPhb+0xHHHNZ2tnZauo3/M0UNpPjIJbn5YZSCecEZyep9E/bju7eS98HWiTI11FHdTPED8yo5iCsR6Eo4H+6aAOA/ZQ0X+1fi9Yzy2H2q2sIpLh3ZcrCwGI3Oe+7GPfntkfc2q/Zf7Mu/7RjSWy8l/PSRN6tHg7gV7jGeK8Z/Za+GzeDvCh1rU1xrGsRq5Ro2RreHqsZz3P3jwOw5xmvZNYtnvdIvrWIqJJ4HiUt0BZSBn25oAz9F1nS9avTJbQyLfRW6upuLZo5PJkOQVLDlSU7Hqoz2rcri/BHhi90W/+0XKW1sn2KO1eK3u5LgTupyJCXVduMsABn7x9BXaUAFFFFABRRRQAUUUUAfMf7cOmXEuh+FNVTZ9ltbie1kyfm3yqjLgemIXz+FW/2Iv+RO8R/wDX+n/osV6R+0V4aXxP8IdegCRm5sov7Qt2cElWi+ZtuP4im9B/vV4j+xP4gMOr69oE1xCkc8a3UMJGHd14Yg9wFxx/9egDyT9oI5+M3izJz/pf/sq19K/sY6ObL4ZX2pTWixS6jqDmOfA3TQxqqrz6B/OA993rXzX8YgfEXxq8Qx6EG1B7u/MUC24LmRsBcKB15BFfeHw98OR+EvBGiaDEsQNjapFK0Wdry4zI4zz8zlm/GgDoa4jwj43fXNWt7OWGzX7RDPKPJnJeLy3VdrAqASd2eCcY6dx29cponh3TtO1K0iXV7m8lsPMe3tJpIf3BfO5sIiseGI+Yng/jQB1dFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUVl+KdZh8O+G9U1m6SWSCwtpLmRYlDMVRSTgEgZ49RQB8r/to3fha41zS4rWaWXxdboIrkRPmKO2+ZlWQdn3NlQOdrMW6pXNa3rHws8TfE7wpPFNr1lpEaKL9792uYy3yvGmZndlUMzq/VePlGCXp/wAC/CqfGX4o6/rPjSGa8sUja6uBHOyr50jbYos7t4QKH2gHgRqCccHN/ap8KaL4R+JFta+HLCOxtrrT1vJYoydnmNNMCVBOFGFUBRgDHAFAH3ZbmI28ZtyhgKjyzHjbtxxjHGMVQ8U31xpnhnV7+yiE11a2c08MZGd7qhZV/EgCuW+BfiH/AISb4WaDfyXYurpYBBcOI9mJE4K4wBxx0GK7TULyHT7C5vbpitvbxNNIwGcKoJJwPYUAZXh+zEJtrka5d6gbi33YlkRkmztPmqoA24zjC4GG5B4rdrmfDUvh06i66VpkWnahLEZSGsPs0kseRlgSo3jJXOCcEjOMiumoAKKKKACiiigAooooAiu7mCztZrq8migtoEaSWWVgqRooyWYngAAEkmvgvw9rHw70v43Xd3GuqReCWaSOB45ZopIyQBvBjZZPLzuwOW2kZGcivpv9qXxanhn4UahaxXHlajrP+gQKoRiUb/XEhv4fL3KWAJBdemQR5H+yx8JtD8TaHeeIfFelteR+cYbNJX/dMAMM20Hk5yPm44455oAufsvHwG/xS8R3GlXV2moyNImkW1+FJa3OGdlc8mXg8cEJk/N8236ur85/BWrx+CvjRp99FP8AYbKw1cxSyMvmeXbGQxygggk/uyw9fTmv0YoAK4bwLFa2mn6PYajpFyuvW4P2i5ewfb9o2MJJvP27Tv8Am5DEnfj1x3Ncj4T8U3GuXsiSQ28MSyzxhVEpf93IyZyUCc7c8HvQB11FFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAea6hrOsW/irVZhPeDTbTWrSzYq0RiSKSC2ymwjeSXm6g8bs84wfR4pY5QTE6uAxUlTnBBwR9QeKwp4vDUWp3ep3lrpdve28wWW9uIY0feI0IIkYZOEZRnPbHatO0bTraCU2jWkMJYzSGIqqlpDuLnHdic575zQB5j4e8TeIrXwvpGqzpe3cWoWVmhe9EWGu5ivzxhCDswTwxGTsAIyxrp7HxFr1xqmlabJp1rb3M8d1LO07FMRwyQKGVFLYLLNnaW49T3392hvaT6RnTWtbSEJNZZQpDEBwGj6KoA6EYwKhs/+Ec065tLey/si1uD5kdvHF5aMcsDIqAc8si7gO6jPSgDnvCfibUtYt7byjbJHbWltcXX2gF5ZvN3cJtKgYCnBIO5sjAxmqlj431ufQ11R9KiW3uorea2dvlRTLLGmwkMxfAkB3gL0IwOK6aOLwzK+lSPa6XFOPksFmhjSRdp6RAjIwRnAqS2sPDI1K4gtrXRvt8v7yaOOOLzX2vncwHJw4Bye49aAOeh8Qa5ceJdO04TWSGO9ubW6KxEJOEijkUqCSVOHI6nkenFVpvGmp2+k2Os31pCLaT7XItvayEtIkMEz4bK9SYxgDpnqa7qbSdOnYNPp9pIRMLnLwqf3oAAk5H3sADd1wKeunWSJAiWdsqQFjEoiUCMsCDt44yGIOPU0AQaI+oPb7tTmsZXZVdTZqwUAjpyTkejcZ9BWjVPTdLsNLjePTLG1s0c7mW3hWMMfUgAZq5QAV4H+2Vrj6f8ADW20uLyD/ad4iSB2+cInz5UZ/vKoJORz6kV75XxT+2Zqlxc/Eqy06XZ9msrFXiwuGzISWye/3RQB6L+xFpMcPg/xHrAkcy3d+lo0ZA2qsMYYEe588/kK8T/alYt8dfEgLEhRbAZPQfZoj/U19Kfsh6QNN+DVrdCYyf2peT3ZXbjy8MIduc8/6ndnj72O2T8m/HK0vrL4v+LotT3faG1GWZdzhz5TnfFzk8eWyYHYccYxQB9OfsZawt78N73TBAyNp962ZC2RJ5g3DA7Yxjv/AEr27xJYy6n4d1Wwt2RZrq1lgQuSFDMhUE4zxk189fsQf8iz4n/6/Iv/AEA19H37tHY3LocOsbMD6ECgDA03StTn1bTbzWI7K3XToHihjtZnmMjOFBZmZEwAF+7g5znPGK6auP8Ahw2rXGi2V7q8lxIbmzhl3y3CyBmZQSQoRdvX1NdhQAUUUUAFFFFABRRRQB8SftieKJtW+JcehbSlrocCqoIHzSzIkjsD1xt8tcHupPevpjwr4cTwl8ERpUXkiWHSZHlkgBUPIYyWfnnJPevjH4iJP4q+POuWl5eNvu9eewW42h9kYm8pMDIyFQKAMjOOvevvTxJB9m8D6pAGLCLTpU3HjOIiM0AfmRX6g+GNWTX/AA3pOsQxNDHqFpDdrGxyUEiBgCfUZr8vq/Sr4T/8ks8G/wDYFsv/AEQlAHVVgeHNHj0xnWy1m8ubQSSyfZXMDIjSOznlYw/VjjLfnW/Xlvg+wX7F4SjsNJu7LVrMqb64ksXtwItjB0Z2VRJuO3AG7nDcYzQB6lRRRQAUUUUAFFFFABRRXNaz4n/s7xTpulLbeZBNt+1XG/H2YyFlg4xzvdGXtg465oA6Wiisbw34l0zxG2qrpMzSnTL6XTrndGV2TR43KM9QMjkcUAbNFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFAHHjwtdHxW+pyNatbHVjfhSSWCfYI7cDGMbt6E9emOc8Vmaf4FvbddAhe4thaQ28EOqRKWInNu2+DZwOAxIbOMqAK9DooA8xuPAGoPpWr2Ia3llntL+C2u5L6XrcBvvQ7MLyw3EMfu5A5wNu/8K3EXiK0u9AhstOtVMCzlJMCSON2Yp5Hllc4ZtrhlILZ52gHs6KAPN4fA+qQ2MtoH0+Rby1itppmkYPbbJpZN0Q2HccSAgErhlzk542NO8L3NrqdldFrUeTqt7fSFSdzRzCQKOnJG5M5446nArsKKACiiigAooooAK+Jv2ytOurf4n219NFttbqxRYZNwO8oTu4zkY3Dr619s1wnxU+Gmj/ES201NUhjE1ndRyCbBDGHeDLFlSCAygjPY4PagCb4KaEPDfwo8L6aUuY5FsknmjuRiSOWXMsikYGMO7DBGQAAcnmvjr9qm3mh+OXiCSaGSNJ0tpImdSBIv2eNdynuNysMjupHavvquV8e+APDfj21tYPE+nLdi2cvC6u0bpkYIDKQcHjI6HA9BQBxX7K+g/2L8ItOmkjthNqLtdmSEfMyE/KHOASQAR3xXrzKHUq4DKRggjIIqKztorO0htrddkMKCNFznCgYAqagDmPBr+H5k8/w5oyWMMsQZZo7D7OsiZ4AOBn6V09c94H8Or4c0G0tXwbxYVSd0ld0Zh/dDdBz2AroaACiiigAooooAKKKKAPzm+GvhnUZfjJougSrHb6laaoFmSV8hGgctIuVyCf3bAYyCcc45r9DtYs/7R0m+sfM8v7TA8O/Gdu5SM479a4CD4Q6FB8XX8dQqYZ/K3i2iyqm6YuJJ256lWAwOM7mOSa9KoA/MtfC17J46j8Kr+6v5dQXT0a5RogHaQIrMMEqOQeh49a/S+0toLO0htbOGKC2hRY4ookCpGgGAqgcAAAAAVzdx4B8PXHju38Yy2THX7dPLjn81woGxk+5naTtYjpXU0AFcr4d8TTaxrV7aYsY47a5ngMYlYzERuVDY245wD1711VUdI0yHS4biO3aRlmuJblt5BIaRy7AYA4yeKAL1FFFABRRRQAUUUUAFctqnhHQtSv76W9CPql28ciXDeWZ7YxquzySVyoBXf35LduK6mvJ/F2m3U3izV5oLOaWcy2M1qv9mySLM0ZDbRcAYiGRgnIxQB6xXk/wA/1/xJ/7HHUP5pXqlzcQ2ltLcXUscNvChkklkYKqKBksSeAAOSTXj37O+raddX/xEgtdQs5p5vFN/dxxRzqzvASgEoAOShJADdPegD2WiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACse78SaZaazPpdxOyXsNn9vZNjY8rLDIOME/I3y9cAmtiuK8WeErzV77Wbyznt4rmawtobJ3J+SaNrndvwOEZLjYSMnBbjgZAOnt9WsJ3tY0vIBNdRCaGFnAkdCM5CnnFE2r6bBG8k+oWccaffZ51AX6knjpXIW/hDUYpEgLWLW8l1Y3klz5jedE1ukSmNF2YKt5J5LDAlfjmptF8GHT4/Dv7qwWSwup7i6aNceaXSVVI+XkgyDk470AdSNX00i4I1CzIt1DzETr+6UjILc8AjuaiTXbCW506K2nS5W/8zyJYGDxnYMt8wNcbB4L1ey0rTIdOuLKC5tNM+xuVYqHbzonYA7DgFUkXfglSwIBq14b8Jahp+rwXly1usa3tzcmMXUtwwWSGNAN7qCx3KxOcdR9KAO7ooooAKKKKACuN8b6/f6VrOnWdjMsQuLK7uP8Ajye6aSSJoAiBUIOD5rZ+g6V2VVpLG3k1KDUHjzdwQyQRybj8qSFGcY6cmNOevHHU5AOU0rxu95qtvYy6VNG5kW2uGQs5hnMYZhwu3YpO0tuBz/DjmqsXj9m03S9VudNuLWzvrGS9ihLJJJKoWIpghsKSZcAH6nb0rqRoGnjVH1COOeO4kcSyCK5lSORwAAzRhgjHAHJBPA9BUTeFtGbT7OxexV7SztGsIYndmCwMqqU5PPCLycnjrQBkax4wu9Ia3trzSV/tGZJZhDFcNInlJsyQyx53EuAAVAyDlgMEuXxn5l8qJpsq2YuLa2kllk2SI86Iyfu8di6hskY7ZrSfwrpTpEGF8ZImYpP/AGhcecu4KGXzd+/adq5XOMqDjIqceHtLG/8A0YkvNDcMTK5JkiCiNs57BF+uOc80Ac5o3jHU7nTNHe50VZb7UnmWNLe4UIFjzliW6fTk/wBLWi+KrrU5vstjYi6niDy3LPIIQkf2iWJAow25j5L8cD5eSMgVsWHhzS7GeGW1t3VoJJJIgZ5GWMyff2qWIUH0AwOwFRL4V0dJIpIreaF494DQ3MsZYNIZCrbWG5dzMcNkDJwOaAK3i/xIPDr+bJG0sMen3l88agZYQKjYBzwTuPY1FH4taLUjZ6nYG1dbuO2eRZhIkYkjLxsxwOpGwjsxHJBzWxrOhadrSMupW/nK1vNaEb2XMUoAkXgjqFHPUdsVFqfhzSdUg1GG/tBNHqIQXKl2G/Z9zoeCMDkY6UAc0/xEiP2cwaXcyq9vHdyKNxcQyOwjKKqncxVd5ViuAQMk5AsXPjeaOxnvF0aVbVL+WwW4mnCxbo5JUaRyoZkjzFjJXqwGMc1vXvh3Tby6S4khlimSMQ7ra4kg3RgkqjeWy7lGTgHIGT6mlfQNPaw+xolxDB9okuv3F1LE3mSO7ud6MG5aRzjOOenAoAwYfGMk98ttZ28V1c3RgFtGswEXzwNMxMo3ZUBTyFOcjjByIr3x8IbCS7g0x5I7exlv7oPMEMSROySqMA7mBVsDgHHUVtDwhoiwrFFZtCq+WUaCeSJozGhRSrKwKnazLkEZBOc5NSSeF9Gks5bV7IfZ5bJtPdBI43QNncuQc5OT83XnrQBtUUUUAFc5Lq2q3uq6pa6Jb2RTTXWGVruRl82Vo1k2LtB2gLInzc8k8cc9HXPXmhwS6tdzWWr3unXN4q/aYrV4v3pVdoYh0Yq20AZXHAHoKAOB/aVQXmg+EtJubmWDTNW8R2djfiOTZvgbcWBPpkA/UA1yPxc8KeFfAniL4f3fhC3i0bX5tdgg2WkpV5bZ8rLlc8jO1f8AgZHevbvHXhHSPG/hu50TX7fzrSblXU4khcfdkjb+Fh+R5BBBIPjn7PPgmxXxf4r8QX19qep6nomr3mhWcl/Ms2yBCuHyV3CT5mBKkDDMMcmgD3fV71dM0m9v3RpFtYHnKLjLBVLYGe/FZXgDxPD4y8Iab4gtbeW1hvkZ1hlILLhivJHH8OaseM/+RP13/rwn/wDRbVx37OH/ACRPwt/1wk/9GvQB6PI6RoXkZUQdWY4ApIpY5l3QyJIucZUgiud+ItnNf+E7i2tYmllkntsKI/M4FxGSSvcAAk+wNa+jWH9nWKwH7OW3FmMEAhUk/wCyCfagC9RRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRXlms3tomo+NsapLF4igvEXS7eK7bzWb7FbtGqwhsMpkLZBUg5bPcjTn8ZeJ7yZ28K+D49X06MmI3s+prZrLIvDmJSjFoweA/GSDgYwSAegUV53/wk3xF/6J1Yf+FEn/xmg+MfGVgPtWv+AltdKi+a5ns9WW7liTuwiEal8dSAc4zgE8EA9ErI8P8AiC1163huLCG8FtNCs8U01u0aSIwBUgkc5BBq/p17a6lYwXthcR3NpOgkimibcrqehBrlvh14cufDmlWNneadpkM1tZRWz3VrdPI0zKqgkq0a4BIz1NAHY0UUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABXmeu2VvLqni+K40a8utQuniOnzR2Ln5/s8aqyT7dse1x94sMEV6ZXI6l4puLfxXPpEUNuEhigkMkglYt5hcYARCBjZ3I60AdRZLNHZwJdSCS4WNRI4GAzY5P515b8AP9f8Sf+xx1D+aV6xXk/wAAP9f8Sf8AscdQ/mlAHoHjP/kT9d/68J//AEW1cd+zh/yRPwt/1wk/9GvXY+M/+RP13/rwn/8ARbVx37OH/JE/C3/XCT/0a9AHX+JtVudNGmR2MEM099di1XznKquUd8nAJ/gx+NP0HVpb+a/tL23W2v7GRUmSOTzEYMoZXViASCD0IBBBHPBJ4i0uHU4LN572ewe0uBcxzQmPKvtZcHerKRhz2p+g6dbWMU7wXMl5NcyeZPdSurPK2AoztAUAAAAKAB6cmgDUrlLu91u48SatZ6XdWUMdjbQTJHcQFxIzmTIZgwKj5ByOmc89K6usXUvDGlalfT3d3FcNLPGsUypdyxxyoucK6KwVh8zcEHIJB4oAwNM8cPqLWq2dk0lzfpbNa28reWE823Mzb3wTgKp6KTnAxzkWD41K66NNbS5i8U8NrdGMs5illVGG3CbWRRIhZiy4BJwcGtm78M6TdyvLLassrOknmRTPE6MilFKMrAr8rMvy4yCQarQaNon9uNHAbhNStooJ5VS7nXeuWWN5QGxKcxMMvuPy88YoA57UvH12mi3N3a6XHHI1hcXtn5s24OIJEjfeABt5kUjBORnOKva94uvdPt9bQaU6S6ZpjX884lR0iPlysoCkgucx+w56itl/CuivapbvZBoUtp7NVMjnEUzK0i9e5RTnqMcEU+Tw3pclpqFtNBJLFqFsLO6824kdpYgGG0sW3dHbnOeevAoAbpes3GpajcrbWK/2dBPJbNctNhzInDYjx93dlc7s5HTHNQXGu3Ut/qltp1iskGnkRXFw8wUrIYlkAVMHcAroSSR97jODV630Owt9Ulv4I5o7iVzI6rcSCJnIwWMe7ZuI74zUA0fSNQvZtRhLSSyMY5mt7p1jkeMlCHVW2sykFeQSCuO3ABzOleObuLQbWXVNNeW+e10+ZVglUmf7VKIQeQqo285xnGCOeuNWHxZKbwJcaYYbZLuKwnl88M0dxIqMAFA+ZQXVS2QcnoRzV2Dw/oVxFEILdXS2EFsu2Vzs+yy7416/wuM89cYORxUeq2WhWOsQajepKL24mBjSNpXEsqpgP5KkqWCL98rkBRyABQBijx9ctp4vE0TMT6e+qRg3YBMEeN+fl4fldo5BzyVxWmni4PfKEsXbTmu/sIuRIN5m2b/9Xj7uflznO7tj5q0F8MaQtolstpiBLJ9PVfNfiB8bkznPO0c9eOtKnhrSk1AXq2zicNvx50nl79nl7/L3bd+z5d2M470AYGl+On1KOCK20+D+0biZYo7Rrva8WY3kInBTdEwCEEbW54BPJBe+Plh0+S7g0ySSO3sZb+6DTKpiSJ2SVVwDucFGwOAcdRWuPB+jbWzDdNKWRhcNeztOuwOF2yl96gCSQYBA+dv7xzNL4X0eSzltXsh9nlsm091EjjdA2dy5Bzk5Pzfe560AYt/43awmls7vTtmpC5SCOITF4yGiMoZmVCRhVYEBW5xjIOR0mg6l/a+kW199nmtjKDmKZSrKQSCOe2Rwe4waqaxomiyC5vtSRYSWSeS6+0PCYyilQwcMCmFZgSCMgkHOa1LG1jsrVLeAymNM4MsrSMcnPLMSxP1NAE9FFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUVW0+/tNSt/P0+5iuYA7R74nDDcpKsMjuCCKALNFZlvr+k3OotYQajbPeqzIYRIN25fvADuRg5HbFSarrFhpXlC/uVieXPlx4LO+OuFGSQMjOBxmgDmvGmr3MXjLwh4eQhbHWWuxdMuQ5WKHeFB7Ak4PfHQiuov7yx0XSpbq8lgs9PtItzuxCJEij9ABXA+LbmG8+KnwuuLWVJoJf7RZJEOVYG2HINVfjReTtdWVtYuY7jTNP1DX2LgGMiCBkiIU5DOs8sMi5GBsJzkAEA1f8AhJPGupAXWi+EI7fT4/3pXVbxYri7jPKiFF3eW5AOVm2YLKD0bG74W8W6fr8k1mCbPWrUYvdLnZfPtm6fMASCp6hxlWBBBwRXN+MtQ1Pw5DqFrp+qXF1u0m4u1M3lmS1eNkCMCFHytvYYYHlOOhrm/Hng+K+1Lw7c6zcajpuoXd9/Zq31ndA3RWSNmAWVBHgAx/xBxgn5T1ABveG7m30n4z6p4a0OaMaXLpZ1S6s0OVtrozKvyD+DerFivc88ZOfTK8e8G6CfDXxkstLaaGdo/DdxIZYomj8wteRks+53LSHGWct8x7CvYaACiokuYHlMSTRtIM5QMCRj2qWgAooooAKKKKACiiigAooooAKKKKACiiigAooooAK52/0y3g8QPqI125064vEihaFWg2S+WW2gB0LZ+cg4NdFXDXMVra+IvEb6/pFzqCXpjNq6WD3StAIUUw5VSF/eCRsNgHfn1wAdzXk/wA/1/wASf+xx1D+aV6bqupWOkWMl7q17bWNlFjfcXMqxRpkgDLMQBkkD6mvHP2dfEej3uufEXTbTUbaa9l8S3uoRRxuG823dlVZUPRlyOoJxkZ6jIB6t4z/5E/Xf+vCf/wBFtXHfs4f8kT8Lf9cJP/Rr12PjP/kT9d/68J//AEW1cd+zh/yRPwt/1wk/9GvQBu/Ey2e78PW6JFNIq39q7iG2NwyoJlLN5YB3AAE4wa1fC0cUekqtuZSm9v8AW2RtD/37Kr+eOab4v1htB8P3GopHHI0bxJiRiq/PIqZJAPA3Z6dqsaBeyahpwuJXtX3MQrWzsyEDjqQDnOaANGvPfiBo2s6prCyWFgz+THC1pdW/kB0kEpMgd5DuUbQuPLGTk5OOK9CooA86bwzrC3Ru7KP7PqMt7qO66aUErDIsvkZ5JKhjGQo6HnA5q/4E0WbTtc1G6bRm0uCfTrKEh3jZpZo3uDIxKM2TiRPmPJz65rtqKAPLdT8P+JbnX7y7sLdtPvJftsQu4TAkRRopBbuSCZnYN5RIbADA4GBmpdT8O3Vzbacun+HrixsImP2uxD20jTuUwsmGcxvtOcliGJbdgkCvTaKAPNIPC2qKFnMF1LdW8+lfZprqdGmSKOSP7RkhsAmMOGx97p83FGn+D5/tFtZ3OmSxWa6xfXV1LHchEnhka4eL7j7iB5kalSBz2I5r0uigDzhtC1L+0nl1bSJtXsDNetFbLPHmJnn3Ry4dwPucAg7k7Dk46TxDon9p+J/Dt29qs1vZNOzuxH7sso2nGcnkDp6V0dFAHlTeEtSi8G+HdOfTJbiY2QOot5kU88d2Io1BDTsUC5DgsuSMLtGMkUtt1baxpdlqyC58QPdaa6SC5ieaCFY4hMhXfvxuSZyQCpDcnjj2KigDy+HwXdyW1sLrTw8kmmX6XW+VW8y5MkRti3zfMQvm7TyE9RxUth4d1seJbe91RL+WUS28iXMDwERIsSK8TszeYBuEhKoCG3Z6k49LooA8nfwXqjeGXtBZD7Tc6FJBdhplJmug6GMMc8nAcBug6ZAr07S0SPT4EjtHs0C4Fu5UmP2O0kfkTVqigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKAM7xEb8aFfjR036k0LLb5IAEhGFYk9gTk+wrA8BeH77wxPfafK0E2mvHBLBLBH5Sq6p5ToULsfuxxtnOCWbv17Cuc8W+E4/Esls8us6/pvkBgBpeoPah84+8F+9jHGenNAHM6ZoOsReJIJWtb5I4dZurwPNLA1r5MnmjcqhjJvKyYGQMZOeOD0mp299ZeLU1e20+XUbeSy+yNHBJGskLBy4YCRlBVs4ODnKrwe2F/wq22/wChv8c/+D6b/Gj/AIVbbf8AQ3+Of/B9NQBW8USyXXxY+Gm6BorlE1GeeAEO0CtAFBfbkAbvlz0zwCa0/iZYGJLLxHHZi+j0lZvt1miZkvbJ4mWWEDo45WQRt8rNGoyOGGx4T8Jaf4ZW4e0kvLu8uSPPvb+4a4uJQPuq0jc7RngdBW7PNHbwSTXEiRQxqXeR2CqqgZJJPQAd6AMrTNJ0CTSWGl6fpbaZqEauwt4YzDcow4J2ja6kHg8jBri9M0zT9b+IiNothZWuh+GpJEl8qJRHd3zooDKqjbmEbk3k7gzyLhcEnmNN8DXniWHVtU8J674h0DRZ2km0qEajNFFdO7mRpfKXHlQMSwUL8xDl/wC4K9C+GF9pv/COxaJZWkmm3mjotrd6bO4aW3YDglv41b7yyDhwc9cgAGXckRftCWLS/Ik/hmWKJmGBI4uUYqp7sFGSByBz0r0WsjxR4dsPEunC01JZBscSwzwSGOa3kHSSNxyrD1Fcp/wq22/6G/xz/wCD6b/GgC/4A0Saza/vLuKGNpdR1BkRrQJMA15KVYyHkqVwRxyGHauzrz3/AIVbb/8AQ3+Of/B9N/jWv4Z8FRaBqP2uPX/Et+dhTydR1N7iPnvtbvx1oA6uiiigArL8T399peg3l7pOlvq1/CmYrJJViMxyBjc3A65/CtSigDx7/hZHxI/6I/d/+DuL/wCN0f8ACyPiR/0R+7/8HcX/AMbr2GigDx7/AIWR8SP+iP3f/g7i/wDjdeIfCz9pPWfDp+weM47rXNOBCpPvX7VAo6gkgeb2+8Qevzdq+0K4nwT8LfCHgwSNomjwi4kJLXFx++lIJBxubOBwOB6etAHT6DqtvrekWupWazpBcJvVbiFopF7EMrAEEEH+mRV+iigAooooAKKKKACuI1vxu+meJZ9OMNm0UM1rERJOySv5zAbl+Urhc55IzjqK7euZ1Xwpa6hqF7LPqN7HDqAjFzZoYhHMqDGMlC4GOu1h+FAHmvx8fSn+Ivwyt/F7hfCbXV092JywtmmEa+R5uPl+8f4uNpfPy7qp6vZaNL+0P4K0fwdoqQN4YhuH1V7W1WKG3jmj3RIWGM8uzYHH704yd2PZfFvhzS/Fmg3Wj67arc2NwuGU8FT2ZT2YdQa8q/Zk0LT9Ej8fw2EODbeJLmwWV2LO0MO0Rqx743N/30aAPXPEdpLqHh7U7K22efcWssMe84XcyEDJ7DJrn/hB4cvvCXw30TQ9WMBvbON0kMDlkyZGYYJA7Edq7CigCjrWmQ6vYG0uWkWMyRy5jIBykiuOoPGVGfar1FFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAeeNqWst4v1r7PPe/Y7DU4klLiL7LFa/ZIJJA2fnL5diNvcr2zUUPjPU5VaK6hCbpNLmgnjj8nzIri7WIjaXc4xnk7SQT8q9a7rz9NtJbs+bZwSsTNcncqklUUFn+iBBk9Bt7YrKgt/COn2Ed3BDoNrY3Dx7JkWFI5GRtyYYcEhhkehGRzQBiw+KNVn/sq6uIbaK1udTubWJIZCWZYobskyZXuYUOB+faobTxpqrx2kdxBYi41C3sZ7ZlV9kP2l2XD5OW27cgjbuJxx1rr1GiGcWS/2aZrQtceQNm6EuGDSbf4ch3y3fc3qazNRj8NajYNYR3ulwCXy7BTD9nY/IQywBXVlP8AuFTjJwAeaAJtD1ySfQNQvtUa3jNjPcwyyRqwTELspfGSRwucZP41zlv401cvc2s1nALkPYGCSSMxKyXUrxglBI5+XyyeSpOei9Ts+EbnQbDS7rTNNnUm0luTPDIU81isjeY/lrgbS2cYUDoAB0q1p9p4WtJILeytNHtZ7jy3jgSKKORynzp8uAcruLD0yTxmgDnLzxVq11p9zZW5tLfUIoNReW5KNsItpBH+7XdkFt4OSx2/7Wa7Xw9K8+gabLM5eSS2iZmY5LEoCSax9TufCDafdzXx0W4tLKUvPlI5hDI7YJYAHDMx5PU81qJq2l29tKftNvb2dsqAyswSFVYfLhvu4x6UAadFU59UsLdoVnvrWIzlREHmVfM3fd25POe2OtXKAGTzR28Ek0zhIo1LuzHhQBkk15/Z6dpHxNsUuvEmmXdteWTlBBHqE8JVJESRCfLdckoyZznDBgDwa7bW9Ni1jSbvTrl5Et7qMxSmMgMUPDDJB6jI+hqrpHhzTNG1G6utJto7IXMUcckFvGscRKFiH2gD5vnIJ7gD0FAHj+l+F/CN34nTS30yYJJfXNkAviC/81PKDkOymTBB2YwDn5h1AONrU/hp4abXU0jSNNuvtC2/2qaa51q/2RoWKoAqzZYkq3cYC9813Nv4Rt4b5Z3v7+a3W9k1BLRzH5SzOWO7IQOQCxwCxH1q7qmhpe6jDf297d2F9HGYTNbbCXjJztZXVlIB5Bxkc4PJyAcjZ/CLwo1rEbzT76O4KjzFi1y+dQe+CZQSPwFWYfhJ4MimSQ6bdzBWB8u41O7mjf2aN5SrL6qwIPcV21nCba1ihaaWcouDLKQXc+pwAM/QCpqACuc8U+CtA8Uzwz61ZPJcQrsWaC5lt5Nuc7S8TKSuSTgkgEk966OigDgP+FQeDf8Any1L/wAHN7/8eo/4VB4N/wCfLUv/AAc3v/x6u/ooA8h0HwF4N1m7uI4NE1aOCGe4tzK2v3RJaGVomOwT7gCyHGR0xXV6N8M/C+janb6hp9pfpdW7bo2k1S7lUHGOVeUqevcGtrw34fttEjuCiwyXM91c3D3AhCORNO8uwnkkLvC9edoOB0GzQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFeb+K7XWrnxgNbtNPMttoTwpDl3Ejq3NyYowh8wNG6qOR80Z6kYHpFFABXk/wA/1/xJ/7HHUP5pXrFVNP02x003J0+ytrQ3UzXM/kRLH5srfekbA+ZjgZJ5NAFuiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigDhdY8FSXx8Rzx/ZEvb/Uba8gl5VjHDHbjyncDcoLwv0zjcDgnIplj4W1LT7+HUbez0+WbFysttc38sqkzeVmQSGLO4+VgrsAIbr1z3tFAHASeD9SfNvmwSCK5vruO4V282RrhJVEbrswEXzRyGPESccUs/gm6a3vUhNkjy6Vp9jGeRtkglldz93gEOmMc5XkDArvqKAPPn8IapNLNHINPigS9v72KaOZzJKZ45UVHXYAoAlBOGblFqW18G3kKsWez803un3AcFs7LdIlcZ29TsfA9+cZNd5RQB5e3gXXbuO4bULizluX09rUytdSus8oljkVvLKBYVOw/KmcZ/irXuPDOqtra6xFFppljnhnSzadhEdtvJEw3+XkEGTIO09CMDOR3NFAHnLeA73+zNQgWWyM1xpQs4iSQIpDNLKQPl4QeYoGOflHHFejUUUAFee+KNTi07xhq81teKL+28PzXMcDTkjzFJIJjzjoPTpXoVFAHncviPVdIkvJr28F1Y2As7y7doVDLBMJFkxtH3UKrJ3OFYEms7VvFXiS1+yC4uLLTJZrEX0X2yRII5JHkci3Yspz5aCMMEIYl857V6rRQB5zqet62lvqt5/a9la2sGptZJG6xwsI1wTtlkynmHoNwAxnvg1UXxVdyXCTLdSWlrcWGmNPe3CKrW6SSXYaQrkxgkxoN2CvzZ5AFeo0UAeX3PibW5tOle31BUW307UL2O4SBD9qEEwWJucjaykE7cZzlSARXS+LriR7Hw7OinfJqNu2xTjOQxxmurooA8rtfGGqPpsUqanDcCa3tpb6YRIBpMkkyJIpA6bVZzh8lfLJYkZFWn8VXI+wQ3Gv29pp011cwJqzCIefGiKyOpYeXncWUkDB2nAGePSqrXFjbT3trdyx7ri13+S+4jbuGG46HI9aAKnhW8u9R8NaVeajF5V5cW0csqBSuGKgn5Tyv0PI6VqUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQB/9k=);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f14_40_14978=[""].join("\n");
var outline_f14_40_14978=null;
var title_f14_40_14979="Modified Martius fat pad graft2";
var content_f14_40_14979=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=OBGYN%2F74982&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=OBGYN%2F74982&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Modified Martius fat pad graft",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 410px; height: 395px; background-image: url(data:image/jpeg;base64,/9j/4AAQSkZJRgABAQAAAQABAAD/2wBDAAYEBQYFBAYGBQYHBwYIChAKCgkJChQODwwQFxQYGBcUFhYaHSUfGhsjHBYWICwgIyYnKSopGR8tMC0oMCUoKSj/2wBDAQcHBwoIChMKChMoGhYaKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCj/wAARCAGLAZoDASIAAhEBAxEB/8QAHwAAAQUBAQEBAQEAAAAAAAAAAAECAwQFBgcICQoL/8QAtRAAAgEDAwIEAwUFBAQAAAF9AQIDAAQRBRIhMUEGE1FhByJxFDKBkaEII0KxwRVS0fAkM2JyggkKFhcYGRolJicoKSo0NTY3ODk6Q0RFRkdISUpTVFVWV1hZWmNkZWZnaGlqc3R1dnd4eXqDhIWGh4iJipKTlJWWl5iZmqKjpKWmp6ipqrKztLW2t7i5usLDxMXGx8jJytLT1NXW19jZ2uHi4+Tl5ufo6erx8vP09fb3+Pn6/8QAHwEAAwEBAQEBAQEBAQAAAAAAAAECAwQFBgcICQoL/8QAtREAAgECBAQDBAcFBAQAAQJ3AAECAxEEBSExBhJBUQdhcRMiMoEIFEKRobHBCSMzUvAVYnLRChYkNOEl8RcYGRomJygpKjU2Nzg5OkNERUZHSElKU1RVVldYWVpjZGVmZ2hpanN0dXZ3eHl6goOEhYaHiImKkpOUlZaXmJmaoqOkpaanqKmqsrO0tba3uLm6wsPExcbHyMnK0tPU1dbX2Nna4uPk5ebn6Onq8vP09fb3+Pn6/9oADAMBAAIRAxEAPwD6pooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiio5mKoQrKsjfKhYZG7HHHegCSikQFUUE5IHX1paACiiobi4WIqgBeZvuovU+59B70ATUVlXf9si2lltmsjMo3JbsrYY/wB0vnv0ztrQtJ1urWGePOyVA4z6EZoAlooooAKKKKACiioWuY1uhb5/ebDIQP4RnHP15x9D6UATUVymoeKY9J1GA3iXD6dczCA3CoDHbMSApc8FVYnGSCB69a6ugAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKytY1SbS5o5ZbOWbTiMSzwfO0B/vMnUp6kZI7jHIANWiora4hu7eOe1ljmgkG5JI2DKw9QR1qWgAqnGxn1GRjkRwDYvP3mIBJ/AYH4mpb64FraSznHyLkAnGT2H4nAqgL200awhGo3Ucbtnlj80r9WKr1PJ6DNAGtRXOw+MdIe4jilN7a+YQqyXVjNBHk9AXdQqk9gSM9q6KgCNpU83yQ6+dt3he+OmcemagDRaZp8k17dARxKZJridgoAGSST0AHP0FWBFGJmlCKJWAUtjkgZwP1P51458ctZN74YuLeNTJYyXFvbCPBIlDTorSnH8ICuFzwSrNzhaAPYhMrW3nxfvEKb1x/EMZGKqaAXbQ7BpAFdoEZgOgJUHFXmIUDOB2FJHjYu3pjigB1FFFABRRRQBHcTJb28s0p2xxqXY+gAyaoaEGkt2up/+Pm4xJIv/ADzBGVT8AR+OT3qh49vRaeHmjUFpbyeG0jQEAuZHAIz/ALu4n2BrY09XWEtIfmZixGMAGgDl/E+jW2t2N9YXaF7W5ikWeKNiC6DsO/XHHY49qv8Aw61Ua14J0i980ys0PlvI3V2QlGY+5Kk1fV43u281cyLIdpCkH6fXH5rXKfDBnsta8a6G+QljqvnwIeixTxJIMexfzD9c02B39FFFIAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigArgvEU3iTw1fXOp2t1/aGks277HOBiP2EgG5R6E7h04Fd7SOqurK4DKRggjIIoA858N61ZavPczeEZf7O1UP5l1o18NiTf3nUDOM5/1iZBP3gTWw3jGa61F9I0rSJ5Ncij82e2vJBbxwqSQGMmG3gkHBQN05xXD/FX4cb411TQpZbSa2zJG0MhQxHrw3VOnDDgdGBXlV8HeItQ1Hwe918QYI7y0srqW3/ta0QxT2+xgBI6L8y54+aM/UY5piNq40m5ntr++8f6SL2b5xGsVy1xaQxsTgLFhSMDGXKk55yB01v8AhEPDGhw29/p1pNbXKgRW89k7mZgxB2Dk7lOAcEEYGT0zVyH+2YLGKbS7q08Q6bIm5VncRyvGRxtlXKPx6gZ7tWXp+uW0fjcW13Bd6esOlS3UdrdRbRFiRRIUK5VuNn3WOOemaQzodatLe4kihu082C+U20sb/wAQKnI/LPH8j1Z8P7ma78E6JLcyNLP9lRJJGOS7KNpYnvkjNS+I4pZrOO4t1UTxqxjEwwiuRlWc9lUgE/SsL4barFaeHBoOoo1tq/h+2ihvYzlg67SFnjb+NH2sQeucggEUAbninURa2hgWYxPIpaR05aOIEAlR/fJIVR3Zu+K4nxxp8Evgi404zqNZl2ztGhzscLhY8f3VG0Y6457k11OixNqF/Jqd4ij94VijHOZFyOf9wZUY43bz3FZGjXVvrup6nBazG4aO3eMPGriKN2LKGQngkhDk8nIIzg8gHZ6Tex6ro9jfwgGO6gSdM9gygj+dTWEhlsoHZNjFBuX+6e4rn/AN0p0+607aI2sZiqJ6RP8AvI/yDbfqhrobaLyRIoIILlwPTPP880ATUUUUAFFFFAHH+MLm2k8T+HtOlJaYGW9SIYwdgVdx9h5n4nA7110YARQoAUDgDoK4aELqfxE1SdDcFrNIbEbSRHgDzW+pJkwf9wCu7oAwrt9moyEBgy4YqXyGHXI9MdSO2c9M1lBRp/xVSVF2xaxpZV8DrLbuCuffbM3/AHzWjqZ26hKy7i6lcFWDbc9P9055GeD2PUHN1dl/4SHwZegHa1xPbsQOFLQSHB9OUA9KYHZ0UUUgCiis631a3vt39mOLlVYo0ycxKR1+bofoM/hQBo0UD3ooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigArzfwnYRWWs+OfDNlBDaxpeRalaw7B5ZjmjUkgHjBljl9ga9BvbuCytnuLuVYoU6sx/T3PtXnd0l/efFA3LLc21nPo6KLPcqS3KpMxYg8FCvmJ8ueQ3OOlAFDVLHUfhnqMuu6IzzeFblml1HSZCT9lY8+ZBjIXvkfdPHTrSX+rW/xF1ayv/Ct68ml6LbrfPcQAf6S8jYNqQwyBsjfcODlk9K7+VYPE1jNbOby2t45jDcw/wCraUBclCQc7TuGdpGcY9a5yz8IWvg29lbwZBDp324qTbyMzW87qD8jZJKMV6MvpyDwCAd78ssfZkYfgQa8m8VaVqsuoW134dkjlvLCU28kDyeX9qtZBlF344ZJArLkYDE9ATXa6dq1w+LewtpHQlo0kuMqsMi8NGSM7tpBGeM4IyetMtLSRYY4oIWlDSwqZwADtRzv3f8AfvPf7+PemBn6Xrmh6npnl2U91YmGPybi3clJ7LHHlledr5HvkDOSMGsj4ZL5Oqa1fxG4htPLht/s08fIEZfa6kE53B+RnIKkH1PNftB2Eegajp/iuDz0iuX+x3wTJRSEJSZh0GFVkPqCozxW98DLgalpesOHVZC8OCozw0CkMexySfy/CgDpY2/sbxdDK5VrbUCYBMOBhizxA9uH81c/9NUFda8IM6TDhwNpOeo9K4u+ddb8I2NycR3OTEzbMKsgPL47AOiyD/dHrXUeHtS/tXSYbl4/Kn5jni/55SqSrr+DA89xg0gNGiiigApHZURnchVUZJPYUtc78Q7prPwXqzpIkckkXkIzZwGkIQdPdqAMb4eAyPc33mF2v5ZLqTJzsDMSF9gBtUf7p9a0bTxHe69Jc/8ACL2kEthETGupXUhWGZx18pVGZFHTdkKTnBOK5J4zItl4E0hmtXuYTeapPG3/AB72O4jYrdfMk+6D2G9uoFXdb1y/m1H/AIRzwlZwKbQIuWbZDEgQlE+XLAnC4wAFByfSmBY1C01rS0N5rK2N3ZgkTz2xkDQIerFZC5KjuA2MfwnHFfxRqsFp4d0XUp52Kafqts7NE2EKSSCLceTkYkPf35xWt4C8T3Gqy3Oja7CsOs20SzHa26O4hbjemQDwwKMCMhh3BFecapoF9fT694I0+Ka408SB7eWPDCzBYOFLHCgAbcAkn5TgUAe91iah4jtYfNjsh9tmjB8zy3CxQ46mSU/Kn6n0BrzjWfF13fag3huFJfEXiCONRd2Wkkx2dsejefPwScnOzK+hA60628MXmo3MC+KNUeaK1JMekaOojt7fqR5jDCrjt/EOzGkBZ1zxULq9e0O7Wbgxl1s7ZXW0Uc4yQC9wSRjgbee1Mm07xRqvkPfX8OgWw2+VHLtaRQBxst0O0EZx8zMflHArb0Z/leDwzZotv/EbL7jkcfvLpwd5/wBwMR61s2nhgyxudVuGJk+/FaO8SkejSZ8x/qWA9hQBqaHcxPbLbf2ib67hUGZpAqyAnkbkAGz2GBxWlVbTtPtNNthb6fbQ20IOdkSBQT6nHU+9WaACiiigAooooARiFUseg5paKagwgGckcZoAdRRRQAUUUUAFFFFABRRRQAUUUUAcZ4K8at4hs/FtzPYtCuhavd6ZshJleZYAp3gYHzHP3RmuV1n41ac/h3VLzQLaZtQ026tIbi1vIskJPKEyPLYhjjdwDnI5Fa0Pwk0yK518prviEWGuT3Vze6cLiMW7vcKVc4EYYYyMfN/Cuc85pRfBLQo9Pv7U6vrjm8S0RpjJAHjFs+6PbtiCjnrkHP1yaANJPiXY3t/ptrZCW0uZNX/su6tL+2ZZkfyzIAADgZABDHIx71S1X4v6VHH4jsrK2u4tb0zTbu/hhvYgqTGBCxHysSOQOG2nFT/8IB4Z0W70y61PWrw6j/a41Jbu+uollvLnyzGqN8oBAU4CoFqjZ/BLw1pkFwBqesC0+w3lkqSTQ7YIbkESYby8kjJIZyx9c0AafjPx/deHfhDbeLU08XV7cW1q6wKG8tZJtgyxHIUFvxOB3ph+KNjpF7ouleKLe7tdT1DyE81bUxwiSUDau1m3jGQDwQDkE8GtXXPDWg6z8Mo9DutSdPD8dvb4vY54wfLhZHR/MIKYPljJxjGcYrK1j4UaDrviWXxA2o6pG91c21+8UEsRhkkhx5bZMZbGAMgNj6daANL4ceO18aya4g0i9086ZfzWW6ZTtlCNjOSBh/VOdvHJzUGkfFLQNV1WysbeLUl+2yXENtPJassU0sO7zI1bu2FJHY9M54rY8K+EbTwzqOt3On3l88WrXb30lrM6tFFM5y7R4UMNxxkEnpxiuA8IfCux0s2cPi/WHur5ptQax0+O7CwKJy+9412K7SCNjkkkLkkY60AbVn8ZfCs8GsyXLX1i2lW63U8dxCN5RmCDaFLcliq7Tg5YcVe+H/ja68VeJvFdhPps2n2+kvarDHcxmO4xLDvPmLkgHPTHbFclpPwr8CMLvSI/ElzqEtxp40gQG9t/MiSGQSjYI0U70YKcnPuDXfeDvBlt4Y1LWdQTUtT1K+1ZoWuZr942YmJNi42IoHH8u1AHU1Qv9SW3k+z28Zub5hlYEPQHozn+Ffc/gCeKsQXltcTTw29xDLNbsFmRHDNGSMgMB0OOeaLW0t7Uym3iVGlcySMOrse5PegCnaaYxuhe6lILm8H3ABiOAeiL6/7R5PsOK4LxZBd6h8SINW0l55Z/C9vl7WP/AJbiYZkjA7sYwpA/vBa9QPHWuI+GAknj1zU5txbU7+S6ViOPL+5GPwREFNAWrW/jluNSn0uYXCym21CI5IUxyDyzj/v23Hqa3NfitbjTJrW9kSOO4HlKzjgMfun6g4NcRFoFvB4t8RWyRO0MsIla1DZSW2nyJAqkY3LLG7DH/PTHcYJ7u8uf7N0+/ns3niZYUkVeJ2I4cJnKjAIx6hhxxkA6vwReNf8Ahm1nliWK4JkWdFIOJVdg/TuWBP41YsYorvTJ7KbdgPJFIqsUYfMT1U5GQQeveszRVfSZ9YsIFVpTcC5gRhtULKQOuSThgSenUDHQmLV7m48P65pt5PIHstQK2V3IEVRHMf8AVS9c4J+THPVfSkBKdE+y6pDFNctdaJcI8JsrsmY+YRkfM5JK7Q4Kn1HYceYeA7Ow+F/xR8S6GJJY9Kv/ACLyAyn5IYX3IoB64RwU54Ckehr2K/t2vdNP2hEF3auJY2HQSJyGHoCP0JFeCftQ3q6L4x8HapseLz4LmzkuEw37ptoYFO+A5I9d34EA9s8NyWgtJ7OKRIxptx9jkBIYMAQU59cMo+uR2pIJX0vxXLHM4FrqRG0E8LMq8Ef76Lg/7Uf+1XK/CqW11X4fQGzje0No0lrIAM+auSQ/PY7g4I6c+4rqdb05/EHh3yJiE1CIq6vC3SRSGVkbtyAwPrjOeRTA6aisTwprJ1ewIuF8u+gwlwnYkjh1/wBluo9DkHkGtukAV5d8Y9etrXVPD2k3BkdWd9RlgiXdJMItqpGo/vM8i491Feo14raQxan488RfELxBxoulMLHRoZCFEzQ7g8oJ6jzC+3sTz2BoA2Lcp4I8HajqfiBooNb1Qvf6nIjZ8kY4jU91RQsY/E965v4E+L5J/CdjfXeni71PUHleY2i+ZcSDzWVCw4AAAVcnAwo5rKvbS8+LHj1vDesm807SY7RdSvox8ksqlgIoQDzGDjfzyfSvTIr/AMIfDmxl03RreC3w++SGEkkue7nli3sMn2xTEMg0GHxD4vi1e9aS2ktreW3NvZSfIwkZd6SyDljlBkJgAg8nmrPi7xbp/hvQbi30EWjXihoogCEt7d8E7pX6ALjJUZY9AK47Xta1a60S7ks7RLS0VJH+yx4iEh64+UHrzlm3f7leheENL0e50C3uoNOEZurfy5Un+d0BGHiJ6AA5BAwPagZwnwx1XStc02bwz4VK3Vvp6Ry3V9dRyW63JlBPmCMENLvILFmKjkdeK9Es/DFqrRPqUjahJHyiSKFgjP8AsRL8o+pyfevD/CfhuX4S/H2C1UpH4X8QwvbWchJASThliPONwK4B77/XOPo+kAiqFUKoAUDAA4AFLRRQAUUUUAFFFFABRRRQAUgwCcd+aWo3IWSP5cliVz6cZ/pQBJRRRQAUUUUAFFFFABRRRQAUUUUAfN2neJ/EyfEHS7C/1HXV1e61fUIrm0ZSLMwRxSGIQYGGA2gkgk5B3Voyr41t/hf4buby58X3Wr6nNGb8qrCTTwqSDBihjEpUkrkE9QpLAcHr7Pxf4E034g31jHoSab4hk+0u93/Z8Ub3PlBnlO9fnOQrMCwG4cjOas2Xxm8KXEU80/8AadjbR6cdUSa8sniSeAEKWjz945ZR754zQB5lo/hjxR4uu/AN14qHiBL2PS9TiuJZIPLMMizMIS29CEd028nlgqkdye7+DNlf6b8EGsZoNZi1S3t5o2t9Qt2R45BHwsSlRuj6YIyCS3Jrd+H/AI6ufFnivxPp0mmT6fa6ZFZSQJdRGO4PnI7HeuSB9wYx2PNQX3xd8PWmszab9k1ueeO9l07fb6e8kbXKLu8lWHViOgH1OBzQB5N4qg8Y33guy07U7TxQbeXwmqw2unWb4kvzkOlyqLlfl24VsDrjmtW7f4gW3i6ziEuuWdhAlh9hS2spZrd4hGnnRyhF2hi24EyFSOxwK9Eb4veGzpGnahax6ndpeWs18Ybe1LSwQROUlklXPyhWBU9ckcZrOvvi/Zab4l1WO8tpp/DttY2d9Hf2du0m2OfP7yTnhPu4wM8ng4OADmtOtvHMmraXfXGo+KVFz4hvLC4tjHiGGxPmeXKF2cAYXbISRyMdqyvhRo/iGwsvh3pMtt4jtEhm1ODVPtFoyLaEwN5ZjcphVJIIYEgsSMnpXf3PxJuF8TWmm2gsrmGXxCNHkYRupjTyPNzndhm6cjjB6U+2+LOnWfgvTte1mG9ntrp5U+02FjIYQyztEqnJJDEqBjPJ6UAed/DPw94o8PaJ8Po9O0/UIrya11ia8S7tdqwTlFECyEqCgLDIDHJy3XoKml3fxPTw9rDrceJ21B9PjNzBNYS+ZFMJ4xK9u7qELGNpcJHkYAIwQK9d/wCFs+GR4og0JnvFuZbpLEytBiKO5cArCxzkNyAeMAnBOaoab8VIdc8c+GtK0KynfR9U+3A6hcQlFm8hRhoDn5l3bgSR6YoArfA+wubXWfG9xLba3HaXV9A9tNrEMkc86CBQWO8AnkY/nXq9FFAGJ40v/wCzfC2o3CzLDIY/JikbosjkIh/76YVP4dtpLTTkhkZHRQBG6nO5QBis7xvZjU4LLTyqv5s3mbW6fKDgn1wzKfwrS1K9GkaQrsqSTKFiijDBA744GT0HcnsAT2p9AOW8YeIYNE8b6FKFaRNklvqDIM/Z4ZMFJG9AHQZP8KsxOOM6l3pEGoT6usMcUOpxypcW115YLo2xdrZx03IQR3AIrI063On+GNW12/Vby6voXZIyhIlDA4G08/OccdlCL/DVD4fWs+gxxaRNM1xr2mWkccsRmYi6tuCCoYnDIWK9ge+AwwCJLfVJNZ1rRbi1uYI9X+yzRMyDfGZEZQ6MCMhckggEEHB5wK6bxxZ2+qaHJZ3Vxc26TqygxLuBOMgEEe2R05Fcr4js49I1S38UWAu7qOK93zRLn9xHIFEwK9sbQ/Trkd67TU4pbhFntQt1ayqGAQhuo6jkBlPB4IIIBGaBkMU8q28Mc8q3FxdW7qoB2tJjGDtIHPzHJx+Fcd8T/h1p/jWO4GtXcrx2lt5VpEqgLa78AzZ+8zgqD1xtGMZ5rtILJbtg+oQNErL5NtC5UPEoBJfIPDH26AD3qppDHVn1i0mkLeWI7aWYL94gHd+OMfTdQB4X8DfEFz4f8W/8IzdRTSanHF9jvEml2gmHcqrGDwxG1gDnBA7ZFex+EL5bbVHsJhN5e5/JlkJVlLMWEciHBBIyy8YxuA6c+E/Gy3l8LfH2z1C0jZYNWghuN6xhjHMjFSyAkAsNqsR33dM4Nekr8U/COraD9t1ovBOhS21CCaAwumHHzknn5CdwCnIJ49wR0N4l7Y6rdXkUUdtfRStiUSE277grbH7qjDBOR8j5YZBau30bU4dVshPCGR1YxywvjfDIPvI2O4/IjBGQQa5OHxJo8NrewzXFvJBMvmx3sM+9ZlxwWJPysAvGflIHB6geSatceINX8c6fbeCbhJtO1BQdSsWBWKKNRjfJICPlViwC8ZwE+ZcAAz0Tx74yudS2aH4PtZNSnupDDJJb3CxFlH3xG/O1R0aXGF6LlyMZ2tXaeHJU8qCLW/ElnEq29vkx6doycBQT2OMAcNK+PlABwOXv/GdlofmaB4Muf7R1HYqahrUYTzJdowI4sfKigDapOFXoMnLDI03wf4k1uVbvS7i6e/idJ4w7GCOyfeNy4PDyFGDbzksA3PIFFhHo/gbw7qdtr2qa/q2qMNY1WKNbqYRhH2KQESGDB8pRkDc5ZieqitZLDwh4cjgEWkCKOXduuirnKyFGd5n64y4JLccHpVrw74fOmS2NtcpGLySBjIiOWWNQMHk8sCSuBxjn0p+oX/8AZviux0afTfP/ALRci1kB+Rkw7TB+uNgZsKeGDKAcg0DKrw2eo6Q0U9vA9m8ZikS2JAZG4Ygg9vlGQc/Oai0e2bwhHHY21xM+lzNi3kkcuYpDgFST1UkAjPqe7VrxaNZQ+Jrq3sWltxcQB5FRvlDrwSq9iRIpJHGVB65zJDaLPLc6Nq6IYGtzggbVYAkbh6cFQPTHsCQCj430q28ReG57S9t5blAfNjKnbMgB+bY3aWM/MvqVA9a1PB2tSXdrFp+rSxnWYYVd2UbVuo/4Z4x3Vu4/hJIPbOP4OuZLHUJ/CXiK4mfVrcebZXcj/Nf2y/dlBwB5q52uBzwDyGror7wzpt5ZtbskkYDtJDLFIUkt3JyWiccpz2HHtjigDborl0vNY0Axx6okmr6d90X1vF+/j56yxL94Y/iQdvujrXQ2N5bahaR3VjPHcW8gykkbBlb8RSAnooooAKKKKACiiigAqG7UtFx1VlbrjoQampsqh4nU9CCKAHUU2Iho1YdCAadQAUUUUAFFFFABRRRQAUUUUAeZ2fwa0C01xNSi1DWMxy3k0du0sRjRrmNkl58veeHJG5iQQO3FT3Xwh8OXmmWNhdy6hNbWejtoqK0qDMJZW3khfvgopBGB7V6LRQByng3wTbeF9V1fU01XVdTv9USBLibUJI3YiEMqY2IvZzn6D3zTi+Gmjxakt6tzqBlXXZPEABkTb9oeMRlfuf6vA6dc967eigDzRfg3oMWk2VjZ6jrVobe2ubJriCeNZZ7eeVpZIZDswV3McYAI9c80/Vvg/oOoXUxW+1ezsLi0trGfT7WdEgmgg4jjYlC+McHDAmvSKKAOGT4ZaKmtLqaXF+sy6v8A20EDoEE3leVtxs+5t7Zznv2rNPwf0xNP8P2dpr3iC0h0OWae08qWAjzZZHcyMrxMpYF2CnHA9+a9LooA4GH4W6Rb+J21u1v9ThnkuY7y4hVoTHPMuPnbMZZSxUFgjKD6Uzw38KtI8P63pGoWWpaxJFpH2kWFlNNG0Fus/wB9VGwNj0yxPua9BooAKKKKAOWnBufHoLMjQ2dqkYQ9mkZiTj1/dp+vrVK72eJfEQt9jSWMIeM5OF2A7ZG9y7ZiH+ysvrzV1i4ittb12a2kCXzyQQ7i3ER8vcJGHcIqyPz/AHSO9bmjwJomgS3LjypJFXZHIc7AAFij6demfVmb1pgWdQgXVdQjtA6LDalJnXGdx3cDrwPlP5V5h4w+xr4m1jxYizeTol3bm6lglZXeJFaOVV2kf89CcdzDjuK7fxBLcaF4YnnikhttV1CRITPIwPls3yjnuQOnbPPTNeU+KxcaDplnpdvaqYXd5xAvy+aw+4GIBLEuUABGSCcckkAj2qHT7HW9O1W2vY47vTr6QOAD8skbRpggg+3BHpXPfDzVLiy13V/Bl/CyppKI2nzHGJrU8KCRxuXgEYHUVd8I+GYfBOg2drpMDhTBHFLCZGkHnf38kkgZJBA4AxgcVj6NZyJ8YtSZN8ssdkkk1wxyGDkKVHPGTH0xx5fXk0DOtmuE028tYJZMQJKQrSMTtQxOw59BsYc54xVbTprHRZb2d1a2t75Vv2ZgzHe2EYdM/wDPPj3rF+Ib22o61oehyMd+p3RhKrHkvHHHI0vPYbXwT/tYGea1vHdrbz6XLBOrGE2cyFE/u5jPOOccDPtQBT+I3g/TPiF4fsRLFBeC2mF1BudlWQYKsm5eVypPI6MAcHGK8a1D4DXWo3Uo0rWLV7NCrPaatbMs0B64LJ8rZ2jJAGcA9ea1fhzqfijwp5cNpFHqulXZVvs7s++FySvysA2VJCgHHQ85IydvWPGni/xBrL6Bo6WWlxxNtv7+BxO8akZCRHO0O2G5YcAFsADJLCPBtW0DxP4U+1x6PqA1C0sWYhrKQr9nU/NkOckdAoB+ZsjAwVz69NfXWo+B7a8s5r2JdXlEM124Mc+oLGrPKfmy0dvHEkwUfeY4JxuJZPCvhi21vWLIaOiJb28QS3uIj/yzZ/39yu7nLYKo5yzEM/fjqfjGYotLg0bSI0+2XUD6PaxhDi2gZVa5cEZ4EQRQexYetAHnPwe8H2MHh+31y5triMGITZA2qUdchP8Aa2t0B6HBzhjX0B4L01LOGecLNG04jZYpOBChQNsA/wB5mJ5PJPbAGL4CtLabQNPto2mNrLFHNJFK/Q7MBQPcgk/7p9K6iCZdNuobW6GxJFEUM38Lbein0bBP1xx6BsEjE1fWBpvjgKYWffaRKxzwFLycgeuRXP8AjXxBHF478PPC6LdQWF9LFGw3E5e2XcPX5S34g+ldR4x0ZLi8s9VSJ5JYAYpArYJjJBz9QRn8T0zkLN4c0fUJ7bXLZTDfRGJ1uo1JfZGXzHtOcAh5AQBk7vUCkMh02Mt40iYo+6C1mDuTxl2ibA9eAv0xWn4gheUrLGF3wnClfvHcrBh6dDn/ACKltDNLNdamlsxLxrHbxP8Au2ZRk5bP3ck9DyAB34q3bWmbbF6I5JnJd8D5QSMYGe2OKAOW8SWKeKrI29pNFaeItNK3en3PJMUuzGe2VJLIw7jr2qx4M8WHVVGn6zEllr8A2XEAPyO6nDGMnqM8464KnkEE0fF0k0NpHrmgwvc3OnytKLccNI2CHiOcbcqz9ehKntUut6dZeJNNg1qzRnWeONzG4wQUbKkjqHVsg85H1WgDtqwr3QBHPNe6FL/Z+oSN5j4BMM7f9NI84Of7ww3vxisTQvE1xaqsWo757dU3GQ8yx4znI/5aAAZyPmAzkHBI7SCaK4hSa3kSWJxuV0YFWHqCOtIDL0jWftVy9jqEBstUjGWgZsrIv9+Jv41/IjuBWxXN+PNPvbvRGu9Hb/ib6eftdmhOFllUf6tu+GGU4P8AF3rU8P6rBrmiWOqWgYQXcKzKrcMu4Z2n0I6EeooA0KKKKACiiigAooooAhtCPs6AAADK4BJAwcd6mqOAMFbeMHc2PpnipKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiisbxlrsPhnwtqes3A3LZwNIqd5H6Ig92YhR7mgDj7iabWPiKNPePGn287kkMP3u2OJpGI/uhjFHz6yCupvru1tIV1TWliM0YLWsCfO/0QHG5zx0HH5k8L8M7RdO8OTaprlyTdXYEl3cMD90sXZR3zJK8hAHJUqPSny3rXWuX+p2ZUarNGIOCipbRDO1Xl3E56kqMc4HbJYit448U6xpxjvbq3iWaX9zZWKyI4iZhnfM2RtHAHGe45zXI/DKCTxX8ZGu9auIr9tMtftqvlT+9O1IyFX5UUAuVAJ7Eknmug8X22kaD9kuBbjWNZvQyW8SIZprhyN3mEZBADHOVwBu6c1k/AvSNY0bxnca94gMQtvEEP2O1ZZS/wC8jG/aMgHBAlAz/wA88980Ae5ak0j3MSxg+XADcSY/iIztT8Tz+A9a5n4fSZl1G+u0gjm1C4Zklz80oV3ULn0AUYHufWtfxdObPwzrtwokMnlFVCYLZKgDA+p6Vzeoab4k1P4fW9l4WurC0vJIk33N5GzNufDSOhHRgSSMg8jt1pDJRYR+KviDealtb7JolpLpkDgkGSeXa0pB/wBkKi/Ut6CuWk8Ra0vxam0PVzbmB4oYY5SgUR+YrFNhzncXUhufm7DgV6hoFhp3hnTNM0O1kVNsZSJXb55ioy7n1J6k+9eKfHkXl18R/D2maLGlrq10IfLv0Yb4wJSxYg9kWN2zyBgevLQjc8Savqk+nx6V4btItOAla11XVJl2xWqpnzGjX+LBCnjgsyjua5Lx6i27+H/h94XMtvc6uVkv7hyZGgtGb5vMI5Mku0lzkcKF+7jHbzpb2k1rp1vbSPp9tE9zK0jkNKEbCq3OSWkY8/3i2egrzDRY/svxm8VzaneO0jzmxc7d2crHGFX0GZDgHCjaM9gWFz3/AEGzSx8KajLaLJb7o3MTCMKwVFwhHtgZA4HOOleb6bdXepeNr3UtSRmWwtvsKPGcItwy77kgH0dtn0iFev6nKiaJIr/KGVI5Af4VYgHJ9lJryfwK8F74S0+/n89Jb8zXZULu3OXeV3wByFBAwe5X1pLuB6H4YsYNMtBcspEFughhHLM3QE467jwMdck+pqh4k8faHpUjW2t6no9kTw9tcSGaQE5IDogO0nB456Hriua+JvjhbOI+HNAnkj8TT22VQsAunq3JllfoJSpO1c9efeuV8EfDnVNe23V/HDp9mGwztGd02F27ghBBBIVgSx6556UBc9BtPid4YWBVttd0Da3JxK644yfl288c9q4rxR8WjcXE8Hhjfcm3Yqbm6aSztgRk4RF+eThTklgOK3U+EXha1Lf2jrLi4KhdyvFDnAIBOQTuweufStaD4ZaGLSGNntNUt41Aja7s0k2gDs0WwDqccd6NA1OE8NfGApcxL4gglstNlVc6nps8k8ET5PyusisV4GeM/lzXq/h/xjY6lcTW9lf22rrEAzSWbAzRA/8APWHO4fUDn0Fcvq3gPQrizns5LbRxG2MD7W0QQdwIyrAD3Bzya87uPAc/hHUrbUNBuJdNuo3JtXsmWfzCV5RztJZWPOCMYUADODRp0BXPoh7e31Erd2VwMk4codySAdVYfp6iuU0uN/CHi1bKUu2kawcI5bKw3Qzgc9PMX/x5R3bnG8M/EWQ64ll4g0ySxvWdbaae2Iktp5iPlAGd6PxjaQc8rkkCu+8Q6dH4g8P3MNpMizSxE21wOfLkBDI4+jqp/CkMxvE/h6KWWWVtogkfzQQOYpMcuD+ZPtuHeuZ+B8F1pVprNtel3lm1IyBclVjDqWwEzhfmVs4xknmu20q/n8R+D7e8iX7PdyxlZoWH3JVJSSPnOMMGGfauR0O5+weJzbA7DeqqoX4/fIWZQfZh5gJ9T7imB6PqXlfYZvtDbIiuGf8Au/7X4dfwrA+HjyjR7q2mj8tra8kj2ZzgnDkfm5qbxfex/wDCH3c4VysipHtHBBZwuD9CefoaTwUS8OryMNrtqU+5MglSMLz9dufxpAdHRRRQAUUUUAFFFFADUADPgd+fyp1MQYeQ88kfyp9ABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABUF9n7Dcbbj7KfLbE+AfK4+9zxx1544qemyxrLE8cgyjgqwzjINAHJQXd5EHUeMNIuGU5PnW6ZUY4zskWl+2eJjxDe+GLk545ljyPwZq3v7GsMKPJbCnI/eN/jVS78M6dcsWcThs5z5rH9DkUAVBeeLUjBOkaJcHuY9SkT9DCf51GNW8WbwG8L2e3uRqoP6eUKu/8I5FHGFt7mVGH8TRoT+YUH9ar/2LqccoeO/DBegSSWP8wWdT/wB80CGSap4rwPK8M2RP+3qm3+UZrl/HPh3xx4wTTrVjoelafbzC4mjS7mmeZlHyDIjTAB5x3IHpg9UL3W7E/wCmQ+bCAcv5fmd+Pmj56f8ATP8AHvWb/wALM0G11mPSdYm+wXsiCRGP7yFgd3HmKPlOEY4cKQBmgDyrxqNX0XxhZaFqd/ZQxTWAfSRFNJbQ7wxSWNizMWkIKneeccDFdHYeFfEGoaJPBea8LNpoQIYrFlfBxw7uYssM7eB6DntWJ401fS/EfxM1KfMtzY2NlBZWt9ZFJY45GJllb8mjGV/ukZBrtdR/tey8OxyWDC5BH7uS0IY428M0L71I7nZg+g7U0ByOqeG7fwh4a1S+ury5uHeGQ/aZWhDltq4BIAP3gWHQ56dq9X1vRrceDYLGKSWF7RYjaTpgPHMpARxnjOeueCCQetfPPj/x/f6ppN5Et/FPp0yyqwyI5AFGCcADb0IxyDk1794n1CO/0mOG1lAtZbeO5eVRnKsRsCntnBbP+z70MDA+JVovhf4W6tHHcTXDSzRsHaURu0jOu47jkDnnGAMcd816JpVstnplpbI29YolTfjG7A6/j1qn4q0u21vw5qGnXztHbXEJV3U4KjrkfQgGq3gead/D0NreTie7sWNnNKFK72TjOD3IxnrzSGcX8TNQt9K8R6Tcx3ItbjzD88pOxjuTB3c4UEkEcd/asnS5JdV8X+N/EZC3l7YTx6LpSOqlYZWCswH/AAJ4wxyeEbscVe+NljBefDzWL8O9tPYtJcl0XBDR8kDg8PsTrweM1Q8OabLoPwt8OaZI4Oo3UP2+8nk+8ZpgSSx9QrPz/wBMxTEX4dIkuJHvxdQtZwSI7TXMhRZLa1Pylz2DSvLIx77R2rFbSvD3iTx5H4r0HV7i4sp5liltBZssTuQAZUchS4OEOFOedwOKzfi7banL8F7lLeby4UmtbW8kXMZMCpvf8DK+PpipvgRDaG2h02JpLiO1uUYE4ZPlXI5B4YMMnj+7wOcgHoHxD1CS1+EWqXkkm6f+zp5d/wBz5/KcjAGf4scZrgvBNze+H/CEdxcWwlMFiGwXBWH7PAZJFwOArPGF4PT1rT+OF7JF4TudAksbxYpI3dpo1whV7mKNVQjqcTZ24/hrC+Jfi2y8L/CrVI7opHqeq2htrWEnJ3yDZKw7gBctk9zjvydBmX8BtGvvEGmN4hv0gludYuZJpLqZC7SHeQ2VztGDuAIOQAO3X6Fazs4AkcwmvJEHyxn5wOmPlGFHbHAryj4EWt3B4P8ADMX2i2tbE2oyIpd0kpZS3bgZJP8AtfSvaIAqDbFEVTrk8Z/r+dAFFZ5Tx/Y0wUcDLRdPpuqpd6YsVwLqG2sVYruINmWcv7sh9D6Gt1d25txXb2wOaztXtbG7IW+jhcAc72KkenT3pIDNmDSzqs0umpOFAVms3fA5yCSwx9O1ULjTI7m7CwCwuGA2vHHFLbllXOAGVyvGehHNajafpUNmVSws3CkbkUbsD16EmqlrbaVcXKPo18YJFcM0Ntc+UoB4yY8YJ9ARTuB4V8VfCk2madc3sVlNBCGw0IjzLb7W3LLGys2egPXj2JJr2P4Y+KIPEmh22oW0ifablBHdxjICXarljt7B1w4PGRg96b4uS4nEun6lcWj21yDCrYch2xgI6A/xDI44PTjNeIfs7699j8d3Xh+dXjkliDxu/AknhndZCBgYJRnA4yAuKHqJHvOg3JsPGdxahwtrrEJvRCTzBdJhJVHswAb6o571zXj+wtrjxjp+n+XJA808Ey3CnBTMy5ZD2bI9Dg4NdL40txYah4f1YvGHh1eOIE4U+XODEV9/mkzWf8S777PpeqztsgntEWaCSUjCuhDhs9hlU/76oGd2kLzWoj1BYnZWDHbyrbWyrYPQ8A47Gue8ITqfEPii3jl82MXENwGyDy8QHUdtqL+db8d9HJpkF4Ffy5kRlXHPz4wP1Fct8P4BHqWsyx5KSJajcVxkrFj+W0/jSA7WiiigAooooAKKKKAGIDvk47j+VPqvbyM1xdKwIVHAUnv8oPFWKACiiigAooooAKKK574i39zpfw+8T6hYSmG8tNLup4ZAASjrEzK3PHBANAHQ0V85eGfiF4y0Hwbf+J9VTUtV0X+y7GSF9VhjgzezMiuY2RQTbjfnJB6AA8k10kPxT8SNbWNjcaTptrq97qosYLq4kZLXyjEZPMZclgx2lQpPJ5BoA9por538DfEHUrW10i61aa81Rxa65eSeXcsRKLeUlUC9G44UnpWpqHjbxJqMHgG7nv8AR7eLVdb09/J0q6dpBBLHMWimB+8vyryMAlSMcUAe6UV4/wDD/wCKes+KvFttbNosEOiXU91bLIHImtnh3EeZk4YsEPyqAVyOo5rb1TxvrMHjjXtJsdLsZ9O0Wxiv7mV53Wd0ZXJWNApDN8mBkj8aAPRaK8BtPjb4gPhPVtdutBsTbR6Ymo2jRysFyZo42hfJyxAkB3AAZBGBWonxQ8VWniUadq2k6IIIPEFtol09tcSsx+0qGjZNygfLnkn73YL1oA9qorwa++MWoy+Ib3TI7azuNIuI9Ujtby1MkMitbQyP95jknCYJCgAngtinT/FLxHaaBC2j6dps8dh4XstduZL+5laR1dfmQED5m4+8SOeuc0Ae70V47J8V9SHj3TdKlsLOy0e9mtYIbmUSTGZ5kVigePKxuCcBXHOM5APHr1zcQ2sDTXMscMK/eeRgqj6k0ASV538Wbb7HJo3iONBnTbjdIVX5iOq5PocGP/trXXN4i0r5fLuxMScDyEaXn/gINVtclg1fRruy+z3pE6FFb7K/yt/C2GA6HB/CgDkPEGhaRpljaal4YSO2guc3Js7ZSsVwrDLOAowuQRkHCtnB5wai0CG50jw9dT6Uj3Ft5hultpDuOCcuqsdvOQ2Ac/e9qrfDHXtVjmv/AA9c6JKxsgHghcxx+XGSVdQSx3KrhlBA6bc8MKqX58Q+HNQuIbSwszZkPMtrJdHzCGxxE6KDleTtJOe3SmI89+Ivhjw5qsi6z4ak1CL+05JJZmjlT7OzMpJR0baULMCvAIJ7givU/A7x6X8P7B9SZpLeOOwQFjkpbSxoqhj3C+a659Fya8E+JWkytPd3+mXc6yzyLNe6ckQkERU8yEbi6FQTkEA89a9r8D283ib4O6LdfbJJbWXSv7Pure2jjy4iVkHzMCQQynntuz2oA9Jt49Qu782141sLG1C7/LyzTv1XOfuAAAkc5JHIHBo6LqkMf9tGKB0Zr6URRgFmldQAxA+oz6Y571T8P2k1x4TTVb691KW4lgNwY0ucZO3gfuwuTgAU34W28mneH40ljkX7ZJNcM0js7792OScjlQCPx69aBnlnjKe+8R6Xa+EY7+2CX+qQQ3IhjbLQu+4KpBwAyrLLk4wPlxXp2sOt5rMyKUjtbe1fbk8FmJhjXHc8TY/CvJPBdpdt8eJZJo4Rp1nb3N/5qAbXlB+zKz474O7acEF2r0pNxu3UAiKHULVGOR86wwpIT1z/AKyQ8c8/WgRpWyxsZNPmQX1pdTzWk1u/IkBZi5OMjAU9OP5V454Pvr7wj8SrjSrXS9GsfC0l8DFeWqi4+XzQBEJckh8sNyk5GCQBip/HfiDVNB+GsGkaP50Gpa7fSWTTBSXVNqmVl9z0z6NnI7eg+A9It5PA1kqFXmL2j724wY5IyiqBnA2qM44Oc4wckAsfH1PM8KMrMqopidmaTYFAurf5t3bHUe4FfN/xxt5L3x5ZTSRyXdtLpkchZF5SSSRl3Y9dx4GRnFfRfxyhnj0HVrjczWosFk2DqrpcwEkE8AFeo9q+Y/Hd5FrfxRmiEgeGz2WYeFh5a+WGYkDnKByMn/GhbAz3b9nq7jufDWlXUOmi5vbQGxnnRY1kCrlVJIbONu3qO/417bI2oyq3kR29v6GUmQ/iBj+dfH/wy8XP4U8UJDb3Maabq5V0lefaqzAbcYBKgMNpBYenI7fU2m69f3Nstw9rbpCBlgWm347HHl96BmykOpZJlvLX2CW5/q9ZWrXsltdLFNOWwpZttlcY9RhkO38K0V1eNlTZDKWYZ+YeWv5vgkfhXOarquppf747GwlJAjVYdV+cqe+xtq557En3pAaFhq1pOlsGvbVLqYnZF9qkXeueoVgDn2xxWlfNBaWOJX2zsuVO7cxI9CSM4JHU1iQ61Eqn7RZXrAfeWW3uCQ2OgAVg3HocVnX0+l2dvLeXUMdiqgnBR4yzegSQAHueBTFcwvEOrL4Y0PUdQv7hJtOsYGmjUu0oZwPlC7pztbeV4II6YxXy/wDBp72T4s+E5iJlea/YvKM7WEiZOMjjh29ua7j4ieOZfGk39leGpy2gWLCW4k8s/v5SG2rsICkLjPI9+1YPwcS5T44+GmuCht55zIqxuCqt5MgPyhjt5U43AHjIAoA+p/ja9zF4Dkks4g7RXtpMzH/lmqXEblvw21D8WbKG+09NOlSVjqv+h/JwAHwhye33h05+WtT4s2a33w+1mB2dVMByFOM9v65+oFUvEUzaj4d8Ham2GzfWE745HzlRnP1YGgZ2E9qv2OK3iPlwx7ep6KvI/kKz/CUaHTGvUV1F9Ibgb+uzAWP6fIqU/wAWybdDliyyi6kjtC69VErrGT+TVrRosUaxxqFRQFVR0AHakA6iiigAooooAKKKKAK1q4ee7I/hkC/jtX/GrNV7FNscjHq8jt+vH6AVYoAKKKKACiiigAqvqMdpLp91HqSQPYvEy3C3ABjaMg7g4PBXGc54xVisbxpp19q/hLV9O0qe3t767tZIYpLiISRgspHzKQQQc4PB69D0oAzNR8TeDdL8KLJPf6T/AMI8jR2AWALNAu7CpFsQEAYwMYwAOwFZ1gPhtcNqvhyzs/DXk2Qiu7yzFnEsA3KWSTlQjfKCcjOO+M15tB8E9efRPFMN2+hm61GbTbm1jaeWeMSWzP5m9miBXeGIyqngkYxW9ffDLXhqnim90eDwvYy63pVtbxt5Rf7DPHGUdI1MWDE+cbuDgA7TjFAHoekw+DoLGPUtIj8Px2dkJES6tVhEcAcgyAOvC7jgnkZ71z1tqHw3svEy6db2Hh62mMEesrepb26QM3mPEjiUdZA2/B6jJweTXD2Hwa1+K11RpZtHEkuq2GqQ2T3Es8E5gjZXjmZo1OGLbshTyBxjitHVPhLqGuX+tX2p6b4Vt5Lvw7Pplrb2ys0dtdtNK6SgtGMcOpLgBt2cL6gHpb2HhLT/ABNDePaaFa+IbvPlTmOFLqbPB2tje2enFVb/AMSeGdJ8Z2VgPsjeINXk+yu1ssbTDYjOomIO4LjdjOeteXan8F9ZuNXjumn02+jltNPilE11LC1tLbRqmYysbF1JXcBlDkn1rS0H4Wa7pnjHSLxzob2Gn6zeak14HkF5crOrgLINmNylgPvYIHbGCAdzLo3g601m902TwzpEJu7I3V3O1lAsUsYkHyyHq3zYbkY4znNQ+J9a8DaLpGp69qEej3MdncxXFw0EUU0puhhYmIHPmjgKTyB3AFZHxF+H+q+JfEWsX9hcWMcN54Xn0SMTO4YTvMrhjhT8mAcnk57Vy3iT4J3V5barBpMOg2sV3pmnWyoFKKLiCcPJIQsfdAyhupzg4BoA9D0208D3tzaX8mjaFZ6vqiNMsd1bW6XcokUqxOMltylgcE5BPrU+qjwpp1hKRpWmXSNDHpskFtBCzGAOEERU4HlqTjb0HYdq8/8AEXwfvrrx5d6tYf2ZLpdxNaTxxSzyW8lkYFVVVAkbBlG3KgMmM45qVvhBcjwjq1pFFoq67e65/aBvQpDNbfalmEbSbN2cL93pnv3oA9Gt9L8Ir4n8y2sdBHiKCMfNHDD9qjQKAOQN4G3A+lGt+MdG0s6SJbhbkanfRWEJtmWQCSQOVLc8L+7bn2rgdH+Fuq2Xjm31CS40v+z7bWrrWVvYw/26fzlI8h/l27Ru5O45AHyiq/hz4QXOjeDvA9hDHosWr6TrMGo6pdQKV+1JF5+Bv2BnYCUAbsAc8juAewQahZTmEQXdvIZwWiCSqfMA6lcHkD2qzXi3wZ8FXWk+O/FN/dw3UWk6bPNp2hxXEJjEcMkpmlaMEcruYKrjqAa9poA8v+KV7eeFtY0zWtKjSaWaUgwN1k2puljX1LxIcL/fhjx1Oem8WWSa34YmvNKKXTyxJPApQSxzrg/LtPUMrsPxrmv2g7A33g7TmWa5tzb6rbSedbffjySu4DvgsDj2q58J7q4htpdKvGWGSDLC3KnCnjdsb+5uJIHoy+hpiPCvipbTeGotL8QadplrNpDwpDeF7bIdf4JCpJ2OBwSDXQfs3Xzp491DRbG+3+HDYNf29qp+RZWdFbGeeA2D2yM9eT6Xf2c2mazqmk3IZ9EvQZbZZ1LwruB8yLB+VRkkj2NeL+ChF8L/AI5aRp91O8eh3UL28D3DAbGl25AbuokVR24YHHBoDqe7+DRqSaBq/hm9YPqenb4oJXXaksRyYjxnAAwPXjp2q34e1NZPCVld8R/ZLiVJ1Z8FdhkVs9z0z6nrVnxtocGsNZLFcz2Gp+aqR3trIUljXliOCNwO0jByOSetc74Gvf7L8cavod3LILq6Zrh42gZVlcADzlY9QygA9spx1NAHL+CrzZrvjKRD5sUrxi3kcYkzcGaVlbAwfuphh1BFb07w2mhR3FwXMt5qV04IAOSZZAhPccKi/jVTw1obWuq+JLfT1gtVj8RRR8kECFLcSqB6f6zGOwrQ1GZZvAmlXOz5TJEzccjdMQcfmaLgcF8RbFRpnhe7wqR2OvzJMjkHAkgZioPQ524B6cjrXXfB2+n1XTb91ZE+yyNHZ2iPlZI1KO0nI6sSFB56ZJySawPifol/q3gPxLDbtu1CzeHUo9vAlaAsHGByrGMLn1PFY37Pl5eDSJPEGn20bQzlLOaSQk5lB3MqgHpt2jPBz60wPQ/iPdXmteC73Sp/Jiub19Rs1BQ5KxxytGwPQcpGDngk46kV8o+BlsoL7Tb7U4d1y9sWiiOxVbLCNWyRww27xk9iRivt21Mdzo2orEyTbZ3uF2nIkRm8xcHuGU4yPf0r4ssfC8tv8SLzw7DbyPaWl9JBJNHht9uGyikcEEhsbif4u+KSBnT2HgqXxRp8NtYxbNLildhqMsZkto8AYRRgbnK4DdAGyMkgmvQ/C3w1utMtxpuh+JPE1reMCHha4eKADngR7SAvHUtz0yetejeDdBjjht3tdOt/s8CeVEt7Pv256lEVSq+mFwD7V1M2j+a372PSQo5BW3ZWDY4IYMCKYbHlEHh3xppTSPD4olVQCPL1CwWdRzx8+wNtHA4YeuaSfWvFGlAvqmgeHtRaNDJHc2T3JDc4B2bWKHp3+nAzXrdpb3tqm1nEsY7xXDE/lJn/ANCqlctY2szX5vIra6UbmF1CkZIAx97APAJGQe560h9TyXxF4q8UtGVttI0mIA/MXs7uZlIBJAUsq7u68ndmuM1bStf1++lt/wC2del026iLp9isYtLjUY+ZJGchSOnBck88GvpaOefUI5DCgeIqRvDKcnGAQRIR6HJFcZrTXVjZ3k832Ty9uwSx3+2UD/bXkHHHQ/hTsLU+XtX8M6j4NtrCw1N7ebT7qMyfabZl8ozYP7oueNwyCcZyB8ueasfDJ7q0+JHh4SGHbDrkQkePdn5mCD2wVkHv29a911/w7J4w8DQ2P/CPWvktEWmvJI9kkLA5/cg+Wcg4yCFXAPXpXzx4QluLH4taFo5843sOtwRzvIqgybbgdcZ44BxnsPQUCPuDx4yJ4T1AzFvLKhWCnBYFgMD864axu3j+BXhiecMzx2loCFyMlAME+n3Qa7H4kyJF4Nv5HKjZscbsY4cHv6AE/hXMah5Vn8Craa/Z4vL0xLkqrcgmPcR7gZP5UijsvFxzp1njodQs8+4+0JW5XO+JCWtNEth/rJr+2x/wA+af0jNdFSAKKKKACiiigApHYIpZjgAZNLVXVJBDp1w7Z+4QMdyeB+poAbo7b9KtJM58yNXz65Gf61cpsSCONEAACgAAU6gAooooAKKKKACua+Jeo6hpHw98Salo0kcWoWenz3EMkgyEKIW3YIIJABIBGCcZ4rpajuVha3lW5EZgKESCTBUrjnOeMYoA8Pn+K3iLT9E04SxaFPfReHP+Egu55pmVLlAcCKLAGJT1PBALAAciu88ceNbnQ/h7aeI9OsElnumtAltdOUC+e6LhiASCN/oelW7PS/AeoWFlb2Vj4YurK1mItIooYHjilPzHywBhWPXjmtPWbzw7cWTJrVxpMtmr7yt28bRhkYc4bjKtj6HFAHmWg/E/xNN4jsbDWNL0ZbU6/P4euZLWaUuZkj8xZEDDATBAOSSTnpXP3nxo1K9ttYi+zWs2mzaVe3lje2Ly27nyeOCx3YPTdtXkcA17LPD4Ts7iOS4j0K3ne6F6jOsSs1w42iYE8mRgMbupHGaxNJtvAd9ruvWMHh/RoL21uPsV28thCn2h5ow5UHGX3KRkHrjvQBxXiD4r+IdIttdn07S9MuNP8PWem3V011cSefMtygJCYGNwOeSfwOeJX+IniHSdZ+Izare6R9g0i6igsI5Vcuhk8vYNqLucEOc5P3yBkLyPU10Tw7fwXyLpmk3MN0Egu1FvG6zCLhEk4w2zoAfu9sU+88M6De3V3c3uiaXcXN3EILmWW0jd54wQQjkjLL8q8Hj5R6UAeSaH8TdU1270ODU7L7HeR+JjpUwtZ2jR18gyAsoLZ64KkkZGc1f+HnxP8QeINV8IDV9L0u303xNa3ctsbWaRpYnt8bt+4AYOeAPzr0qy8K+HrBYlsdB0m2EMwuIxDZxpslC7RIMDhtvGRzjip7TQNHs/sH2PSdPt/sCutn5VsifZg/3xHgfIG74xnvQB47468e674S8eeM7u0ns7nTdMsLGc2N7OyBt7MGEIHAduOT6Dg54da+P9Y03UfEMMbLPcXvipNKszqUjCCyRrdX+bHPY4UEZJ6161e+F9Av8AVY9TvtD0q51KMqUu5rSN5lK/dw5GRjtzxUlx4e0W5t723udI06aC9k866jktkZbh+PmcEYY8Dk5PAoA8jHxi1e8sLFLKw0i3vmh1Cee4u53+yyC0fawhYYLb+uT90etZXxC+K2tan4T1D+wEt9FCeHrfV5ZriZluczn5VgxjO3HLHrkcCvbrvwzoN7p9tYXmiaXcWNqcwW8tpG8cP+4pGF/Ck1jwvoGtSxSazoelahJEhjja6tI5SiHqoLA4HtQBf0x2k020d2LM0SEk9ScCrNIiqiqqKFVRgADAApaAOS+K2mpqvw+1m3dnULF52+M4ZdhD5HuADWHHE0OiaVqVrPGt3YonmNIxZSnIDE9cAllJ7IzHsMei3MMdzbywTKGilUo6nuCMEVwPwvmS40KSwvlWWXT3k0u5aUfxqdhHPJVsD6nnvTQhNa+1+NPARutPDRataTSgwqSkiyRsytH14bjjPBOO3NeK+M7ST4j+HBpOr38i61osnnN5yJvKBGDD+E4JC85ODnPI59p0y3uPDvjJ/KlKWMxWG8ibJEm75be5B6hsL5L+pCE+tcn8fNBjs5YPE+nzz27wSRxajCibo5YpSUVyM8HeFBI7H2oQM7rwPN/afw80HUYZjLfGxRomnIkdWCjdGTxuIKlSevFV7+4gf4q6E5BS5ewfBxw8ZDEgnHYgHr3NedfBfxEBrFr4Yu2VbqO9e+tPLQeWY2hfzUQjjAY7geh3euQPU2sbJfHtuJLyLzGsZVW0KtmRCVGR/D8oDDjnDDPuAcn8PtXg1fU/E1xpsouLK58SsvnFhyrWMY4PqCMYqleXlxN4A851jEVrNEE2nk4Z2YH061BolrY+FPEvibTdIU29hZ6xpd1sJLgCdfJbk89V6nn61o2/ky/27prKwS11S2JI5L5dwuAPYKOfQmgC5rWptpHihzOFaGWZo8FcBi2HXn0IZBz1ZAPWuT8ALF4V17xV4Uit5ZdFcrqmmxq+AIZcH5T/ALLhkJ/2a6bxPpbag0sW4vcS2cF1abQA6vGQjLnvklBnsZAeMV51qVv4kv8A4q6afCtuYtWgsAsjF0KQKZmLmRDwsb5J2feywC42mmB6f8Pr+z+12+lW9w4k0lnteMYntpPmgcjuvDJns6kcZIPhnxdsbvwn8b4L7TYAw1bZHzPJES0YAZdycrlfLO7nqfeu1sfA2tWXiy41vXILTX4rspbQLYTyQXVuVYlpLZvlUqD8zA4HoeObvx80WfW/AI1aO3fU73SJlnhmihPmlVPzRzxjBUgFskccZ+XpSA9I0CG/gtoVn03TNO2qCBFbPcg+/mrtB+uM1vRzW0xjV5dOMmSsitHtJbtgE5/nXC/Djxn/AGxothDd3N1Y63JCG+xsn2mKRR/y0jcD5lPpvJHQ9K7s3k/mwQu9nJNKCUimRoWbB5IBzQMtQQbrIRuLN5wPm2R/Jz/s5zj8axZDa6he3ujQy6PNe2qRvcWvlMrIr5KE4bIzg4NQePfFqeC/CtxqV7bxfanYW9nbxPkzTMPlXkD3J9ga8s/sDxF4JurXx1PC11qUZkl1WMBt89o+CyEqWBZDhxwPusBxgBK4HpB0z7LJJElu64wrxnUXIx2IDP09OlFxaNABObGwtbWMEPnlWXj5SxkVR36gircjyanZQajptx5FvcATrJb36hJgRkfejYAY9MVFbw6bc5u3mW5kiwJZGka4RG7BSUIPocYqr6CH6yqyWxayvpp0QY8myslmXGOi46f99V896/DaSfFPwPerAYb1dYt4GeVAksirIASwLsQB8oGOADycmvpq9vpTpsvkwRQW6phri8XZEB3wh5P0OM+tfPWnQxaj8UfCttBIzy3eqyX5d4UjLQwb5AMBQQMkEDOOaQz2r4vxNc+D7u28xY45YZgx4LZ8p8YBIzzS+P7WR/CVnpEXkp9txYGWQcR7onUEfXp+NVPiQiajregaSyCX7TdJG6M2AE3CV2A7nbCw/wCBfWuq1Ww+2a1pMrxeZFbGSQ5bAVsDacd+aAGzRm58VWoyPKsbZpdv+3Idqn8FWQf8CrZrF8NqZ31HUnHzXdwRH7RR/In54Zv+B1tUgCiiigAooooAKztYVpfsVuvSS5Qt/up8/wDNQPxrRqiJPN1loxjEEILc93PH6IfzoAvUUUUAFFFFABRRRQAVheOtGfxD4P1bSIo4JHvLdoQk7uiHPqyfMPqM/Q9K3aKAPB9L+FHi7TdP0+aC/wBFfUNP1iLULa2nLMgiWJoyjzpEjufmyMpxjGTkmsWT4deK7DxLo1u2maNqt1ONYuJJZllNjCbh0K7m8skNgnC45wRnvX0lRQB81Xfwq159XuPDVpa2N3b/APCMWmmPq+pRSCOMiR95gIUguBjC7lwNuTW/428AarpPhXxrqFsZb7UWvrHU9GNnG89yJrdI41LIF6khs4yArEmvdqKAOX+GXhxvCngbStKmO+8SLzbuTqZLhyXlYnv8zH8MV1FFFABRRRQAUUUUAFFFFABRRRQAVwNxKugfEUBwFs9VXzC2OFk4U59iQp9iR6iu+rlfiHp/n6RHqEMQe505/OA7mM8SDP8Au8jryopoGXPFunNd2QuYRI01urhokJzNCwxJHx3IAKnsyr71n2d3DfaUkt832mSz2iWROPNiJDxy4/2gqkjsdw7Vu6BcNPpcG8kuihSx/ix3/wA965zVIf7C1bzVt/NsZQ52qP8AlmTuljx3KnMqj08wDtkA8Q1mxPwx+Nug6hK0EPh1HdfOdQGVJgy7d3UgcsARxhsdQK948WZsJNJ1a0jT7PbT5mZDhRG+AzEDqMEnNcl8SfDdn4w8P3lhqLiG5t4iLadDkXNuwDd+GI2g+xXIxms34G6nqesfDO+0HV2W8vtNAsvLm+WRYnQGNnOcFdp4I5+QjkjJBHL+Pbye/wDiH8RbLT2CxyeH4bqKdTtVpLaSOT73fAkHIrq9btnhsfFmq6cXF5PBa3Wwng4kcrj/AIC361gSaXpWj+MNNg+1fbNTvrK8t7gzr809tNGxiwOg2+Sqhf7sgHaresXlxf8Ah/VH0dzPcz+H44hCGC4kLwgneeBjeee2PagDpfiBqR0i+0bUBEbq6M0lpbWqNtM4uSUMfv8AOsZ4xjGe1bnh3wrF4d8PyC5nS81e9mEmr34GJbmRsZRSOgztQLxhffmuMutC8Q+I7jw54rnlhhTT5Ijp2mou5rpmyDO7MBsO12cLg8KMnnj0vUCmlC2gthHthRrg+afvncqlifX5ycnuaANSythbK9xclPPZRvboqKBwq+ijn9TXy/8AEr4z6tb/ABUto/BqwxRxKEeSVcx30WN2WHUjHKkc4PH3jn0rxP48fxWtpovhyNWF6Srl1LBwGYHd0HljYe/7xvkHG9h5n8cvBU+i6HovimwgkuDpE7RX7u3zyiRv9a5X/byOnAdR0WiwXO10a58MePXln0118NeJ2dfOt5I1mtLmTAZXaM4ViQRhhskyevFdJF4h8TeErVk8VWksEMbYF/bq99ZOvq2P38A/3t6j1rivBOhaF4t0K2m00SLPbupd4oP3Uy4wNzIGBwQeGHZcjiu20vxG3hzTryO4vbhZrQSyNBeI7xvjLAK2AY8gcDkY7ZosBleI4b3xd4x0HVtR0xLvwpaRPsutOuvtce51+Z9iYYggbc7cgZxyTjprnUNFt9KdtLuFtXlfbaXNw4Kwsv8ACWLZUHBwr4HOCMVhfC3xBpM2sXOtafaxadpfiKGOWSFdhS3u4sowLJx8685IHKE85BPRXfwv0CUtPou7TvNGCsDbomB6gLngewIHtSGYnw9istG8Yar4G1C1t5FSH+09LL2239w7lZIyD2STO3k/IwGeK9PW3uVIVLmOOIYAWOEDA545JHp27V5Pr3hPVtJ1jR9RtUu7iSwWWKO6tlEgETgBklXcshGACCpbBGevW5Z+L51meFdPTXDbrulisdXzOmOctbzsjd+9MR2viOOwg02e61ORbsQ5J89/kjx1OACAR64z715D8HLCHX/izqevQRhLTR7MQIQ2fMmuPnyOOgjAHIB+bHarXj3xFq17o0i6B4J1bTLyV2KXM9pjyThgZXGxlHBzwdxPGRXSfAizsvDvw6gae7jl1e83X98GlBl3t0VgeQVUKuD0INIZf0+Y6t8WS0jF4bG1mkhw25QSUiBB/wC/nHvXWaxfPa6fqF3BteZF8i3A5zISAAf+BkD8K4f4c337rxRrlzhCtx9ijiCbVVkJbag6/M0oHuRXZ3CiXWdN07KFbdDezZHLEfKn5sWb6qKYGpptqLLT7a1DF/JjWPcerYGM1ZoopAFFFFABRRRQAVQ0lVYXV0G3faZiwP8AsgBRj2wufxp+rzNFYuInVJ5cRRE/324H5dfwqzBEsEMcUYwiKFA9hQA+iiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKR1DoVcBlYYIPQilooA5DwmW0jVbzQZXZkt8zW+7JIhdztGe+DlfbFdJqthHqNk0EpZDkPHIv3o3Byrr7g81j+LLcRTWGr7zGtk585x/DG3Vj7AgE+2a3rWZbi3SRSp3AHggj8xTA4C0tzcAaJdyNa3sEpNlNjiJ1wzRA91I+Zc/wEjqhrzq8SX4Q+PR4iltpf+Eb1h1ttUKsXFoTwjc/wBjkezMOu0V7T4s0aS/g+1WG8ahCo2hHCGQA7gATwGB5UnoeD8pYFmhanZ+IrH7NqEMUt1HlZoZ4QAxHyk7DnHoV6gnB7ElwPFPjnrFjba74L1Kw1OynT7ZBHJHC6EbEfazBgc4KyEEc4GOlQWd01/ceH7Sy8pNEukeTUFIKgWkV2GJzj7jfKgGefpmtTWPhL4Cs7y+bUfCOuWUCndv0+5aWKcEnIVEbdxnptBx+rvCupeHNPik8P+B/BusXVrdkQ3FzdRSszAEZjcuDtQjd1IUZPGSaBHtdm0t1b2c13EkUgkMiRqCCiEMFyPXB5964z41X1pa6RYx3e8ebMU3Q480hgVEaMeVZmYfN2Cs3G2uutCljp95esRyzbSBkKinagGO2AD9Sa8K1XWpdZ8cpr2p3og8O2tx/Zu7aSoLHa82eQCsiom48fK5+oM2fg9bi4t9W0ia0WDXreQNK7AiP5flVY2A4RQqBeOBg8ljn2HVNMtNe8PXml3yCS2u4HtplwOhBU9utYGtxQeGdQg1YssdrJsgnmbOPMJCozkdFO7bnoDiukhmUKl2ilYp8eYP7rdM/0P0FAHzd8ORL4B8VtoWuuXvLeV7QXFqRC7hstEGH3WDgqylup3LyVIHsfjWxuNb8J61Y7UmlksZ0xNF5coyhAPQq/1GBUXxW8DN4hSDWdGjjHiGxRo41fHl3cLfehkB4YfxLngMO2SaPhnrLajpBghvyGgYwNb3Slnhdcgxtkhhg9ASTjuRzQI8p8D3l34V8B22tXMlxe2VpZuojkjjIVY8qsa8h1ycEOBg55wBmuF8O/HTVk8XWk+qPBp2j3Q/eJp6eX5eScOwbIYgEDcRg+hrt/Ca2Gl3HxA8E+KpRut3MsJjsnkYQY4YspZtpUpxjjJ5JNY1l+zksPiKzfV9eMWg7gXScIsrxrzsDByD6ZA6c4HAoA90k8dS2mtadpltB/b320kLLaFI3jUJu3MrNgj3GPpUmrTeCfF8a2viexs/PZPli1OERyKP8AZc8d/wCFq840nS5bD4mXl+z/AGfSbZAkLQXMmIyxG1GJOT8mRgDCg49DWv4n8R6PnUJb4XF1pkcaSq0yOUlj56Fz8zYzgbTkqQO2SwGrqOt2nhC3stL1/Wtb0VLWFYYNRhtvPs5414Qs7RuqvtA3A45yRwQa6DSNT0/X7ON4dV8OeJIAAplBQOT743DJx0wK574S+EX0vTLuS+vr7T9R1Cc3C6dDdb4bKP8AhiVCChODlvl5OccCo9Y8KeHL7VLmVtIt7maHd5t9pwNlKpzhVOw7ZnJLAcYyDQM7D+zbTT1aKHSr2xjMnm77EiSMPj7wQZwffZVqxETX097Z6lHLcSqkTC6jw4VckLj5SOWY9Op+lefTeBdU0e4iPh3xbq+nxhtxttSy0bk4481PlHI7qep9a3Yr/wAaWdszXtmt6qglZIFjuUf0A2lHxyMnb0HegDv4HuCU82OLaRksjk8/TFT1zvhG+1HUIWlvtKSxhCgIx3Ru5BOf3ZGVA46n9Oa6KkAUUUUAFFFQ3lwlpayzyAlY1zgdT6Ae56UAVjsutVx1WzGfYSMP5hT/AOPVfqppcDW9mol/17kyS85+duTz7dB7AVboAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAjuIY7m3lgnQPDKpR1PRlIwRXL+CzcadPeaJdNvFq/7ph18sjKk/UfqG9q6yud8Us2ltDrkRZYrbC3wUZLW/OWx32E7vpu68UwOirB8RaF9tjluLAJFqO0lXyU3MBgHcOVYcDcAeOCGHFbiOroGRgynkEHINOpAebnUJ9Xs4YNVk1DTNXs5EV3hKq24naFljyVYNkkEZVv4SD8oyZtQ8QabqtpFfa/4di0uF/MeMy+WXQk4YRoiknJ6bsZHOe3ovibw7Za/ZvFdRr5pQxiQj+E9Vb1U4HGewIIIBHDeIbaQwvaXrRW95bzRPBdzgvs+ddokI5ZGI2iXHBwHGR8zAb8SNel03wHsgjubTcRDC8iANLIzbYyqgk43FWP1HvW14N8KWtl4Ngs3hhuIPsogCONyumBubn+9ye/X3rnvGEU+o+P8AwJoGoJFHCpuL1442Lr+7BEQyRyQSpJwOfTiu+164e3ji06zDxPNHtikTqhBXp64Xc2D12470AZ2gSPAr+H9cjWa0kUpZyyruWeLBzE+eC6gH/eXB55pdIhm8PztpmozGfTpf3dnNIxZmXn90+erqP4v4lHqpzak0251BbmOeQQJvUxohIKKBkMD2cP0I4wBx1qezlF9FLpGsANdonzMvyiZR/wAtEI6EHGQOVOO2CQC/ayNbMltO5dW/1Mp/iH90n1A79/zrkvFnhK6Gup4l8LyCHVFXbdWhAEV8oxgt0xIv8LenB46ac8smjEW+rES6NIQqXfIMLE8eZj7oz/EMAH07WrvULq2l/s+123FyU3C4f7sCdmlxj8APvYPTBNAHhHiCSSTxHB4w8J3ss3jCyT7FfaVfHyGmjHVHICFHBK7SSd+QBnGDpeEPG3hh9FhaxvdXudcunW1l0yS6MZE5+URmPP7sZByw4ChjuJ4PqereCfDeoRJPrOmpqF0WDPfFSJycdS6YYDgYA4GBxxWPL8MPh5NdR3smnwC6U5Wf7bKrg5yed+aBGVc+N9E8GWFvoNhL/auuXQO+PT4zJJLMRyVjHOBwBzwFAJ4p3hP4czahqsOt+LrS2tvs7CSz0uEhljkH3ZpWH3nHZclVPOSea6/w3pPhXw4kieFtJtIncfO1jAGaT/ek7nP95q1bzUHhjja4WS3d5MRQR4klmxztAHA9zngdSOtAzM1jS544GK3ItbSJfMkniOyTHdEHYYz3zzgetVPDO2W6ed7QQRxykRWzcGJgAC7Z6NtC4B6DPriuhjs57u4E+pFREhDRWqHKqRyGc/xN7dBjueazvFETanMmk6fI8N3KA9xcR4/cQ5G7Of4mAKr7jP8ADRcCfQ5jq1/c6oGP2Vc2tsmf7rfvGI9S42/RPetSSygbonln1jJQ/pVXTtLj06CK2tFEdvEoRAv8KgAAfkAPwB9a0lyFG45Pr60gFAwAM5ooooAKKKKACs+Y/bNSWADMNsRLIT0L/wAK/h97/vmptTvBZWbS7S8hISOMdXcnCj8/yGTSaZafY7UIz+ZM5Mk0mMb3PU/4DsABQBbooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKR1V0ZXAZWGCCMgilooA57w0f7Lll0K4YlrfMlq7HJlgJGPxUnaf+An+Kuhqhq+mRalHFveSGaFxJFPEQHQgjIBIPDAbSO4Jq8hYqN4AbuAc0ALVHVdNh1GNQ5Mc0eTFMgG+M98Z4IPQg8EdavVQ1S0nmTzdPuBb3qD5GcFo2/2XXIyPpgjsaAPMNYjn0T4u+D7zWfMTT3judNhnTiETSbWiUnnG7ayhT0YDBI4HoGuxmPXNFu2KiEPJA7NJtCs6/Icd/mUD/gVT3c9rPbS2uvQQpGR83mDdE4x94E9PxxiqPiW8sr7TlsbW4imuZJYjGImDmMo6tvPPbaDyeTgd6YGv9lkWG3eBUgmjyTGpyjA9Vzx35B9fyplzBBqlsWjJSZG+WQcPE4/z9CPUGrdrIjRhUI4HTPb29qzbq5lvLmaz0plRgcXN0BkR9tq9i+PwXjPYFAUX1m6lvDohSIakTte42Zg2YzkZ6uR/yzzkdT8vJt2GkyaLA6aW3nRs294p25JxyVbHBPXB47DAp0lpBaWTWr6c8tmG37oz5jls5Ln+LdnnIyc0lpczIrLZXCagi8+VK+yZB6ZI5/4EAfU0AXIr+3GEmV7ST+5Ku0Z9m+6fwJqz5cE5WXZFJ3V8A/karxahE5KTRzQPjlZkIH/fXKnr2NXFVVUBQAPQUAUpUv5XdI3gtYRwrqPMc++DgD9adYabbWTM8as87/fnkO6R/qx7e3T0FZV7rWqpfzW1l4dupYoyALqaeOOKT/dCln491FVprrWbwKlxJHp8T/eWyQ3EpHfDkDb9dnHsaANXUdSkNybDSwst/wAFywJjt1P8Tkd8dFzk8dBzVjStOh022McRZ5HYvLM/LyuerMf8gDgcCq+kotpbGK00+WKPcWLMw3O3dmLHcSfU81pxlmQF12t3Gc4oAdRRRQAUUUUAFFFVdTS4ltGitGKSS/IZAcGMHqw9wOnvigCpZv8A2lqL3WAbW2ZooD13v0dx9OVH/AvUVq1Fa28VpbRW9ugSGJQiKOwHSpaACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigCK5gW4iKNke4rPXR0WJkSdwGGNu1dg4x93GPwrVrEaaTXHaK0do9LGVkuUbDTnusZ7L6v8A98+oAKoSa/mltdOu5RboxWe8XAKtjlIjjlvVjkD3bpr6faSWmni0QxRLH8sTRjt6kHv1z1z1q3BFHBCkUKLHGg2qqjAA9BSyOsaF5GVVHUscAUAVjcSosgKCVkOP3fXPuO3bpmq15BaX8Sf2hZozr91jztPsw5X68VavLOK72uWeOVfuSxNtYfj3Hsciq1xa6gEUQz2s7DvcREE/ipGPyoAw/s09pIZNOuLmFSAqoZWmTr1G4kMc+hBPt1qknjC8m0nT5JbN4L7+1Dp93HDhgNqM5ZSw+6wCnnkbsZyM1t3YvwmL610mZWOFG9lJPpyp5rMs7fSr61MMKnSLi01ISzIxOHn2dNzY3hlOPpxgYxT3A6ZzYXyq8oik2lcbxypPTr0q0vlgkLt3IMEDqK5+xt9RuMybLGJHODiUykjOD2AJ/wA9ea1EsJFCHzQGTABAOVHoDnp7HNAF2GaOZN0Tq6+xp9VBab3LXPluR9x0Qow/HNTQw+UABJIwA6Oc/r1pAS0UijCgZJ9zS0AFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAjsqKzOwVVGSScACmefFtjbzY9shwh3DDfT1pLy2hvLSe1uoxJbzo0ciN0ZWGCD9Qa+efh94c8UQa9Do+saVfyaV4FjvW0uZwUGpSyEiDYzDaSse4AjIUkZoA+i6gury2tDCLq4hgM8ghi8xwvmOc4Vc9WODwOeK+YLLV/iVb6Vrrw/8JPFBLpdvMftltN5tvKblUlSF5lG6URlvugAn7o4BrZ8Pa1rus6qsej3Gu6lpdl4vsYQ17C0k0Nr9mcyGTK5QbiMk4IyM4zQB9G1Be3ltYWslzfXENtbRjLyzOERRnHJPA5rwfRT4+tbrw/q883ii8muL7UoLzTpU2RLAokMBwU+TJCbXY9x24rjL1PHus+DvF2n3ll4ou7W80SCaO1vLO4d0uhcpujRnXLMEyTtAB6gYGaAPrKivPPjbJ4mi8N2B8KC9wb6MX5sVZrgW21s7AoLfe252fNjp3ry2613xPaHw1perar4tlWe01JiLGxljvZ9jJ5OUK+ZxuxuIXIGTxk0AfRy3ls169mtxCbtEEjQBxvVScBivUAkHmhby2a9ezW4hN2iCRoA43qpOAxXqASDzXzp4h0jx3rnhbX7LWrTUZL+TwpaFvJgH766WVmePcFwz7QNyA9enWm6noPiKe91nVtBn8Y2s9t4Xga0mNu0U9zcJLIfJcGPLEf3Bg4IznigD6UqjBq+m3EkEdvqNnK9wXWFUnVjIU++FAPO3vjp3rwqS7+IsnxAtpb6bW7WD7TZvBHb2MstrLblU81HCLsRsl9xkKle3AFV/Dmm+LrCx8OW2nadqVtIT4jaQtalfLkYk2xZmX5NzHKkkBvegD6Lor56g8RePdR02b7Pp/im1ntfBbo5uLB4zLqqPGCycfM5G4j1GSBUE9r8QbK41SW31Txfciyn0i4tY5Ity3DTY+1KQIxuRMcoMBcnIoA+jKa7rGjPIwVFBLMxwAPU06qmoWEd/wCUtyzNAjbmh42SHtu9QPTp65oAziJNeODvi0gEgjo12P6R/q30+9toixoqIoVFGAoGAB6UtFABUc0iRqPMDEH0Ut/KpKKAKnnWcSsRNFEq5z820D+lV7u8t03H+0LdDjhWlC59if8A61aTAMMMAR6GmmGMnJjTPrtFAHA3/iidLR/Ktlkm3+Ukc9wkaPx1EwLIR7Nk8dBVvU/CdzqXhBrWWeB9Te5S/Lx/LEZAQdqnGQMDAbGf4utdPqd4lsI7dFDTzZ2JtyAoGWY9sAeuMkgd6r+EoXt/D1pHJwwDHZv3eWCxIjz/ALIIX/gNMDHt9F11IYlS+09FCbZFEcjMzAYzvDDB4Hbt+V+1i8Q2xPmf2fclmwWEroMY67SG5z6Gt5AqAIvHGcU6i4Fa2a7Zv9KigRcf8s5C3P4gVZoopAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAMmlSCF5ZmCRxqWZmOAAOSTXnmj/GHwzrBvRp6alK1vZtqCKLY7rm3VgrPEM5OMg7ThscgV6HcQx3EEkM6B4pFKOrdGBGCDXnuifCfTdDtbq20jW9dtIJbZ7WJY5Id1sjkE+W/lbyQBgFy2AeOcGgBNQ+JHg7WNCnLwy61pdxcxWEUSWfnpfTuu8RRq3DkDrnAB6mqdj478PeGJbq3XT08P6JaaQdVlsf7NaCeJvtDQElV+XkqAABzwc4NXLb4Q6BZaUunabd6tZWsF3Hf2Kw3AzYTqm0vCWUn5sksr7lJJOBVpvhnYy3FxdXGt67cX1xpn9lyXUs8bSNF57T5/1eM7mK4xt2YXbigCpN8X/D8Gl2t5Paaskl3K8VtbG3UyT7FDOyENsKgMMnd1OOvFUfFPxm0e18MPfeGornVryTSn1WJUt2McMQJUNOcjaNylcDJ4P1pYPgb4Xt7SJbefUYr6K6e7S+jMKyBnUKw8vy/J2kKuR5fbNWtV+D+j6hb+WdX1y2aTT20y6kt5olN3CXZ8SAxlcgscFQvHHTigDptR8VQ6T4OtNe1C2uJUlhikeO1QMVLqD/EQAo9SRXKp8UPBt8NB1iKxvb2/vRdw2Qg01ri6QxbfOjAQMw6r0OCOc4FdH4q8C6b4l8N6Zo15cXsEWmzQ3FtPAyeYrxAqpIZWRuCcgqRz06Vm+G/hdo2gaho17a3mpzT6XNezxGeSMh2ugvmb8IM42jGMY5zmgCzZfEnQbzxKujRfbQz3cthFeNbkW0tzGMvEr92GD2wcHBNV/wDhavhn+xdK1Xzbr7JqdneX1ufIOTFarulyOxx0Hen2Pwy0Wz8Spq8dxqLRxXsupQ6e8ym1huZAQ8qrt3ZOScFioJOAKw7b4H+H7eCK3XVfED2cFre2dtbyXSNHbxXSFJFQFOMA5Gc89c9KANC3+MPhh7bU57oanYx2NlHqP+mWTxGeCRgqPEDywLEKOmSat/D/AMbXXirxN4rsJ9Nm0+30l7VYY7mMx3GJYd58xckA56Y7YqHVfhRoGqRNHeTagyNosOh4EqrtihkEscgIXPmBwDnpx92tfwd4MtvDGpazqCalqepX2rNC1zNfvGzExJsXGxFA4/l2oA4Twn8V9T13Vozc2UGnabc622k2sc9rN50m0SE5bIUN8gyMfL0OetT6v8dNGi8LatrWhaVqeqQWKB1kMflQyjzVj+/8xTk5G5QTjgV0tp8NNHtf7O8u51A/YdYm1uPdInM0m7crfJ9z5zgDB6cmsP8A4Ud4ZkXV/tl3qt3NqdqbOWeSSJZFQur5yka723Kp3Sbzx9aAOin+Iui2yakbyO/tpNO00arcwzWxSSOElhyp/i+U8Vjad8T0Z/FVze2UsmnaVc28UBtY8yOksKybn3MFGN3XIH41J4i+Emma/K819rviJbibTv7Mu5YrmNDeRbiwMo8vBILHoAOxBovfhBoN3aXUJvdVjae9tr8SpJGWilgiESFQYypG3qGDDJzxxgA6nwT4q0zxloEer6K8ptXd4isqbXR1OGUjkfkSK3q57wN4TsvBujS6bp093cRSXMt00l0ys5eRtzcqqjGfauhoAKKKKACq9/eQWNs09zNHEg4DSHAJ7D3PsOaddzrbQNKySOAQNsaFmJJAHA+tY2nRrc6xLPPi5aJnWOZ14U56RjOAAPlLdWOewoArPPf38rLYW0p84Y+1zxmKOJM9kbDMce2D0yK6DT7SKwsobW3BEcS7Rk5J9ST3JPJPrVikDqXZQwLAAkZ5GelAENw/lESMCEQEs3t39/f8KdHLulK7lIYB0x3H9f8A69V71ppoVbT5V81GDgE/LIB1QnBxkHr9KTTfIltVkt4fJKlh5Z/5ZtnDDA46+nFAF6imRSCRFYAjIzhhgin0AFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFAEN22y1mbLAhDgr1zjt71W0TaLBI1kVzEfKOB93bxim6tpn9oPAWmZFiD/IBwxZcc/Tn8zWbe3t5pVpeSFYmmWRzEojfbIpGQWIHB9T0ABpga+oahBYSWi3JZRdTCBHx8ocglQT2zjA9yB3rI07UYv+Ej8SBm4tWtomwOhMe4D/AMfH51Fb+JfCfinTUtl1bS7uK7jDfZ/tKb/XpnIYEexBHtXlvhXXLk/FDxxoiRahqt19pge0nhw1uUWAJidxwMZUNnJPPGaSA9i0yMpd3H2eNhbySeb8xOFJH8PoD1I9WNLp8qprV3CrhjIC747Mu0f+gsg/D3qzY26aXpcMBZT5a4ZsY3uTy34sSfxqhFJjxVDCqAK1pLMzDg5LxqM/UD9KYGwyv9pjKgeWFbcffjH9aloopAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFAENydojbGdrZ/Q1KGBAII5GRUN4V8oBnVCzAKW6bs8Cm2sEkWfMmMoHC5UDaPTjr9aAMzWNM8OxW80+sWOmCKR9zvcQoQzkY7jkkD614X8DtVstI8feMrTRPsy6Df3rT6a0WNtwsYw6ITydodTj6+9fQk2mWs2qQahMjSXMCFItzErHnqwXoGI43dccdCa4Xw5pun+HviF42vRHgXf2adVC52koxcKO25uT6nrTFY62VpLmYSJ9wfcLY+U8jIH6/TFQJe20HiBo5IZxcBY4FfaAjK5ZhjnoNhH4VrPdRCLcmC+DtToSRgY/MgVk3sCS61YyiFVla6GZF6uscUn3vYFyBQM6CiiikAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAQX1sLu1kh3FCwyrjqrDkN+BANVbTUFkWAzyIkzZikjzjbIvJA/U/TBrRqtdWVvcpIskYy+CXXhsj7pz6jtQBZrmNZ0m4GsXepW8Udwk9tFCYj95WQyHePXh8Y9hVuFdXsT5bj7dbqSEkRlEpGP4lbAyOmQefQVeL3Nxa7ktmhkaNiFml2lW7A7M8H1BoAxZ7qO1ubK3Jea4kkSNYosM4PJJPooJLE9MKvqK0bTM+uSeWP9FsovJDH+KViGbn2AX8WPpWdp9k1vcTi2eOXVrjJuLpE/d2+cZAzkk8Dg5JwCcDArorO2S0tkhi3FVySzHLMSckk9ySSaYE1FFFIAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigBFVVGFAUegFLRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFAH/9k=);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    The graft is sharply mobilized with care taken to preserve the inferior blood supply.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f14_40_14979=[""].join("\n");
var outline_f14_40_14979=null;
var title_f14_40_14980="Microfollicular adenoma FNA";
var content_f14_40_14980=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ENDO%2F74281&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ENDO%2F74281&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Microfollicular adenoma: Findings on fine needle aspirate",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 360px; height: 238px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Fine needle aspirate of a thyroid nodule showing microfollicles with little or no colloid in the backround. There is no clumping or pleomorphism. Nevertheless, surgical excision was advised because of the microfollicular pattern. The nodule was benign.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f14_40_14980=[""].join("\n");
var outline_f14_40_14980=null;
var title_f14_40_14981="Tracheal papillomatosis";
var content_f14_40_14981=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PULM%2F68678&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PULM%2F68678&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Tracheobronchial papillomatosis",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 400px; height: 502px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Upper image shows computed tomographic scan with multiple intraluminal tracheal filling defects in conjunction with parenchymal nodules and cavities. Bronchoscopy (lower image) confirmed the presence of tracheobroncial papillomatosis.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Bronchoscopic image courtesy of James Harrell, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f14_40_14981=[""].join("\n");
var outline_f14_40_14981=null;
var title_f14_40_14982="Insulin lispro: Pediatric drug information";
var content_f14_40_14982=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Insulin lispro: Pediatric drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_general\" href=\"UTD.htm?16/48/17160?source=see_link\">",
"    see \"Insulin lispro: Drug information\"",
"   </a>",
"   and",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?41/49/42772?source=see_link\">",
"    see \"Insulin lispro: Patient drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F2127784\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      HumaLOG&reg;;",
"     </li>",
"     <li>",
"      HumaLOG&reg; KwikPen&trade;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F2127785\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Humalog&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list_set htclist drugH1Div drugBrandNames\" id=\"F991022\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Therapeutic Category",
"    </span>",
"    <ul>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Antidiabetic Agent, Parenteral",
"      </span>",
"     </li>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Insulin, Rapid-Acting",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block dos drugH1Div\" id=\"F991030\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Usual",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_general\" href=\"UTD.htm?16/48/17160?source=see_link\">",
"      see \"Insulin lispro: Drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Insulin lispro is a rapid-acting insulin analog which is normally administered SubQ as a premeal component of the insulin regimen or as a continuous SubQ infusion and should be used with intermediate- or long-acting insulin. When compared to insulin regular, insulin lispro has a more rapid onset and shorter duration of activity. Insulin requirements vary dramatically between patients and dictate frequent monitoring and close medical supervision. See Insulin Regular for additional information.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      General insulin dosing:",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     <b>",
"      Type 1 diabetes mellitus:",
"     </b>",
"     Children, Adolescents, and Adults:",
"     <b>",
"      Note:",
"     </b>",
"     Multiple daily doses or continuous subcutaneous infusions guided by blood glucose monitoring are the standard of diabetes care. Combinations of insulin formulations are commonly used. The daily doses presented below are expressed as the",
"     <b>",
"      total units/kg/day of all insulin formulations combined",
"     </b>",
"     .",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     <b>",
"      Initial dose:",
"     </b>",
"     SubQ: 0.2-0.6 units/kg/day in divided doses. Conservative initial doses of 0.2-0.4 units/kg/day are often recommended to avoid the potential for hypoglycemia. Regular insulin may be the only insulin formulation used initially.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     <b>",
"      Usual maintenance range:",
"     </b>",
"     SubQ: 0.5-1 unit/kg/day in divided doses. An estimate of anticipated needs may be based on body weight and/or activity factors as follows:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;\">",
"     Adolescents: May require &le;1.2 units/kg/day during growth spurts",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;\">",
"     Nonobese: 0.4-0.6 units/kg/day",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;\">",
"     Obese: 0.8-1.2 units/kg/day",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     <b>",
"      Adjustment of dose:",
"     </b>",
"     Dosage must be titrated to achieve glucose control and avoid hypoglycemia. Adjust dose to maintain premeal and bedtime glucose in target range. Since combinations of agents are frequently used, dosage adjustment must address the individual component of the insulin regimen which most directly influences the blood glucose value in question, based on the known onset and duration of the insulin component.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     <b>",
"      Continuous SubQ insulin infusion (insulin pump):",
"     </b>",
"     A combination of a \"basal\" continuous insulin infusion rate with preprogrammed, premeal bolus doses which are patient controlled. When converting from multiple daily SubQ doses of maintenance insulin, it is advisable to reduce the basal rate to less than the equivalent of the total daily units of longer-acting insulin (eg, NPH); divide the total number of units by 24 to get the basal rate in units/hour. Do not include the total units of regular insulin or other rapid-acting insulin formulations in this calculation. The same premeal regular insulin dosage may be used.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     <b>",
"      Type 2 diabetes mellitus:",
"     </b>",
"     Augmentation therapy (patients for which diet, exercise, weight reduction, and oral hypoglycemic agents have not been adequate): Adults: SubQ: Initial dosage of 00.2 units/kg/day or 10 units/day of an intermediate- or long-acting insulin administered at bedtime has been recommended. As an alternative, regular insulin or rapid-acting insulin (eg, insulin lispro) formulations administered before meals have also been used. Dosage must be carefully adjusted.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      Dosing adjustment in renal impairment:",
"     </b>",
"     Insulin requirements are reduced due to changes in insulin clearance or metabolism. No dosage adjustment provided in manufacturer&rsquo;s labeling; however, the following adjustments have been used by some clinicians (Aronoff, 2007):",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Cl",
"     <sub>",
"      cr",
"     </sub>",
"     &gt;50 mL/minute: No adjustment necessary",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Cl",
"     <sub>",
"      cr",
"     </sub>",
"     10-50 mL/minute: Administer at 75% of recommended dose",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Cl",
"     <sub>",
"      cr",
"     </sub>",
"     &lt;10 mL/minute: Administer at 50% of recommended dose and monitor glucose closely",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Hemodialysis: Because of a large molecular weight (6000 daltons), insulin is not significantly removed by either peritoneal or hemodialysis; supplemental dose is not necessary",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Peritoneal dialysis: Supplemental dose is not necessary",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Continuous renal replacement therapy: Administer at 75% of recommended dose",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F2104242\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Injection, solution:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     HumaLOG&reg;: 100 units/mL (3 mL) [cartridge]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     HumaLOG&reg;: 100 units/mL (3 mL, 10 mL) [vial]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     HumaLOG&reg; KwikPen&trade;: 100 units/mL (3 mL)",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F2127787\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F2529659\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Parenteral: SubQ: Administration is usually made into the subcutaneous fat of the thighs, arms, buttocks, or abdomen, with sites rotated; cold injections should be avoided. Administer 15 minutes before meals or immediately after. May be mixed in the same syringe with NPH insulin. When mixing insulin lispro with NPH insulin, lispro should be drawn into the syringe first; administer immediately after mixing. Insulin lispro can be infused SubQ by external insulin pump; however, when used in an external pump, it is not recommended to be diluted or mixed with other insulins. Insulin in the reservoir of an external pump should be changed every 7 days; infusion sets and insertion sites should be changed every 3 days; rotate infusion sites.",
"    </p>",
"   </div>",
"   <div class=\"block scp drugH1Div\" id=\"F2127815\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Compatibility",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Stable in D",
"     <sub>",
"      5",
"     </sub>",
"     W, D",
"     <sub>",
"      10",
"     </sub>",
"     W and NS.",
"     <b>",
"      Note:",
"     </b>",
"     A universal sterile diluent, Sterile Diluent for Humalog&reg;, Humulin&reg; N, Humulin&reg; R, Humulin&reg; 70/30, and Humulin&reg; R U-500, is available from the manufacturer for SubQ administration.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      Compatibility in syringe: Compatible:",
"     </b>",
"     Insulin NPH.",
"     <b>",
"      Incompatible:",
"     </b>",
"     Insulin aspart, insulin detemir, insulin glargine, insulin glulisine, insulin regular.",
"    </p>",
"   </div>",
"   <div class=\"block sta drugH1Div\" id=\"F2984380\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Stability",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Store unopened vials, pens, and cartridges in the refrigerator at 2&deg;C to 8&deg;C (36&deg;F to 46&deg;F); do not freeze; protect from heat and light. Once opened (in use) vials may be stored in refrigerator or at room temperature for up to 28 days. Cartridges and pens that are in use should be stored at room temperature and used within 28 days; do not refrigerate. Insulin lispro in an insulin pump reservoir should be replaced every 7 days. Discard if exposed to temperatures &ge;37&deg;C (98.6&deg;F).",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;text-align:justify;\">",
"     May be mixed in the same syringe with NPH insulin; insulin lispro should be drawn into the syringe first. A sterile diluent is available from the manufacturer for preparing dilutions of Humalog&reg;. Diluted Humalog&reg; may be stored at 5&deg;C (41&deg;F) for 28 days or 30&deg;C (86&deg;F) for 14 days. Do not dilute insulin in cartridges or used in insulin pumps.",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F991023\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Treatment of type 1 diabetes mellitus (insulin dependent, IDDM); type 2 diabetes mellitus (noninsulin dependent, NIDDM) to control hyperglycemia",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F2127781\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Sound-alike/look-alike issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       HumaLOG&reg; may be confused with HumaLOG&reg; Mix 50/50, Humira&reg;, HumuLIN&reg; N, HumuLIN&reg; R, NovoLOG&reg;",
"      </p>",
"     </div>",
"    </div>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      High alert medication:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       The Institute for Safe Medication Practices (ISMP) includes this medication among its list of drugs which have a heightened risk of causing significant patient harm when used in error.",
"       <b>",
"        <i>",
"         Due to the number of insulin preparations, it is essential to identify/clarify the type of insulin to be used.",
"        </i>",
"       </b>",
"      </p>",
"     </div>",
"    </div>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Other safety concerns:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       Cross-contamination may occur if insulin pens are shared among multiple patients. Steps should be taken to prohibit sharing of insulin pens.",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block arm drugH1Div\" id=\"F2127805\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Primarily symptoms of hypoglycemia",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Cardiovascular: Pallor, palpitation, tachycardia",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Central nervous system: Fatigue, headache, hypothermia, loss of consciousness, mental confusion",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Dermatologic: Redness, urticaria",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Endocrine &amp; metabolic: Hypoglycemia, hypokalemia",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Gastrointestinal: Hunger, nausea, numbness of mouth",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Local: Atrophy or hypertrophy of SubQ fat tissue; edema, itching, pain or warmth at injection site; stinging",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Neuromuscular &amp; skeletal: Muscle weakness, paresthesia, tremor",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Ocular: Transient presbyopia or blurred vision",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Miscellaneous: Anaphylaxis, diaphoresis, local and/or systemic hypersensitivity reactions",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F991025\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity lispro insulin or any component; hypoglycemia",
"    </p>",
"   </div>",
"   <div class=\"block pre drugH1Div\" id=\"F2984378\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Precautions",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Use with caution and adjust dosage in patients with renal impairment; use with caution and monitor closely in patient with hepatic impairment.",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F991026\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypoglycemia is the most common adverse effect of insulin. The timing of hypoglycemia differs among various insulin formulations. Any change of insulin should be made cautiously; changing manufacturers, type, and/or method of manufacture may result in the need for a change of dosage. Hypoglycemia may result from increased work or exercise without eating.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F2127810\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     None known.",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F2127809\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Antidiabetic Agents (Thiazolidinedione): Insulin may enhance the fluid-retaining effect of Antidiabetic Agents (Thiazolidinedione).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Beta-Blockers: May enhance the hypoglycemic effect of Insulin.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Levobunolol; Metipranolol.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Corticosteroids (Orally Inhaled): May diminish the hypoglycemic effect of Antidiabetic Agents. In some instances, corticosteroid-mediated HPA axis suppression has led to episodes of acute adrenal crisis, which may manifest as enhanced hypoglycemia, particularly in the setting of insulin or other antidiabetic agent use.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Corticosteroids (Systemic): May diminish the hypoglycemic effect of Antidiabetic Agents. In some instances, corticosteroid-mediated HPA axis suppression has led to episodes of acute adrenal crisis, which may manifest as enhanced hypoglycemia, particularly in the setting of insulin or other antidiabetic agent use.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Edetate CALCIUM Disodium: May enhance the hypoglycemic effect of Insulin.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Edetate Disodium: May enhance the hypoglycemic effect of Insulin.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Herbs (Hypoglycemic Properties): May enhance the hypoglycemic effect of Hypoglycemic Agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Hypoglycemic Agents: May enhance the adverse/toxic effect of other Hypoglycemic Agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Loop Diuretics: May diminish the hypoglycemic effect of Hypoglycemic Agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Luteinizing Hormone-Releasing Hormone Analogs: May diminish the therapeutic effect of Antidiabetic Agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     MAO Inhibitors: May enhance the hypoglycemic effect of Hypoglycemic Agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pegvisomant: May enhance the hypoglycemic effect of Antidiabetic Agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Quinolone Antibiotics: Insulin may enhance the hyperglycemic effect of Quinolone Antibiotics. Insulin may enhance the hypoglycemic effect of Quinolone Antibiotics.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Salicylates: May enhance the hypoglycemic effect of Hypoglycemic Agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Selective Serotonin Reuptake Inhibitors: May enhance the hypoglycemic effect of Hypoglycemic Agents. Selective Serotonin Reuptake Inhibitors may increase the serum concentration of Hypoglycemic Agents. Management: Consider increased monitoring of glycemic control with concomitant use of a hypoglycemic agent and an SSRI. Dosage adjustments of the hypoglycemic agent may be necessary upon SSRI initiation or discontinuation.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Somatropin: May diminish the hypoglycemic effect of Antidiabetic Agents.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Thiazide Diuretics: May diminish the therapeutic effect of Antidiabetic Agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block foi drugH1Div\" id=\"F2984379\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Food Interactions",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Use caution with chromium, garlic, gymnema (may increase hypoglycemia).",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F2127793\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     B (",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F2127794\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Adverse events have not been observed in animal reproduction studies. Insulin lispro has not been shown to cross the placenta at standard clinical doses. Although congenital anomalies have been noted in case reports, when compared to regular insulin, insulin lispro has not been found to increase the risk of adverse events to the fetus in larger studies. Maternal hyperglycemia can be associated with adverse effects in the fetus, including macrosomia, neonatal hyperglycemia, and hyperbilirubinemia; the risk of congenital malformations is increased when Hb A",
"     <sub>",
"      1c",
"     </sub>",
"     is &gt;1% above the normal range.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     Insulin requirements tend to fall during the first trimester of pregnancy and increase in the later trimesters, peaking at 28-32 weeks of gestation. Following delivery, insulin requirements decrease rapidly. Diabetes can also be associated with adverse effects in the mother. Poorly-treated diabetes may cause end-organ damage that may in turn negatively affect obstetric outcomes. Physiologic glucose levels should be maintained prior to and during pregnancy to decrease the risk of adverse events in the fetus and mother. Insulin is the drug of choice for the control of diabetes mellitus during pregnancy. The use of insulin lispro has been shown to be as effective as regular insulin to treat diabetes in pregnancy and may have advantages over regular insulin during pregnancy.",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F991031\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Urine sugar and acetone, serum glucose, electrolytes, Hb A",
"     <sub>",
"      1c",
"     </sub>",
"     , lipid profile",
"    </p>",
"   </div>",
"   <div class=\"block rer drugH1Div\" id=\"F991028\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Reference Range",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Glucose, fasting:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Newborns: 30-90 mg/dL",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Adults: 70-110 mg/dL",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Recommendations for glycemic control with type 1 diabetes:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Hb A",
"     <sub>",
"      1c",
"     </sub>",
"     :",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     &lt;6 years: &le;8.5% and &ge;7.5%",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     6-12 years: &lt;8%",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     13-19 years: &lt;7.5%",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Adults: &lt;7%",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Plasma glucose*:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Preprandial:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">",
"     &lt;6 years: 90-130 mg/dL",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">",
"     6-12 years: 90-180 mg/dL",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">",
"     13 years to Adults: 90-130 mg/dL",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Bedtime and overnight:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">",
"     &lt;6 years: 110-200 mg/dL",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">",
"     6-12 years: 100-180 mg/dL",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">",
"     13-19 years: 90-150 mg/dL",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Peak postprandial**: Adults: &lt;180 mg/dL",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     *Plasma glucose concentrations are generally 10% to 15% higher than those in whole blood",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     **Peak postprandial plasma glucose is measured 1-2 hours after a meal",
"    </p>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F991027\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Insulin lispro is a rapid-acting form of insulin.",
"    </p>",
"   </div>",
"   <div class=\"block phd drugH1Div\" id=\"F2984421\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Onset and duration of hypoglycemic effects depend upon the route of administration (adsorption and onset of action are more rapid after deeper I.M. injections than after SubQ), site of injection (onset and duration are progressively slower with SubQ injection into the abdomen, arm, buttock, or thigh respectively), volume and concentration of injection, and the preparation administered; local heat, and massage also increase the rate of absorption.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Onset of action: 15-30 minutes",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Maximum effect: 0.5-2.5 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Duration: 3-6.5 hours",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F991029\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacokinetics (Adult data unless noted)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Distribution: V",
"     <sub>",
"      d",
"     </sub>",
"     : 0.26-0.36 L/kg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Bioavailability: 55% to 77%",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Half-life: SubQ: 1 hour",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Excretion: Urine",
"    </p>",
"   </div>",
"   <div class=\"block pai drugH1Div\" id=\"F2984422\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Patient Information",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?41/49/42772?source=see_link\">",
"      see \"Insulin lispro: Patient drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Do not take any new medication during therapy unless approved by healthcare provider. This medication is used to control diabetes; it is not a cure. It is imperative to follow other components of prescribed treatment (eg, diet and exercise regimen). Take exactly as directed. Do not change dose or discontinue unless advised by healthcare provider. With insulin lispro (Humalog&reg;), you must administer 15 minutes before meals or immediately after. If you experience hypoglycemic reaction, contact healthcare provider immediately. Always carry quick source of sugar with you. Monitor glucose levels as directed by healthcare provider. Report adverse side effects, including chest pain or palpitations; persistent fatigue, confusion, headache; skin rash or redness; numbness of mouth, lips, or tongue; muscle weakness or tremors; vision changes; respiratory difficulty; or nausea, vomiting, or flu-like symptoms.",
"    </p>",
"   </div>",
"   <div class=\"block adi drugH1Div\" id=\"F14455439\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Additional Information",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      Division of daily insulin requirement (\"conventional therapy\"):",
"     </b>",
"     Generally, 50% to 75% of the daily insulin dose is given as an intermediate- or long-acting form of insulin (in 1-2 daily injections). The remaining portion of the 24-hour insulin requirement is divided and administered as either regular insulin or a rapid-acting form of insulin (eg, insulin lispro) at the same time before breakfast and dinner.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      Division of daily insulin requirement (\"intensive therapy\"):",
"     </b>",
"     Basal insulin delivery with 1 or 2 doses of intermediate- or long-acting insulin formulations superimposed with doses of rapid- or very rapid-acting insulin (eg, insulin lispro) formulations 3 or more times daily.",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 12772 Version 31.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0604-203.80.222.8-89ED0DCEDC-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f14_40_14982=[""].join("\n");
var outline_f14_40_14982=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F2127784\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F2127785\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F991022\">",
"      Therapeutic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F991030\">",
"      Dosing: Usual",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F2104242\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F2127787\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F2529659\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F2127815\">",
"      Compatibility",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F2984380\">",
"      Stability",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F991023\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F2127781\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F2127805\">",
"      Adverse Reactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F991025\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F2984378\">",
"      Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F991026\">",
"      Warnings",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F2127810\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F2127809\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F2984379\">",
"      Food Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F2127793\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F2127794\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F991031\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F991028\">",
"      Reference Range",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F991027\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F2984421\">",
"      Pharmacodynamics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F991029\">",
"      Pharmacokinetics (Adult data unless noted)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F2984422\">",
"      Patient Information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F14455439\">",
"      Additional Information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_PED/12772\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_PED/12772|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?16/48/17160?source=related_link\">",
"      Insulin lispro: Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?41/49/42772?source=related_link\">",
"      Insulin lispro: Patient drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f14_40_14983="Evaluation of elbow pain in adults";
var content_f14_40_14983=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"   </img>",
"  </div>",
"  <div id=\"printHeaderText\">",
"   Official reprint from  UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"   <a href=\"file://www.uptodate.com\">",
"    www.uptodate.com",
"   </a>",
"   <br>",
"    &copy;2013 UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"   </br>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Evaluation of elbow pain in adults",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?14/40/14983/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?14/40/14983/contributors\">",
"     Bruce C Anderson, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?14/40/14983/contributors\">",
"     Ronald J Anderson, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?14/40/14983/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?14/40/14983/contributors\">",
"     Karl B Fields, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?14/40/14983/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?14/40/14983/contributors\">",
"     Jonathan Grayzel, MD, FAAEM",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?14/40/14983/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jun 5, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Elbow pain may be due to disorders involving the joint itself or the surrounding structures. These include the epicondyles (medial and lateral), the olecranon bursa, and the radial and ulnar nerves, which course near the elbow joint. In addition, referred pain may arise from a cervical radiculopathy or from the shoulder.",
"   </p>",
"   <p>",
"    This topic will discuss how to approach the adult patient with nontraumatic elbow pain and the most common causes for such pain. Discussions of specific problems affecting the elbow are found separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?1/20/1354?source=see_link\">",
"     \"Epicondylitis (tennis and golf elbow)\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?13/45/14041?source=see_link\">",
"     \"Bursitis: An overview of clinical manifestations, diagnosis, and management\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?8/44/8906?source=see_link\">",
"     \"Overview of upper extremity peripheral nerve syndromes\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     ANATOMY",
"    </span>",
"    &nbsp;&mdash;&nbsp;The elbow joint is formed by the articulation of the distal end of the humerus with the proximal radius (radial head) and ulna (",
"    <a class=\"graphic graphic_figure graphicRef81300 \" href=\"UTD.htm?6/41/6802\">",
"     figure 1",
"    </a>",
"    and",
"    <a class=\"graphic graphic_figure graphicRef68107 \" href=\"UTD.htm?15/25/15761\">",
"     figure 2",
"    </a>",
"    and",
"    <a class=\"graphic graphic_figure graphicRef82540 \" href=\"UTD.htm?22/52/23365\">",
"     figure 3",
"    </a>",
"    ).",
"    <span class=\"nowrap\">",
"     Flexion/extension",
"    </span>",
"    occurs at the ulnohumeral joint and is powered by the biceps and triceps muscles, respectively. The normal arc of motion ranges from full extension or 0 degrees, to 135 degrees of flexion.",
"   </p>",
"   <p>",
"    <span class=\"nowrap\">",
"     Supination/pronation",
"    </span>",
"    (rotation) occurs at the radiohumeral and proximal radioulnar articulations of the elbow joint. The biceps muscle supinates and the pronator teres muscle pronates the elbow. The elbow can rotate from 0 to 180 degrees.",
"   </p>",
"   <p>",
"    The epicondyles are bony prominences easily palpated on the medial and lateral sides of the distal humerus, proximal to the elbow joint, and they are a common source of pain. The tendinous origin of the muscles that flex and extend the wrist are located at the medial and lateral epicondyle, respectively.",
"   </p>",
"   <p>",
"    Multiple bursae have been identified around the elbow joint; the olecranon bursa is the most superficial, and swelling of this bursa is both common and easily observed.",
"   </p>",
"   <p>",
"    The ulnar nerve courses through the elbow joint in the ulnar groove posterior and medial to the elbow. Its course is contiguous with the joint capsule; thus, any process that distends the joint tends to impinge upon the ulnar nerve, causing paresthesias in the ulnar aspect of the hand and occasional weakness in the flexor digiti quinti. The median nerve runs anterior to the joint capsule; entrapment in this region typically is due to elbow trauma, repetitive elbow flexion, or supination and pronation of the forearm. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?8/44/8906?source=see_link\">",
"     \"Overview of upper extremity peripheral nerve syndromes\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     ETIOLOGY AND PRESENTATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Many of the common causes of elbow pain are periarticular, including epicondylitis, olecranon bursitis, nerve entrapment syndromes, and referred pain. Systemic diseases (eg, rheumatoid arthritis) usually have polyarticular involvement that is revealed by a careful musculoskeletal examination. However, oligoarticular involvement can occur, as in the seronegative spondyloarthritides. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?12/46/13033?source=see_link\">",
"     \"Clinical features of rheumatoid arthritis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?8/57/9114?source=see_link\">",
"     \"Clinical manifestations, diagnosis, and management of undifferentiated spondyloarthritis and related spondyloarthritides\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/27/33210?source=see_link\">",
"     \"Reactive arthritis (formerly Reiter syndrome)\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?29/49/30488?source=see_link\">",
"     \"Clinical manifestations and diagnosis of psoriatic arthritis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Pain patterns",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients who are experiencing a problem unique or intrinsic to the elbow present either with complaints of pain (epicondylitis), swelling (olecranon bursitis), or a loss of motion (joint).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h3\">",
"     Lateral elbow pain",
"    </span>",
"    &nbsp;&mdash;&nbsp;Lateral elbow pain is the most common complaint at the elbow. The source of pain may be the lateral epicondyle, the radiohumeral joint, or referred pain from the shoulder or neck.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The pain of lateral epicondylitis (tennis elbow) is typically well localized (the patient often points to the lateral epicondylar process) and is aggravated by activity that contracts the wrist extensors, including repetitious use of the forearm and wrist and shaking hands. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?1/20/1354?source=see_link\">",
"       \"Epicondylitis (tennis and golf elbow)\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Pain arising from the elbow joint is located slightly more posterior to the epicondyle (between the epicondyle and the olecranon process), is not well localized, and is readily distinguished from the pain of lateral epicondylitis by its effect upon range of motion of the elbow (it is exceedingly rare for lateral epicondylitis to affect the range of motion of the joint). A joint effusion will limit elbow extension.",
"     </li>",
"     <li>",
"      Lateral elbow pain that is referred to the elbow is suggested by absence of increased pain with elbow movement, a vague description, and aggravation of the pain with movement of the shoulder or neck.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h3\">",
"     Medial elbow pain",
"    </span>",
"    &nbsp;&mdash;&nbsp;Medial elbow pain is the second most common complaint at the elbow. It frequently arises either from the medial epicondyle or the ulnar nerve as it travels through the cubital tunnel.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      As with lateral epicondylitis, the pain of medial epicondylitis is well localized and is aggravated by actions that contract the wrist flexors, such as lifting or repetitious use of the forearm and wrist. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?1/20/1354?source=see_link\">",
"       \"Epicondylitis (tennis and golf elbow)\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Pain arising from the ulnar nerve is suggested by radiation into the ulnar side of the hand and associated sensory (or occasionally motor) symptoms in the fourth and fifth fingers. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?8/44/8906?source=see_link\">",
"       \"Overview of upper extremity peripheral nerve syndromes\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h3\">",
"     Elbow swelling",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients who complain of elbow swelling most often have olecranon bursitis. The warmth and redness that accompany the swelling and the rapidity with which the symptoms appear are clues to distinguish the underlying cause (usually trauma, sepsis, or gout). The ability of the patient to extend and flex the elbow completely generally excludes an intra-articular process as the cause of the elbow pain.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h3\">",
"     Impaired range of motion",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with an intraarticular process occasionally complain of elbow swelling as well as elbow pain. However, these symptoms are virtually always overshadowed by their universal complaint, \"I cannot straighten my elbow!\" Causes of synovitis include rheumatoid arthritis, seronegative spondyloarthropathies, such as reactive arthritis, psoriasis, or inflammatory bowel disease, crystal-induced synovitis due to gout or pseudogout, and septic bacterial arthritis.",
"   </p>",
"   <p>",
"    Loss of smooth motion of the elbow is a unique symptom that occurs almost exclusively in athletes, particularly baseball players and gymnasts who cause trauma to the joint by throwing, vaulting, and the floor exercise. This symptom in the appropriate patient is a strong clue to the presence of osteonecrosis (osteochondritis dissecans) of the humerus. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/43/28346?source=see_link\">",
"     \"Osteonecrosis (avascular necrosis of bone)\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h3\">",
"     Referred pain",
"    </span>",
"    &nbsp;&mdash;&nbsp;Cervical radiculopathy and shoulder pathology, particularly rotator cuff tendinopathy, may refer pain to or \"through\" the elbow [",
"    <a class=\"abstract\" href=\"UTD.htm?14/40/14983/abstract/1\">",
"     1",
"    </a>",
"    ]. The pain is a deep ache that is not related to elbow motion. These diagnoses are suggested by the associated symptoms (paresthesias or hypesthesias), the lack of local tenderness and swelling, and aggravation of the symptoms by shoulder or neck movement.",
"   </p>",
"   <p>",
"    As an example, lateral herniation between C6-7 produces pain at the shoulder blade, pectoral area, and medial axilla with radiation to posterolateral upper arm, dorsal elbow and forearm, index and medial digits or all of the fingers, and sensory impairment in these areas. There is also weakness in extension of the forearm and sometimes the wrist and diminished or absent triceps reflex. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?1/24/1418?source=see_link\">",
"     \"Evaluation of the patient with neck pain and cervical spine disorders\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h1\">",
"     EXAMINATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Efficient examination of the elbow includes the following (",
"    <a class=\"graphic graphic_table graphicRef79000 \" href=\"UTD.htm?20/35/21052\">",
"     table 1",
"    </a>",
"    ):",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Perform range of motion testing of the elbow joint (flexion, extension, pronation, and supination).",
"     </li>",
"     <li>",
"      Palpate the extensor tendons at the lateral epicondyle and the flexor tendons at the medial epicondyle to determine the presence and extent of forearm extensor or flexor tendinopathy, respectively.",
"     </li>",
"     <li>",
"      Palpate the radiohumeral joint to determine the presence of an effusion or focal tenderness.",
"     </li>",
"     <li>",
"      Inspect and palpate the olecranon bursa for swelling, chronic thickening, or both.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Confirmatory tests may be necessary if these examinations are consistent with a particular diagnosis. If these tests are normal, examination of the neck, shoulder, and wrist should be performed to identify a source of referred pain.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Range of motion",
"    </span>",
"    &nbsp;&mdash;&nbsp;The first task in assessing the patient presenting with elbow pain is to evaluate the joint with range of motion testing (",
"    <a class=\"graphic graphic_table graphicRef70587 \" href=\"UTD.htm?42/6/43115\">",
"     table 2",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h3\">",
"     Ulnohumeral joint",
"    </span>",
"    &nbsp;&mdash;&nbsp;Passive range of motion testing of the ulnohumeral joint assesses the integrity of the elbow in flexion and extension (",
"    <a class=\"graphic graphic_picture graphicRef54946 \" href=\"UTD.htm?3/21/3408\">",
"     picture 1",
"    </a>",
"    ). Full arm extension and flexion are compared side to side.",
"   </p>",
"   <p>",
"    Full elbow extension dramatically reduces the intraarticular volume of the joint. With an inflammatory synovitis, the elbow joint assumes a position of flexion in order to increase the joint volume, thereby reducing the intraarticular pressure and associated pain felt within the elbow. Thus, full elbow extension will cause pain with an elbow synovitis (but not with olecranon bursitis).",
"   </p>",
"   <p>",
"    Loss of full extension with end-point stiffness suggests the presence of a small effusion with mild arthritis. Loss of full extension AND flexion suggests the presence of a large effusion with moderate to severe arthritis. A joint effusion related to either an inflammatory arthritis or hemarthrosis can be readily excluded by documenting normal range of motion.",
"   </p>",
"   <p>",
"    Osteoarthritis of the joint is uncommon, unless there is a history of elbow fracture. A fracture involving the elbow is uncommon in patients who are able to perform full elbow extension [",
"    <a class=\"abstract\" href=\"UTD.htm?14/40/14983/abstract/2\">",
"     2",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h3\">",
"     Radiohumeral joint",
"    </span>",
"    &nbsp;&mdash;&nbsp;Passive range of motion of the radiohumeral joint assesses the integrity of the elbow in supination and pronation (",
"    <a class=\"graphic graphic_picture graphicRef51261 \" href=\"UTD.htm?39/37/40543\">",
"     picture 2",
"    </a>",
"    ). Passive supination and pronation are compared side to side while palpating the radial head.",
"   </p>",
"   <p>",
"    Loss of full supination or pronation suggests previous fracture or dislocation of the elbow or osteonecrosis. Pronation and supination are painful and limited in patients with synovitis; this may help distinguish patients with a joint effusion from those with bursal swelling, since olecranon bursitis is associated with normal joint motion.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Epicondylar palpation",
"    </span>",
"    &nbsp;&mdash;&nbsp;The lateral and medial epicondyles are palpated for tenderness with the elbow flexed at 90 degrees (",
"    <a class=\"graphic graphic_picture graphicRef64356 \" href=\"UTD.htm?17/46/18145\">",
"     picture 3",
"    </a>",
"    and",
"    <a class=\"graphic graphic_picture graphicRef55147 \" href=\"UTD.htm?40/20/41280\">",
"     picture 4",
"    </a>",
"    ). Local tenderness is the hallmark feature of lateral and medial epicondylitis, respectively. Patients with pain in one of these areas should go on to have confirmatory testing as outlined below.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Inspection and palpation of the olecranon bursa",
"    </span>",
"    &nbsp;&mdash;&nbsp;The bursa is palpated for ballotable cystic swelling with the elbow flexed at 90 degrees (",
"    <a class=\"graphic graphic_picture graphicRef58894 \" href=\"UTD.htm?29/11/29886\">",
"     picture 5",
"    </a>",
"    ). An acutely swollen and red bursa suggests the diagnosis of acute bursitis, a swollen and thickened bursa is consistent with a flare of chronic bursitis, and a thickened bursa alone suggests chronic bursitis. Fluid should be aspirated to determine the underlying cause of swelling if there is associated pain, local inflammation, or if the patient is febrile (see below).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     Palpation of ligaments",
"    </span>",
"    &nbsp;&mdash;&nbsp;While not directly palpable, the general location of the medial and lateral collateral ligaments is palpated for tenderness in patients, particularly throwing athletes, suspected of ligamentous injury. (See",
"    <a class=\"local\" href=\"#H23\">",
"     'Ligamentous injury'",
"    </a>",
"    below.) They are further tested for laxity with the elbow in both 0 degrees and 30 degrees of flexion [",
"    <a class=\"abstract\" href=\"UTD.htm?14/40/14983/abstract/3\">",
"     3",
"    </a>",
"    ]. This is done by placing one hand behind the elbow with the thumb and middle finger over the location of the medial and lateral collateral ligaments (just distal to the epicondyles) while the other hand holds the patient's wrist and exerts a valgus and varus stress [",
"    <a class=\"abstract\" href=\"UTD.htm?14/40/14983/abstract/4\">",
"     4",
"    </a>",
"    ]. The degree of joint laxity is compared with the unaffected elbow.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1198469\">",
"    <span class=\"h2\">",
"     Tinels sign",
"    </span>",
"    &nbsp;&mdash;&nbsp;In patients with suspected ulnar nerve entrapment, tapping a finger over the ulnar groove may reproduce the patient&rsquo;s symptoms (positive Tinels sign) (",
"    <a class=\"graphic graphic_picture graphicRef53954 \" href=\"UTD.htm?7/46/7904\">",
"     picture 6",
"    </a>",
"    ). A positive sign at the medial elbow usually consists of lancinating pain or numbness felt in the fourth and fifth fingers; the response should be distinctly different from the opposite side. Abnormal responses can be confirmed with nerve conduction velocity testing. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?8/44/8906?source=see_link\">",
"     \"Overview of upper extremity peripheral nerve syndromes\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h2\">",
"     Clinical pearls",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Normal range of motion testing of the elbow effectively rules out involvement of the elbow joint itself. This is particularly important when it is not clear if the source of swelling is bursal or intraarticular.",
"     </li>",
"     <li>",
"      Epicondylitis and olecranon bursitis rarely affect elbow range of motion. The only exceptions to this rule are cellulitis accompanying a septic olecranon bursitis or chronic lateral epicondylitis in the patient with an extremely low pain threshold. Any loss of full extension or flexion reflects involvement of the elbow joint.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h1\">",
"     DIFFERENTIAL DIAGNOSIS",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h2\">",
"     Epicondylitis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Epicondylitis (medial or lateral) has numerous etiologies including repetitive wrist turning or hand gripping, tool use, shaking hands, or twisting movements that may exceed tissue capacity. It is an occupational hazard in carpenters, gardeners, dentists, and politicians. Tennis players, particularly novices, often suffer lateral epicondylitis as a result of pressure grip strain, or due to backhand shots performed with a \"leading elbow\" in which the elbow is pointed to the net during racquet impact with the ball. Medial epicondylitis has been called golfer's elbow. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?1/20/1354?source=see_link\">",
"     \"Epicondylitis (tennis and golf elbow)\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Lateral epicondylitis is caused by",
"    <span class=\"nowrap\">",
"     microtearing/microavulsion",
"    </span>",
"    of the extensor carpi radialis brevis and longus tendons. A presumptive diagnosis requires:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Local tenderness directly over the lateral epicondyle",
"     </li>",
"     <li>",
"      Pain aggravated by resisted wrist extension and radial deviation",
"     </li>",
"     <li>",
"      Pain aggravated by strong gripping or decreased grip strength",
"     </li>",
"     <li>",
"      Normal elbow range of motion",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Medial epicondylitis is much less common than lateral epicondylitis. It is caused by",
"    <span class=\"nowrap\">",
"     microtearing/microavulsion",
"    </span>",
"    of the flexor carpi radialis tendon. A presumptive diagnosis requires:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Local tenderness directly over the medial epicondyle",
"     </li>",
"     <li>",
"      Pain aggravated by resisted wrist flexion and ulnar deviation",
"     </li>",
"     <li>",
"      Pain aggravated by strong gripping or decreased grip strength",
"     </li>",
"     <li>",
"      Normal elbow range of motion",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h2\">",
"     Olecranon bursitis",
"    </span>",
"    &nbsp;&mdash;&nbsp;The olecranon bursa, at the posterior point of the elbow, has a synovial membrane that may be affected by gout, rheumatoid arthritis, sepsis, hemorrhage, or trauma. Traumatic bursitis accounts for most cases. Common traumatic etiologies include leaning on the elbow or using the elbow to arise from bed or as part of an occupation such as laying carpet. The onset is seldom acute when trauma is the inciting cause, and the surrounding tissues are usually normal.",
"   </p>",
"   <p>",
"    Infection of the bursa usually follows an abrasion or occurs in association with an initial cellulitis. Involvement of the olecranon bursa may be the initial presentation of gout, but it most commonly occurs with recurrent episodes of gouty arthritis. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?4/49/4890?source=see_link\">",
"     \"Clinical manifestations and diagnosis of gout\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The diagnosis of acute olecranon bursitis is readily made by noting the cystic swelling over the posterior olecranon process. As this swelling does not involve the joint, it does not prevent the patient from fully extending the elbow, a movement that will reduce the pain. However, bursal aspiration and laboratory analysis are necessary to distinguish the three common causes of bursal swelling. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?13/45/14041?source=see_link\">",
"     \"Bursitis: An overview of clinical manifestations, diagnosis, and management\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h2\">",
"     Nerve entrapment",
"    </span>",
"    &nbsp;&mdash;&nbsp;The ulnar, radial, and median nerves course in close proximity to the elbow. Any disease process affecting the elbow can involve these nerves or their branches and cause sensory or motor symptoms in the hand. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?8/44/8906?source=see_link\">",
"     \"Overview of upper extremity peripheral nerve syndromes\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Ulnar neuropathy is the most common compression neuropathy affecting the elbow. In mild cases, symptoms include sensory loss and paresthesias over the ring and small fingers. In more severe cases, weakness of the interossei becomes apparent, and the patient may complain of a weakened grip and clumsiness with the hand.",
"   </p>",
"   <p>",
"    Elbow joint inflammation due to rheumatoid arthritis rarely causes an entrapment neuropathy of either the anterior interosseous nerve, a pure motor branch of the median nerve, or the posterior interosseous nerve, a pure motor branch of the radial nerve. In the anterior interosseous syndrome, there is motor dysfunction of the flexor pollicis longus and of the flexor digitorum profundus of the index and middle fingers; there is no sensory loss in the hand, but a paresthetic pain may be felt in the elbow and over the proximal volar aspect of the forearm [",
"    <a class=\"abstract\" href=\"UTD.htm?14/40/14983/abstract/5\">",
"     5",
"    </a>",
"    ]. The posterior interosseous nerve syndrome is associated with a deep-seated pain within the elbow and weakness upon extension of the third, fourth, and fifth digits [",
"    <a class=\"abstract\" href=\"UTD.htm?14/40/14983/abstract/6\">",
"     6",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?8/44/8906?source=see_link&amp;anchor=H29#H29\">",
"     \"Overview of upper extremity peripheral nerve syndromes\", section on 'Anterior interosseous neuropathy'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?8/44/8906?source=see_link&amp;anchor=H38#H38\">",
"     \"Overview of upper extremity peripheral nerve syndromes\", section on 'Posterior interosseous neuropathy'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h2\">",
"     Osteoarthritis",
"    </span>",
"    &nbsp;&mdash;&nbsp;The elbow is a non-weight bearing joint. Thus, degenerative processes are exceptionally rare [",
"    <a class=\"abstract\" href=\"UTD.htm?14/40/14983/abstract/7\">",
"     7",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?11/49/12056?source=see_link\">",
"     \"Clinical manifestations of osteoarthritis\"",
"    </a>",
"    .) When present, osteoarthritis is usually related to prior intraarticular fractures, avulsion injuries to the humeral condyles (\"Little League\" elbow), or previous episodes of osteonecrosis [",
"    <a class=\"abstract\" href=\"UTD.htm?14/40/14983/abstract/8\">",
"     8",
"    </a>",
"    ]. Nevertheless, the presence of an elbow deformity generally should be interpreted as strong evidence for an underlying inflammatory arthritis.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h2\">",
"     Ligamentous injury",
"    </span>",
"    &nbsp;&mdash;&nbsp;Primarily in throwing athletes, injury can occur to the supporting ligaments of the elbow, particularly the medial (ie, ulnar) collateral ligament (MCL). Great force is generated during the late cocking and early acceleration phases of throwing (eg, pitching a baseball or serving a tennis ball), which results in valgus stress on the elbow, born primarily by the MCL [",
"    <a class=\"abstract\" href=\"UTD.htm?14/40/14983/abstract/3\">",
"     3",
"    </a>",
"    ]. Repetitive throwing can create cumulative microtrauma to this ligament resulting in medial elbow pain and possibly ligamentous laxity.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h1\">",
"     CONFIRMATORY TESTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;A number of confirmatory tests may be warranted in patients with a suspected diagnosis based upon the above findings.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25\">",
"    <span class=\"h2\">",
"     Suspected lateral or medial epicondylitis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with a suggestive history and lateral or medial epicondylar tenderness should have testing to confirm the diagnosis of lateral or medial epicondylitis, respectively. Local anesthetic block may be necessary to sort out difficult cases. The diagnosis and management of epicondylitis is reviewed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?1/20/1354?source=see_link\">",
"     \"Epicondylitis (tennis and golf elbow)\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H29\">",
"    <span class=\"h2\">",
"     Olecranon bursa aspiration",
"    </span>",
"    &nbsp;&mdash;&nbsp;When the bursa has accumulated fluid that is detectable by palpation, the fluid should be aspirated if there is pain, local inflammation, or fever (",
"    <a class=\"graphic graphic_picture graphicRef72647 \" href=\"UTD.htm?21/62/22496\">",
"     picture 7",
"    </a>",
"    ). Bursal fluid should be sent for culture and Gram stain. A white cell count should be obtained and the fluid examined for the presence of crystals. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?13/45/14041?source=see_link\">",
"     \"Bursitis: An overview of clinical manifestations, diagnosis, and management\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A bursal fluid white cell count of more than",
"      <span class=\"nowrap\">",
"       1000/mm3",
"      </span>",
"      is suggestive of inflammation from infection, rheumatoid arthritis, or gout.",
"     </li>",
"     <li>",
"      The identification of crystal is helpful in establishing the diagnosis of gout. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?4/49/4890?source=see_link\">",
"       \"Clinical manifestations and diagnosis of gout\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?7/38/7785?source=see_link\">",
"       \"Clinical manifestations and diagnosis of calcium pyrophosphate crystal deposition disease\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H30\">",
"    <span class=\"h2\">",
"     Radiohumeral joint aspiration",
"    </span>",
"    &nbsp;&mdash;&nbsp;Aspiration of the radiohumeral joint is indicated in patients with a history and physical examination that are suspicious for joint effusion to differentiate traumatic hemarthrosis from inflammatory arthritis, to diagnose crystal-induced arthritis, and to detect the rare case of septic arthritis (",
"    <a class=\"graphic graphic_picture graphicRef51542 \" href=\"UTD.htm?2/23/2416\">",
"     picture 8",
"    </a>",
"    ). Involvement of the elbow with bacterial arthritis is unusual relative to other joints (eg, the knee, wrists, ankles, and hips). However, early diagnosis and therapy are important to preserve joint function. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?10/50/11049?source=see_link\">",
"     \"Septic arthritis in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H31\">",
"    <span class=\"h2\">",
"     Radiography",
"    </span>",
"    &nbsp;&mdash;&nbsp;X-ray of the elbow is rarely necessary in patients with nontraumatic elbow pain (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef61667 graphicRef60057 \" href=\"UTD.htm?33/36/34374\">",
"     image 1A-B",
"    </a>",
"    ). Osteoarthritis of the elbow is uncommon outside of the setting of previous trauma or underlying congenital bony abnormalities. Loss of joint space and the presence of osteophytes between the humerus and the pseudoarticulation of the ulna and radius on plain film are consistent with a diagnosis of osteoarthritis (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef77197 graphicRef63975 \" href=\"UTD.htm?23/41/24213\">",
"     image 2A-B",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1198165\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Elbow pain may be due to disorders involving the joint itself or surrounding structures, such as the epicondyles (medial and lateral), the olecranon bursa, and the radial and ulnar nerves. Referred pain may arise from the neck (cervical radiculopathy) or shoulder. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Anatomy'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Lateral elbow pain is the most common complaint at the elbow. The source may be the lateral epicondyle, the radiohumeral joint, or referred pain. Medial elbow pain is the second most common complaint, and frequently arises either from the medial epicondyle or the ulnar nerve as it travels through the cubital tunnel. Patients who complain of elbow swelling most often have olecranon bursitis. Limited elbow motion suggests an intra-articular process. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Etiology and presentation'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H18\">",
"       'Differential diagnosis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Efficient examination of the elbow includes range of motion testing and inspection and palpation of the following (",
"      <a class=\"graphic graphic_table graphicRef79000 \" href=\"UTD.htm?20/35/21052\">",
"       table 1",
"      </a>",
"      ):",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Lateral epicondyle and extensor tendons",
"     </li>",
"     <li>",
"      Medial epicondyle and flexor tendons",
"     </li>",
"     <li>",
"      Radiohumeral joint",
"     </li>",
"     <li>",
"      Olecranon bursa (see",
"      <a class=\"local\" href=\"#H10\">",
"       'Examination'",
"      </a>",
"      above)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Normal range of motion testing of the elbow effectively rules out involvement of the elbow joint itself. X-ray of the elbow is rarely necessary in patients with nontraumatic pain. (See",
"      <a class=\"local\" href=\"#H24\">",
"       'Confirmatory tests'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/40/14983/abstract/1\">",
"      Gunn CC, Milbrandt WE. Tennis elbow and the cervical spine. Can Med Assoc J 1976; 114:803.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/40/14983/abstract/2\">",
"      Appelboam A, Reuben AD, Benger JR, et al. Elbow extension test to rule out elbow fracture: multicentre, prospective validation and observational study of diagnostic accuracy in adults and children. BMJ 2008; 337:a2428.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/40/14983/abstract/3\">",
"      Behr CT, Altchek DW. The elbow. Clin Sports Med 1997; 16:681.",
"     </a>",
"    </li>",
"    <li>",
"     Hoppenfeld S. Physical examination of the spine and extremities, Prentice Hall, Upper Saddle River 1976.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/40/14983/abstract/5\">",
"      Dawson DM. Entrapment neuropathies of the upper extremities. N Engl J Med 1993; 329:2013.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/40/14983/abstract/6\">",
"      Miller RG. The cubital tunnel syndrome: diagnosis and precise localization. Ann Neurol 1979; 6:56.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/40/14983/abstract/7\">",
"      van Saase JL, van Romunde LK, Cats A, et al. Epidemiology of osteoarthritis: Zoetermeer survey. Comparison of radiological osteoarthritis in a Dutch population with that in 10 other populations. Ann Rheum Dis 1989; 48:271.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/40/14983/abstract/8\">",
"      Woods GW, Tullos HS. Elbow instability and medial epicondyle fractures. Am J Sports Med 1977; 5:23.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 247 Version 5.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.3 - C21.34",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Morehouse School of Medicine",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1104-200.215.4.194-6EBEB1F6CE-S473950.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f14_40_14983=[""].join("\n");
var outline_f14_40_14983=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H1198165\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      ANATOMY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      ETIOLOGY AND PRESENTATION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Pain patterns",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      - Lateral elbow pain",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      - Medial elbow pain",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      - Elbow swelling",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      - Impaired range of motion",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      - Referred pain",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      EXAMINATION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Range of motion",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      - Ulnohumeral joint",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      - Radiohumeral joint",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Epicondylar palpation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Inspection and palpation of the olecranon bursa",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      Palpation of ligaments",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1198469\">",
"      Tinels sign",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      Clinical pearls",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      DIFFERENTIAL DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      Epicondylitis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      Olecranon bursitis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      Nerve entrapment",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      Osteoarthritis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      Ligamentous injury",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      CONFIRMATORY TESTS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H25\">",
"      Suspected lateral or medial epicondylitis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H29\">",
"      Olecranon bursa aspiration",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H30\">",
"      Radiohumeral joint aspiration",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H31\">",
"      Radiography",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1198165\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"EM/247\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"EM/247|DiagnosticImage\">",
"      <a href=\"#\" title=\"DIAGNOSTIC IMAGES\">",
"       DIAGNOSTIC IMAGES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?40/61/41938\" title=\"diagnostic image 1A\">",
"      Elbow lateral view",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?5/32/5632\" title=\"diagnostic image 1B\">",
"      Elbow posterior lateral view",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?16/57/17296\" title=\"diagnostic image 2A\">",
"      Osteoarthritis of the elbow",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?28/49/29456\" title=\"diagnostic image 2B\">",
"      Post traumatic arthritis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"EM/247|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?6/41/6802\" title=\"figure 1\">",
"      Posteromedial view right elbow",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?15/25/15761\" title=\"figure 2\">",
"      Posterolateral view right elbow",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?22/52/23365\" title=\"figure 3\">",
"      Major arteries and nerves of the anterior elbow region",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"EM/247|PIC\">",
"      <a href=\"#\" title=\"PICTURES\">",
"       PICTURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?3/21/3408\" title=\"picture 1\">",
"      Ulnarhumeral range of motion",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?39/37/40543\" title=\"picture 2\">",
"      Radiohumeral range of motion",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?17/46/18145\" title=\"picture 3\">",
"      Palpation lateral epicondyle",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?40/20/41280\" title=\"picture 4\">",
"      Palpation of elbow medial epicondyle",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?29/11/29886\" title=\"picture 5\">",
"      Olecranon bursa",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?7/46/7904\" title=\"picture 6\">",
"      Tinel sign for ulnar neuropathy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?21/62/22496\" title=\"picture 7\">",
"      Aspiration olecranon bursa",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?2/23/2416\" title=\"picture 8\">",
"      Aspiration radiohumeral joint",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"EM/247|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?20/35/21052\" title=\"table 1\">",
"      Elbow examination findings and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?42/6/43115\" title=\"table 2\">",
"      Range of motion elbow",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?13/45/14041?source=related_link\">",
"      Bursitis: An overview of clinical manifestations, diagnosis, and management",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?12/46/13033?source=related_link\">",
"      Clinical features of rheumatoid arthritis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?7/38/7785?source=related_link\">",
"      Clinical manifestations and diagnosis of calcium pyrophosphate crystal deposition disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?4/49/4890?source=related_link\">",
"      Clinical manifestations and diagnosis of gout",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?29/49/30488?source=related_link\">",
"      Clinical manifestations and diagnosis of psoriatic arthritis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?11/49/12056?source=related_link\">",
"      Clinical manifestations of osteoarthritis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?8/57/9114?source=related_link\">",
"      Clinical manifestations, diagnosis, and management of undifferentiated spondyloarthritis and related spondyloarthritides",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?1/20/1354?source=related_link\">",
"      Epicondylitis (tennis and golf elbow)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?1/24/1418?source=related_link\">",
"      Evaluation of the patient with neck pain and cervical spine disorders",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?27/43/28346?source=related_link\">",
"      Osteonecrosis (avascular necrosis of bone)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?8/44/8906?source=related_link\">",
"      Overview of upper extremity peripheral nerve syndromes",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?32/27/33210?source=related_link\">",
"      Reactive arthritis (formerly Reiter syndrome)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?10/50/11049?source=related_link\">",
"      Septic arthritis in adults",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f14_40_14984="Devices for dissection and hemostasis in laparoscopic surgery";
var content_f14_40_14984=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Devices for dissection and hemostasis in laparoscopic surgery",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?14/40/14984/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?14/40/14984/contributors\">",
"     Jon Gould, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?14/40/14984/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?14/40/14984/contributors\">",
"     Jeffrey Marks, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?14/40/14984/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?14/40/14984/contributors\">",
"     Kathryn A Collins, MD, PhD, FACS",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?14/40/14984/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Aug 3, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Adequate hemostasis is essential during laparoscopic procedures. Bleeding can jeopardize visualization and lead to complications. Conversion to an open procedure may be required to control hemorrhage, negating the advantages of the laparoscopic approach. New technologies allow laparoscopic surgeons to perform precise dissection in a virtually bloodless operative field through even the most vascular dissection planes and organs. These devices can be employed for primary dissection or control of bleeding when it is encountered. Primary prevention of bleeding is fundamental.",
"   </p>",
"   <p>",
"    This topic will discuss devices and techniques available to the surgeon for dissection and control of bleeding encountered during laparoscopic surgery.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     THE LAPAROSCOPIC FIELD",
"    </span>",
"    &nbsp;&mdash;&nbsp;The laparoscopic operative field and instrumentation have unique technical issues, which can challenge even the most experienced surgeon, especially when significant bleeding is encountered.",
"   </p>",
"   <p>",
"    Compared with the open surgical field, the laparoscopic field has:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A two-dimensional field of view with a loss of depth perception.",
"     </li>",
"     <li>",
"      Limited field of view. Instruments may leave field of view or manipulate structures outside of the field. Bleeding outside the current field of vision (eg, torn adhesion) can occur.",
"     </li>",
"     <li>",
"      Limited working space for laparoscopic instruments. Complete exposure of the operative field can be difficult due to the limited number and size of instruments that can be inserted into the abdominal cavity. The configuration for port placement also depends upon the patient&rsquo;s anatomy, which can present additional challenges.",
"     </li>",
"     <li>",
"      Altered perception of the amount of bleeding which can appear dramatic in a laparoscopic field. Judgement and experience are needed to determine the severity of bleeding.",
"     </li>",
"     <li>",
"      Altered light absorption. Blood stains the tissues deeply, leading to difficulties visualizing and dissecting the correct anatomic tissue planes.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In addition, intra-abdominal smoke from energy sources used in dissection and hemostasis may obscure vision, and frequent opening of ports to clear the smoke can lead to loss of pneumoperitoneum, instrument placement or exposure of the region of interest. The laparoscopic camera lens is prone to frequent fogging, particularly early in the case before it has warmed to body temperature. Vision can also be impaired by blood or body fluids that accumulate on the tip of the laparoscope. (See",
"    <a class=\"local\" href=\"#H16\">",
"     'Management of hemorrhage'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     DEVICES FOR HEMOSTASIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Most devices used for dissection and hemostasis in the laparoscopic environment are adapted from open surgery.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Surgical clips",
"    </span>",
"    &nbsp;&mdash;&nbsp;As with open surgery, U-shaped hemostatic clips are used to prevent bleeding from vessels encountered during dissection. The vessel is identified, dissected and then clipped prior to division of the vessel. In laparoscopic surgery, titanium clips are used instead of stainless steel because titanium does not magnetize and is, therefore, easier to handle. A variety of clip sizes are available for 5 and 10 mm disposable clip appliers. Reusable clip appliers can also be used. However, there is a tendency for the clip to fall off the reusable applier, and the extra time needed to reload the device limits its usefulness in laparoscopic surgery.",
"   </p>",
"   <p>",
"    Standard U-shaped hemostatic clips can dislodge as a result of arterial pulsation or manipulation of the operative field during further dissection. Multiple clips (up to five) can be applied, as needed. Caution is advised when using standard clips to occlude vessels with a diameter more than 3 mm.",
"   </p>",
"   <p>",
"    A polymer ligation clip system (ie, Hem-o-lok&reg;) contains a self-locking mechanism that may decrease slippage from larger vessels (",
"    <a class=\"graphic graphic_picture graphicRef74988 \" href=\"UTD.htm?11/29/11728\">",
"     picture 1",
"    </a>",
"    ). Vessels with diameters up to 16 mm can be managed with these clips. Prior to deploying the clip, the vessel should be dissected free of surrounding structures because the hook-like locking mechanism can easily perforate adjacent tissues (eg, veins). Slippage of locking clips can occur, which is more likely if the clip is applied to a vessel at an angle other than 90 degrees or the vessel cuff length &lt;1 mm [",
"    <a class=\"abstract\" href=\"UTD.htm?14/40/14984/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Locking clips are useful in situations where it is important to securely control a pedicle but preserve vessel length (eg, donor nephrectomy, splenectomy, adrenalectomy, pulmonary resection, colectomy). Retrospective reviews have concluded that polymer-locking clips for donor nephrectomy provide rapid control and are economical [",
"    <a class=\"abstract\" href=\"UTD.htm?14/40/14984/abstract/2-5\">",
"     2-5",
"    </a>",
"    ]. Although generally safe and reliable, serious complications, including death, have been reported following slippage of the clips used during donor nephrectomy [",
"    <a class=\"abstract\" href=\"UTD.htm?14/40/14984/abstract/6\">",
"     6",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Suture ligation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Suturing tissues and placing ligatures during laparoscopic surgery are complex technical skills. Intracorporeal knot tying avoids excessive tension and is preferable to extracorporeal knotting when the tissue is friable or tears easily. Ready-to-use, pre-tied endoloops for primary vessel ligation and hemostasis are commercially available [",
"    <a class=\"abstract\" href=\"UTD.htm?14/40/14984/abstract/7,8\">",
"     7,8",
"    </a>",
"    ]. Endoloops are often used for hemostasis when a tissue pedicle can be easily \"lassoed\" by the loop (eg, laparoscopic appendectomy, laparoscopic cholecystectomy) [",
"    <a class=\"abstract\" href=\"UTD.htm?14/40/14984/abstract/9,10\">",
"     9,10",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Suture ligature may be needed for hemostasis of bleeding staple lines when cautery or clip application fail or are undesirable. High-risk staple lines (eg, stapled gastrojejunostomy in a gastric bypass) are best controlled with suture ligature, particularly if brief bursts of low-voltage electrocautery have been ineffective. &nbsp;Thermal spread with excessive electrocautery of the staple line may lead to tissue necrosis and gastrointestinal leakage.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Surgical staplers",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h3\">",
"     Gastrointestinal",
"    </span>",
"    &nbsp;&mdash;&nbsp;In laparoscopic surgery, bowel resection and anastomosis are performed with stapling devices similar to those used in open surgery, although with longer handles. Control of bleeding at the cut tissue edges following staple deployment can be more technically challenging in the laparoscopic field. (See",
"    <a class=\"local\" href=\"#H2\">",
"     'The laparoscopic field'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    Additional buttressing materials have been added to the jaws of laparoscopic stapling devices to improve hemostasis. Buttressing materials can be natural (eg, bovine pericardium; Peri-Strips&reg;) or synthetic (glycolide copolymer; Gore Seamguard&reg;).",
"   </p>",
"   <p>",
"    In a randomized trial of 34 patients, significantly fewer staple line bleeding sites were present in patients randomized to a reinforced staple line compared with those with unreinforced staple lines for all tissues types studied (gastric tissue [0.4 versus 2.5 sites], jejunal tissue [0.1 versus 0.6 sites], mesenteric tissue [0 versus 0.8 sites]) [",
"    <a class=\"abstract\" href=\"UTD.htm?14/40/14984/abstract/11\">",
"     11",
"    </a>",
"    ]. The potential advantage of decreased bleeding with routine staple line reinforcement needs to be balanced against the additional cost of the device and a lack of a clear benefit in reducing anastomotic gastrointestinal leak rates [",
"    <a class=\"abstract\" href=\"UTD.htm?14/40/14984/abstract/12,13\">",
"     12,13",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h3\">",
"     Vascular",
"    </span>",
"    &nbsp;&mdash;&nbsp;Special vascular laparoscopic staplers are used to divide major arteries and veins. Vascular staplers generally require a 12 mm port for insertion. The stapler cartridge typically has six rows of staples with three rows of staples on each side of the divided tissue (",
"    <a class=\"graphic graphic_picture graphicRef76073 \" href=\"UTD.htm?24/25/24976\">",
"     picture 2",
"    </a>",
"    ). In an experimental porcine model, vascular staplers have been shown to seal vessels (arteries up to 17 mm, veins up to 22 mm) to burst pressures three times greater than mean systolic pressure (ie, &gt;310 mmHg) [",
"    <a class=\"abstract\" href=\"UTD.htm?14/40/14984/abstract/14\">",
"     14",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Choosing the appropriate staple height is important. The final fired staple height depends upon the stapler, the selected stapler cartridge, and the tissue itself. A staple cartridge with staples that are 2.0 to 2.5 mm in height provides excellent hemostasis for most larger arteries, provided the vessels can comfortably compress to 0.75 to 1.0 mm. Newer staplers such as the Echelon&trade; and the Endo GIA&trade; employ a technique known as tissue gap control where the final fired staple height is consistent across the length of the staple line. Each individual manufacturer can provide surgeons with specific information for their commercially available staple cartridges.",
"   </p>",
"   <p>",
"    In general:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      For a 2.0 mm cartridge, final tissue compression should be 0.75 mm to 1.0 mm.",
"     </li>",
"     <li>",
"      For a 2.5 mm cartridge, final tissue compression should be 1.0 mm to 1.5 mm.",
"     </li>",
"     <li>",
"      For a 3.5 mm cartridge, final tissue compression should be 1.5 mm to 2.0 mm.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Using too long or too a short staple will lead to bleeding after the stapler is fired. A short staple fired through thick tissue that cannot be compressed to the final staple height will not interlock properly, or will rip through the tissue. Conversely, too long a staple will not adequately compress the tissue and bleeding will occur through the staple line.",
"   </p>",
"   <p>",
"    Hemostasis of residual bleeding through a staple line can be controlled in several ways. A short burst of electrocautery to the compressed tissue at the free edge of the staple line is successful in most cases. Application of titanium clips to the bleeding site of the staple line is another option. Suture ligature and the application of topical hemostatic agents to the staple line can also be effective and may be preferable in gastrointestinal staple lines. (See",
"    <a class=\"local\" href=\"#H5\">",
"     'Suture ligation'",
"    </a>",
"    above and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?17/22/17769?source=see_link\">",
"     \"Overview of topical hemostatic agents used in the operating room\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Electrosurgery",
"    </span>",
"    &nbsp;&mdash;&nbsp;Electrosurgery refers to the coagulation and cutting of tissue using high-frequency electrical current [",
"    <a class=\"abstract\" href=\"UTD.htm?14/40/14984/abstract/15\">",
"     15",
"    </a>",
"    ]. Both monopolar and bipolar electrosurgical techniques are used in laparoscopic surgery. The basic principles of electrosurgery are discussed in detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/54/37737?source=see_link\">",
"     \"Overview of electrosurgery\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    A wide variety of standard disposable and non-disposable laparoscopic instruments have a cautery attachment for monopolar current, including the scissors, hook, spatula, and dissectors. Insulation breaks on these instruments allow transmission of stray current outside of the intended field of dissection (",
"    <a class=\"graphic graphic_picture graphicRef81831 \" href=\"UTD.htm?2/34/2593\">",
"     picture 3",
"    </a>",
"    ). Thermal injury may not be apparent at the time of the injury and delayed hollow viscus perforation or hemorrhage can occur as necrotic bowel or vascular tissue sloughs [",
"    <a class=\"abstract\" href=\"UTD.htm?14/40/14984/abstract/16\">",
"     16",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/54/37737?source=see_link&amp;anchor=H255197510#H255197510\">",
"     \"Overview of electrosurgery\", section on 'Prevention of electrosurgical injuries'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Bipolar electrosurgery minimizes the risk of damage to adjacent tissue by containing electrical current between the jaws of the forceps. However, the application of traditional bipolar devices to laparoscopic surgery is limited because traditional bipolar does not have cutting ability, cannot be applied over a broad surface, and cannot be used for larger vessels.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h3\">",
"     Advanced bipolar sealing",
"    </span>",
"    &nbsp;&mdash;&nbsp;More advanced bipolar devices (eg, LigaSure&trade;, PlasmaKinetic, EnSeal&reg;) combine bipolar current together with tissue apposition and compression to create a tissue seal (",
"    <a class=\"graphic graphic_picture graphicRef66593 \" href=\"UTD.htm?29/1/29716\">",
"     picture 4",
"    </a>",
"    ). Bipolar sealing is used to manage blood vessels contained within other tissue (eg, omentum, mesentery) (",
"    <a class=\"graphic graphic_picture graphicRef80946 \" href=\"UTD.htm?5/53/5972\">",
"     picture 5",
"    </a>",
"    ) or vessels that have been circumferentially dissected (",
"    <a class=\"graphic graphic_picture graphicRef80946 \" href=\"UTD.htm?5/53/5972\">",
"     picture 5",
"    </a>",
"    ). Advanced bipolar sealing devices provide excellent hemostasis for vessels up to 7 mm.",
"   </p>",
"   <p>",
"    In an experimental study, the burst pressure of sealed vessels was two to three times greater than mean systolic blood pressure (&gt;300 mmHg) [",
"    <a class=\"abstract\" href=\"UTD.htm?14/40/14984/abstract/17\">",
"     17",
"    </a>",
"    ]. A trial of 60 patients randomly assigned to bipolar sealing versus suturing for hemostasis during hysterectomy found significantly lower blood loss (68.9 versus 127 mL) and shorter operating times (39 versus 54 minutes) in the bipolar sealing group [",
"    <a class=\"abstract\" href=\"UTD.htm?14/40/14984/abstract/18\">",
"     18",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Lateral thermal spread with bipolar sealing is much less than that seen with monopolar electrocautery, which can be as much as 25 mm [",
"    <a class=\"abstract\" href=\"UTD.htm?14/40/14984/abstract/19\">",
"     19",
"    </a>",
"    ]. With bipolar sealing, lateral thermal spread increases slightly as the diameter of the treated vessel increases. For a 2 to 3 mm vessel, the maximal thermal spread is about 1.5 mm, whereas for a 6 to 7 mm vessel, the maximal thermal spread is about 3 mm [",
"    <a class=\"abstract\" href=\"UTD.htm?14/40/14984/abstract/17\">",
"     17",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/54/37737?source=see_link\">",
"     \"Overview of electrosurgery\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h3\">",
"     Ultrasonic desiccation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Ultrasonic devices (eg, Harmonic&reg; scalpel, UltraCision&reg;, CUSA&reg;, TissueLink, LOTUS&trade;) convert electrical energy into mechanical energy, which produces cutting and coagulation effects. In response to electric current, a piezoelectric crystal located at the tip of the instrument vibrates at about 55,000 Hz, generating mechanical forces that rupture cells and form a coagulum. The range of peak tissue temperatures are much lower (60&ordm;C to 100&ordm;C) compared with those produced by electrocautery (200&ordm;C to 300&ordm;C).",
"   </p>",
"   <p>",
"    In general, the Harmonic Scalpel&reg; can be used in just about any abdominal laparoscopic procedure when hemostatic dissection with relatively little lateral thermal spread to neighboring tissue is desired (eg, cholecystectomy, hysterectomy, colorectal surgery, bariatric surgery, liver surgery) [",
"    <a class=\"abstract\" href=\"UTD.htm?14/40/14984/abstract/20-25\">",
"     20-25",
"    </a>",
"    ]. The main disadvantage of ultrasonic dissection is poor hemostasis with the division of larger vessels (&ge;4 mm). A newer version of the Harmonic&reg; scalpel, the Harmonic ACE&reg;, may be capable of handling vessels up to a maximum of 5 mm due to a higher velocity of transaction.",
"   </p>",
"   <p>",
"    One trial randomly assigned 120 patients undergoing laparoscopic cholecystectomy to traditional hemostatic clipping of the cystic duct and artery with cautery for gallbladder dissection from the liver compared with use of the Harmonic&reg; scalpel [",
"    <a class=\"abstract\" href=\"UTD.htm?14/40/14984/abstract/24\">",
"     24",
"    </a>",
"    ]. No cystic duct stump leaks occurred in either group. Patients in the ultrasonic dissection group experienced fewer intraoperative gallbladder perforations (10 versus 30 percent) and shorter median operative times (32 versus 40 minutes).",
"   </p>",
"   <p>",
"    The Cavitron Ultrasound Surgical Aspirator&reg; (CUSA&reg;) is another ultrasonic device. Tissue is fragmented and rapidly irrigated and aspirated away from the dissection field. The CUSA&reg; device is used primarily for open liver resection; however, a limited experience has demonstrated feasibility for laparoscopic liver resection. The liver parenchyma is destroyed, leaving larger vessels intact to be managed by other means such as clipping, LigaSure&trade;, Hem-o-lok&reg; clips, or vascular staplers.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h3\">",
"     Radiofrequency ablation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Radiofrequency ablation devices generate a high-frequency alternating current in the radio range of frequencies (460 to 500 kHz), which is transmitted through an electrode placed into the tissue under ultrasound-guidance [",
"    <a class=\"abstract\" href=\"UTD.htm?14/40/14984/abstract/26\">",
"     26",
"    </a>",
"    ]. Activation of the device causes focal tissue destruction at the tip of the electrode.",
"   </p>",
"   <p>",
"    Radiofrequency ablation has been applied to laparoscopic segmental liver resection [",
"    <a class=\"abstract\" href=\"UTD.htm?14/40/14984/abstract/27,28\">",
"     27,28",
"    </a>",
"    ]. The technique consists of ultrasound-guided placement of the electrode to target the segmental and subsegmental portal and arterial and feeding vessels prior to liver resection. Once these vessels have coagulated, the liver becomes ischemic in the appropriate distribution (",
"    <a class=\"graphic graphic_figure graphicRef52260 \" href=\"UTD.htm?22/38/23142\">",
"     figure 1",
"    </a>",
"    ). Parenchymal resection is then performed in a relatively bloodless field. In one case series of 30 patients, a blood loss less than 120 mL was reported with the use of this technique [",
"    <a class=\"abstract\" href=\"UTD.htm?14/40/14984/abstract/28\">",
"     28",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Laser fulguration",
"    </span>",
"    &nbsp;&mdash;&nbsp;Lasers use light energy at wavelengths specific to the target tissue to produce their effects. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?31/25/32151?source=see_link\">",
"     \"Basic principles of medical lasers\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Lasers are commonly used in laparoscopic gynecologic (eg, endometriosis) and urologic (eg, prostatectomy, partial nephrectomy) procedures [",
"    <a class=\"abstract\" href=\"UTD.htm?14/40/14984/abstract/29,30\">",
"     29,30",
"    </a>",
"    ] which are discussed in separate topic reviews. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?31/7/31866?source=see_link\">",
"     \"An overview of endometrial ablation\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?39/7/40056?source=see_link\">",
"     \"Surgical and other invasive therapies of benign prostatic hyperplasia\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    When used in laparoscopic surgery, lasers can cause significant tissue vaporization, smoke and can spread liquefied tissue during instrument manipulation. General abdominal laparoscopic surgery rarely requires the use of surgical lasers due to the ready availability of alternative modalities described elsewhere in this topic.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Other devices",
"    </span>",
"    &nbsp;&mdash;&nbsp;Not all devices used successfully in open surgery are suitable for laparoscopic surgery. One example is the argon beam coagulator. This device uses monopolar electrocautery to produce a coagulated surface with very little smoke by passing electric current through a stream of ionized argon gas to blow away blood and debris from the surgical field. High-flow infusion of argon gas can increase abdominal pressure, limiting its usefulness in laparoscopic surgery. In addition, the argon beam coagulator does not provide dissection or control of larger vessels; argon gas embolization has been reported in association with liver resection [",
"    <a class=\"abstract\" href=\"UTD.htm?14/40/14984/abstract/31\">",
"     31",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h1\">",
"     CHOICE OF DEVICE",
"    </span>",
"    &nbsp;&mdash;&nbsp;The availability of the more sophisticated devices determines their usage under most circumstances. The choice of technique is generally according to the surgeon's preference and experience. There are few trials that directly compare devices.",
"   </p>",
"   <p>",
"    Fatty structures, such as the omentum and mesentery, are best addressed with an ultrasonic energy source such as the Harmonic&reg; scalpel. This device produces rapid, hemostatic dissection of these structures. When vessels within the mesentery exceed 5 mm in diameter (eg, inferior mesenteric artery), advanced bipolar sealing devices, such as the LigaSure&trade;, may be indicated. (See",
"    <a class=\"local\" href=\"#H11\">",
"     'Ultrasonic desiccation'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    Gastrointestinal tissues (ie, esophagus, stomach, small and large bowel) are best divided with endoscopic linear cutting staplers rather than thermal methods. However, an ex vivo study evaluating mesenteric vessel sealing found effective sealing for ultrasonic (Harmonic ACE&reg;, LOTUS&trade;) and bipolar sealing (LigaSure&trade;) devices for vessels to 1.25 mm. Cutting staplers divide the tissue along precisely selected cut lines and provide hemostasis without the risk of lateral thermal spread, which could compromise the integrity of the subsequent anastomosis. (See",
"    <a class=\"local\" href=\"#H7\">",
"     'Gastrointestinal'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    Vascular structures up to 7 mm can be managed with an endoscopic linear vascular stapler or advanced bipolar sealing device. For laparoscopic splenectomy, both Endo GIA&trade; and LigaSure&trade; are safe and effective for division of the hilar vessels. In one study, LigaSure&trade; took less time and was associated with less intraoperative bleeding and need for transfusion compared with the use of a linear stapling device [",
"    <a class=\"abstract\" href=\"UTD.htm?14/40/14984/abstract/32\">",
"     32",
"    </a>",
"    ]. Arterial structures between 7 mm and 15 mm should be divided with a vascular stapler. For larger arteries and veins, we prefer suture ligation. (See",
"    <a class=\"local\" href=\"#H10\">",
"     'Advanced bipolar sealing'",
"    </a>",
"    above and",
"    <a class=\"local\" href=\"#H8\">",
"     'Vascular'",
"    </a>",
"    above and",
"    <a class=\"local\" href=\"#H5\">",
"     'Suture ligation'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    Solid organ dissection and hemostasis can be achieved with either the CUSA&reg; or radiofrequency probes. (See",
"    <a class=\"local\" href=\"#H11\">",
"     'Ultrasonic desiccation'",
"    </a>",
"    above and",
"    <a class=\"local\" href=\"#H12\">",
"     'Radiofrequency ablation'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h1\">",
"     MANAGEMENT OF HEMORRHAGE",
"    </span>",
"    &nbsp;&mdash;&nbsp;Prevention of bleeding by meticulous hemostasis during dissection is a fundamental principle of laparoscopic surgery. When significant hemorrhage occurs during the course of laparoscopic surgery, it is often due to a technical error, such as inadvertent cautery away from the field of dissection, excessive thermal spread, improper staple length or height or stapling technique, or failing to recognize a significant vascular structure prior to its division with nonvascular stapling instrument. The identification of significant hemorrhage should prompt the surgeon to immediately notify the anesthesiologist for fluid resuscitation, transfusion or potential need to convert to an open procedure.",
"   </p>",
"   <p>",
"    Mild-to-moderate bleeding can often be controlled with compressive maneuvers. Local compression allows a surgeon time to consider strategies for definitive hemostasis and may, in itself, be a definitive treatment. Most small to mid-sized vessels will spasm, and bleeding slows and often stops altogether with simple compression.",
"   </p>",
"   <p>",
"    A gauze sponge can be passed through a 10 mm port to compress the identified area of bleeding. Soaking the sponge with dilute (1:10,000 or 1:100,000) epinephrine has also been described for controlling bleeding during laparoscopic cholecystectomy [",
"    <a class=\"abstract\" href=\"UTD.htm?14/40/14984/abstract/33\">",
"     33",
"    </a>",
"    ] and laparoscopic Heller myotomy [",
"    <a class=\"abstract\" href=\"UTD.htm?14/40/14984/abstract/34\">",
"     34",
"    </a>",
"    ]. Under some circumstances, a piece of healthy and mobile omentum can be grasped and used to compress the area. As an example, this technique is useful for sudden, significant bleeding from division of the short gastric arteries during laparoscopic fundoplication or laparoscopic splenectomy.",
"   </p>",
"   <p>",
"    Dry hemostatic agents (eg, Surgicel&reg;, Gelfoam&reg;) can easily be passed through a laparoscopic port and used in conjunction with mechanical compression. Fibrin glue has also been used to provide hemostasis during liver biopsy [",
"    <a class=\"abstract\" href=\"UTD.htm?14/40/14984/abstract/35\">",
"     35",
"    </a>",
"    ], splenic surgery for trauma [",
"    <a class=\"abstract\" href=\"UTD.htm?14/40/14984/abstract/36\">",
"     36",
"    </a>",
"    ], partial nephrectomy [",
"    <a class=\"abstract\" href=\"UTD.htm?14/40/14984/abstract/37\">",
"     37",
"    </a>",
"    ], and gastric bypass [",
"    <a class=\"abstract\" href=\"UTD.htm?14/40/14984/abstract/38,39\">",
"     38,39",
"    </a>",
"    ] with the aid of a special laparoscopic applicator. Topical hemostatic agents are discussed in detail elsewhere (",
"    <a class=\"graphic graphic_table graphicRef71852 \" href=\"UTD.htm?19/54/20334\">",
"     table 1",
"    </a>",
"    ). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?17/22/17769?source=see_link\">",
"     \"Overview of topical hemostatic agents used in the operating room\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Once bleeding has slowed or ceased, the area is inspected to identify the bleeding point which is isolated and controlled with a clip, suture, cautery or any of the other modalities described above. The field is irrigated with saline. (See",
"    <a class=\"local\" href=\"#H3\">",
"     'Devices for hemostasis'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    Irrigation should be used judiciously to minimize soiling of the tip of the laparoscope with blood and other fluids. When the insides of the ports get wet or bloody, maintaining a clear view of the operative field becomes difficult. Dissecting instruments (eg, monopolar cautery, CUSA&reg;) also perform poorly when submerged in fluid, and excess splattering of the fluid can occur during their continued use. (See",
"    <a class=\"local\" href=\"#H2\">",
"     'The laparoscopic field'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h2\">",
"     Conversion to an open procedure",
"    </span>",
"    &nbsp;&mdash;&nbsp;The need to convert due to bleeding is determined by the rate of bleeding, the amount of blood loss, the clinical status of the patient (tachycardia, hypotension, sepsis), the presence (or lack) of a clearly defined source, and the comfort of the surgeon with his or her ability to see and control the bleeding quickly with laparoscopic techniques. Patient factors such as advanced age or poor functional status and comorbidities (cardiopulmonary conditions, obesity, cirrhosis, clotting disorders) should be taken into account when deciding how long to persist with laparoscopic attempts at hemostasis and how likely these attempts are to be successful.",
"   </p>",
"   <p>",
"    When moderate-to-heavy bleeding occurs, vision can be obscured when blood on the inside of the port repeatedly contacts the tip of the cleaned scope each time it is reinserted. A long cotton-tipped applicator can be used for cleaning the inside of a 5 mm port, but removal or replacement of the port may be needed. If adequate visibility cannot be maintained, conversion to an open procedure is needed.",
"   </p>",
"   <p>",
"    The decision to convert for bleeding is justifiable and prudent. An important source of patient morbidity results from the failure to convert to an open procedure in a timely fashion when bleeding is encountered. Laparoscopic hemostasis that is partially effective or ineffective can lead to significant blood loss and its associated clinical consequences. The diagnosis, treatment and consequences of volume depletion from hemorrhage are discussed in separate topic reviews. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?5/62/6120?source=see_link\">",
"     \"Shock in adults: Types, presentation, and diagnostic approach\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?29/45/30425?source=see_link&amp;anchor=H6570016#H6570016\">",
"     \"Overview of the management of acute kidney injury (acute renal failure)\", section on 'Volume depletion'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/25/38294?source=see_link\">",
"     \"Massive blood transfusion\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    It is important to be vigilant about the possibility of injury to local anatomic structures when attempting to control bleeding. As an example, during laparoscopic cholecystectomy, efforts to control a bleeding artery without adequate visibility can lead to application of a clip to the common bile duct or right hepatic artery [",
"    <a class=\"abstract\" href=\"UTD.htm?14/40/14984/abstract/26\">",
"     26",
"    </a>",
"    ]. Extensive monopolar electrocautery in this region can also result in a thermal injury to the bile ducts or duodenum. Conversion to open cholecystectomy occurs in roughly 5 percent of laparoscopic cholecystectomies. The most common reasons for conversion include the inability to correctly identify anatomy (most often due to inflammation), bleeding, and a suspicion that bile duct injury has occurred [",
"    <a class=\"abstract\" href=\"UTD.htm?14/40/14984/abstract/40\">",
"     40",
"    </a>",
"    ].The complications of cholecystectomy are discussed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?11/4/11338?source=see_link\">",
"     \"Laparoscopic cholecystectomy: Techniques\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?18/22/18792?source=see_link\">",
"     \"Complications of laparoscopic cholecystectomy\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The laparoscopic field presents unique technical challenges that include limited depth perception, limited field of view, limited working space, and impaired visibility from altered light absorption, smoke, fogging of the laparoscope lens, or blood on the lens. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'The laparoscopic field'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Primary prevention of bleeding during dissection is essential during laparoscopic surgery because even minor bleeding can increase the degree of complexity of the operation and lead to complications. A variety of sutures, clips and stapling devices are available for dissection and hemostasis during laparoscopic surgery. Surgical clips are easy to apply, readily available and useful for vessels &le;3mm, but have a tendency to slip off. Self-locking polymer ligation clips (Hem-o-lok&reg;) clips have been developed for larger vessels. Endoscopic staplers divide larger vessels, and the correct choice of a stapling device and stapler cartridge are essential to minimize the risk of bleeding from the staple line. (See",
"      <a class=\"local\" href=\"#H5\">",
"       'Suture ligation'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H4\">",
"       'Surgical clips'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H6\">",
"       'Surgical staplers'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Electrosurgical devices used for dissection and hemostasis in laparoscopic surgery include monopolar and bipolar electrocautery, advanced bipolar sealing systems, ultrasonic desiccation, radiofrequency ablation and laser ablation. Monopolar cautery is commonly used in conjunction with laparoscopic instruments and can be used for both dissection and hemostasis. Excessive thermal injury to the target tissue and injury to nontarget tissues can occur if settings are inappropriate or stray currents develop. Traditional bipolar devices are not typically used in laparoscopic surgery, but advanced bipolar vessel sealing systems combine tissue compression and bipolar cautery to divide larger vessels. Ultrasonic dissectors cut and coagulate tissue simultaneously. (See",
"      <a class=\"local\" href=\"#H9\">",
"       'Electrosurgery'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The choice of device for dissection and hemostasis during laparoscopic surgery is generally according to device availability and preference and experience of the surgeon. In general, fatty structures such as the omentum or mesentery are divided with an ultrasonic dissector. When mesenteric vessels &gt;5 mm in diameter are encountered, an advanced bipolar sealing device should be used (if available) or the vessel suture ligated. Gastrointestinal tissues should be divided with endoscopic linear cutting staplers to provide hemostasis and a precise line of division for the subsequent anastomosis. Larger vascular structures (7 to 15 mm) can be divided with a vascular endoscopic linear cutting stapler or suture ligated. The Cavitron Ultrasound Surgical Aspirator&reg; and radio frequency probes have been used successfully for solid organ (eg, liver) dissection and hemostasis. (See",
"      <a class=\"local\" href=\"#H15\">",
"       'Choice of device'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Significant hemorrhage during the course of laparoscopic surgery can often be attributed to a technical error such as inadvertent cautery away from the field of dissection, excessive thermal spread of electrocautery, improper staple length, height or stapling technique, or failing to recognize a significant vascular structure prior to its division with nonvascular stapling instrument. As in open surgery, mechanical compression and application of topical hemostatic agents are appropriate initial strategies. Moderate bleeding during laparoscopic surgery can be controlled with clips, suture ligation, or electrosurgical methods depending upon the source of bleeding and nature of surrounding tissues. &nbsp;(See",
"      <a class=\"local\" href=\"#H16\">",
"       'Management of hemorrhage'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      An important source of patient morbidity results from the failure to convert to an open procedure in a timely fashion when control of bleeding is challenging. Laparoscopic hemostasis that is partially effective or ineffective can lead to significant blood loss and its associated clinical consequences. (See",
"      <a class=\"local\" href=\"#H17\">",
"       'Conversion to an open procedure'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/40/14984/abstract/1\">",
"      Sooriakumaran P, Kommu SS, Cooke J, et al. Evaluation of a commercial vascular clip: risk factors and predictors of failure from in vitro studies. BJU Int 2009; 103:1410.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/40/14984/abstract/2\">",
"      Casale P, Pomara G, Simone M, et al. Hem-o-lok clips to control both the artery and the vein during laparoscopic nephrectomy: personal experience and review of the literature. J Endourol 2007; 21:915.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/40/14984/abstract/3\">",
"      Lucchi M, Duranti L, Melfi F, Mussi A. Polymer self-locking clips for vascular control during minimally invasive pulmonary lobectomies. J Thorac Cardiovasc Surg 2010; 139:1345.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/40/14984/abstract/4\">",
"      Izaki H, Fukumori T, Takahashi M, et al. Clinical research of renal vein control using Hem-o-lok clips in laparoscopic nephrectomy. Int J Urol 2006; 13:1147.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/40/14984/abstract/5\">",
"      Ponsky L, Cherullo E, Moinzadeh A, et al. The Hem-o-lok clip is safe for laparoscopic nephrectomy: a multi-institutional review. Urology 2008; 71:593.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/40/14984/abstract/6\">",
"      Dekel Y, Mor E. Hem-o-lok clip dislodgment causing death of the donor after laparoscopic living donor nephrectomy. Transplantation 2008; 86:887.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/40/14984/abstract/7\">",
"      Song J, Cho SJ, Park CS, et al. Two uterine arterial management methods in laparoscopic hysterectomy. J Obstet Gynaecol Res 1998; 24:145.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/40/14984/abstract/8\">",
"      Beck SD, Lifshitz DA, Cheng L, et al. Endoloop-assisted laparoscopic partial nephrectomy. J Endourol 2002; 16:175.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/40/14984/abstract/9\">",
"      Wehrman WE, Tangren CM, Inge TH. Cost analysis of ligature versus stapling techniques of laparoscopic appendectomy in children. J Laparoendosc Adv Surg Tech A 2007; 17:371.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/40/14984/abstract/10\">",
"      Beldi G, Vorburger SA, Bruegger LE, et al. Analysis of stapling versus endoloops in appendiceal stump closure. Br J Surg 2006; 93:1390.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/40/14984/abstract/11\">",
"      Nguyen NT, Longoria M, Welbourne S, et al. Glycolide copolymer staple-line reinforcement reduces staple site bleeding during laparoscopic gastric bypass: a prospective randomized trial. Arch Surg 2005; 140:773.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/40/14984/abstract/12\">",
"      Giannopoulos GA, Tzanakis NE, Rallis GE, et al. Staple line reinforcement in laparoscopic bariatric surgery: does it actually make a difference? A systematic review and meta-analysis. Surg Endosc 2010; 24:2782.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/40/14984/abstract/13\">",
"      Ibele A, Garren M, Gould J. Effect of circular staple line buttressing material on gastrojejunostomy failure in laparoscopic Roux-en-Y gastric bypass. Surg Obes Relat Dis 2010; 6:64.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/40/14984/abstract/14\">",
"      El-Hakim A, Cai Y, Marcovich R, et al. Effect of Endo-GIA vascular staple size on laparoscopic vessel sealing in a porcine model. Surg Endosc 2004; 18:961.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/40/14984/abstract/15\">",
"      Massarweh NN, Cosgriff N, Slakey DP. Electrosurgery: history, principles, and current and future uses. J Am Coll Surg 2006; 202:520.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/40/14984/abstract/16\">",
"      Humes DJ, Ahmed I, Lobo DN. The pedicle effect and direct coupling: delayed thermal injuries to the bile duct after laparoscopic cholecystectomy. Arch Surg 2010; 145:96.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/40/14984/abstract/17\">",
"      Carbonell AM, Joels CS, Kercher KW, et al. A comparison of laparoscopic bipolar vessel sealing devices in the hemostasis of small-, medium-, and large-sized arteries. J Laparoendosc Adv Surg Tech A 2003; 13:377.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/40/14984/abstract/18\">",
"      Levy B, Emery L. Randomized trial of suture versus electrosurgical bipolar vessel sealing in vaginal hysterectomy. Obstet Gynecol 2003; 102:147.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/40/14984/abstract/19\">",
"      Goldstein SL, Harold KL, Lentzner A, et al. Comparison of thermal spread after ureteral ligation with the Laparo-Sonic ultrasonic shears and the Ligasure system. J Laparoendosc Adv Surg Tech A 2002; 12:61.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/40/14984/abstract/20\">",
"      Fullum TM, Kim S, Dan D, Turner PL. Laparoscopic \"Dome-down\" cholecystectomy with the LCS-5 Harmonic scalpel. JSLS 2005; 9:51.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/40/14984/abstract/21\">",
"      Campagnacci R, de Sanctis A, Baldarelli M, et al. Electrothermal bipolar vessel sealing device vs. ultrasonic coagulating shears in laparoscopic colectomies: a comparative study. Surg Endosc 2007; 21:1526.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/40/14984/abstract/22\">",
"      Yung E, Gagner M, Pomp A, et al. Cost comparison of reusable and single-use ultrasonic shears for laparoscopic bariatric surgery. Obes Surg 2010; 20:512.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/40/14984/abstract/23\">",
"      Gyr T, Ghezzi F, Arslanagic S, et al. Minimal invasive laparoscopic hysterectomy with ultrasonic scalpel. Am J Surg 2001; 181:516.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/40/14984/abstract/24\">",
"      Bessa SS, Al-Fayoumi TA, Katri KM, Awad AT. Clipless laparoscopic cholecystectomy by ultrasonic dissection. J Laparoendosc Adv Surg Tech A 2008; 18:593.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/40/14984/abstract/25\">",
"      Abu Hilal M, Underwood T, Taylor MG, et al. Bleeding and hemostasis in laparoscopic liver surgery. Surg Endosc 2010; 24:572.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/40/14984/abstract/26\">",
"      Callery MP. Avoiding biliary injury during laparoscopic cholecystectomy: technical considerations. Surg Endosc 2006; 20:1654.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/40/14984/abstract/27\">",
"      Jiao LR, Ayav A, Navarra G, et al. Laparoscopic liver resection assisted by the laparoscopic Habib Sealer. Surgery 2008; 144:770.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/40/14984/abstract/28\">",
"      Curro G, Bartolotta M, Barbera A, et al. Ultrasound-guided radiofrequency-assisted segmental liver resection: a new technique. Ann Surg 2009; 250:229.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/40/14984/abstract/29\">",
"      Shaw RW. Evaluation of the role of laser treatment for the treatment of pain in endometriosis. Ann N Y Acad Sci 2003; 997:240.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/40/14984/abstract/30\">",
"      Lee J, Gianduzzo TR. Advances in laser technology in urology. Urol Clin North Am 2009; 36:189.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/40/14984/abstract/31\">",
"      Ikegami T, Shimada M, Imura S, et al. Argon gas embolism in the application of laparoscopic microwave coagulation therapy. J Hepatobiliary Pancreat Surg 2009; 16:394.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/40/14984/abstract/32\">",
"      Romano F, Gelmini R, Caprotti R, et al. Laparoscopic splenectomy: ligasure versus EndoGIA: a comparative study. J Laparoendosc Adv Surg Tech A 2007; 17:763.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/40/14984/abstract/33\">",
"      Kuster GG, Fischer B. Pharmacologic hemostasis in laparoscopy: topical epinephrine facilitates cholecystectomy. Am Surg 1993; 59:281.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/40/14984/abstract/34\">",
"      Kuster GG. Local epinephrine facilitates laparoscopic Heller myotomy. Surg Endosc 1998; 12:79.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/40/14984/abstract/35\">",
"      Saxena AK, van Tuil C. Advantages of fibrin glue spray in laparoscopic liver biopsies. Surg Laparosc Endosc Percutan Tech 2007; 17:545.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/40/14984/abstract/36\">",
"      Olmi S, Scaini A, Erba L, et al. Use of fibrin glue (Tissucol) as a hemostatic in laparoscopic conservative treatment of spleen trauma. Surg Endosc 2007; 21:2051.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/40/14984/abstract/37\">",
"      van Dijk JH, Pes PL. Haemostasis in laparoscopic partial nephrectomy: current status. Minim Invasive Ther Allied Technol 2007; 16:31.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/40/14984/abstract/38\">",
"      Lee MG, Provost DA, Jones DB. Use of fibrin sealant in laparoscopic gastric bypass for the morbidly obese. Obes Surg 2004; 14:1321.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/40/14984/abstract/39\">",
"      Bak JB, Singh A, Shekarriz B. Use of gelatin matrix thrombin tissue sealant as an effective hemostatic agent during laparoscopic partial nephrectomy. J Urol 2004; 171:780.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/40/14984/abstract/40\">",
"      Bingener-Casey J, Richards ML, Strodel WE, et al. Reasons for conversion from laparoscopic to open cholecystectomy: a 10-year review. J Gastrointest Surg 2002; 6:800.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 4874 Version 7.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-203.80.222.8-1A4E1675F2-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f14_40_14984=[""].join("\n");
var outline_f14_40_14984=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H18\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      THE LAPAROSCOPIC FIELD",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      DEVICES FOR HEMOSTASIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Surgical clips",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Suture ligation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Surgical staplers",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      - Gastrointestinal",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      - Vascular",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Electrosurgery",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      - Advanced bipolar sealing",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      - Ultrasonic desiccation",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      - Radiofrequency ablation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Laser fulguration",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Other devices",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      CHOICE OF DEVICE",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      MANAGEMENT OF HEMORRHAGE",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      Conversion to an open procedure",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"SURG/4874\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"SURG/4874|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?22/38/23142\" title=\"figure 1\">",
"      Segmental anatomy of the liver",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"SURG/4874|PIC\">",
"      <a href=\"#\" title=\"PICTURES\">",
"       PICTURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?11/29/11728\" title=\"picture 1\">",
"      Hemolok clip",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?24/25/24976\" title=\"picture 2\">",
"      Laparoscopic vascular stapler",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?2/34/2593\" title=\"picture 3\">",
"      Laparoscopic electocautery insulation failure",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?29/1/29716\" title=\"picture 4\">",
"      Ligasure device",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?5/53/5972\" title=\"picture 5\">",
"      Ligasure division",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"SURG/4874|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?19/54/20334\" title=\"table 1\">",
"      Topical hemostatic agents used in surgery",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?31/7/31866?source=related_link\">",
"      An overview of endometrial ablation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?31/25/32151?source=related_link\">",
"      Basic principles of medical lasers",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?18/22/18792?source=related_link\">",
"      Complications of laparoscopic cholecystectomy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?11/4/11338?source=related_link\">",
"      Laparoscopic cholecystectomy: Techniques",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?37/25/38294?source=related_link\">",
"      Massive blood transfusion",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?36/54/37737?source=related_link\">",
"      Overview of electrosurgery",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?29/45/30425?source=related_link\">",
"      Overview of the management of acute kidney injury (acute renal failure)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?17/22/17769?source=related_link\">",
"      Overview of topical hemostatic agents used in the operating room",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?5/62/6120?source=related_link\">",
"      Shock in adults: Types, presentation, and diagnostic approach",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?39/7/40056?source=related_link\">",
"      Surgical and other invasive therapies of benign prostatic hyperplasia",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f14_40_14985="Noncirrhotic portal hypertension: Portal fibrosis and schistosomiasis";
var content_f14_40_14985=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Noncirrhotic portal hypertension: Portal fibrosis and schistosomiasis",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?14/40/14985/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?14/40/14985/contributors\">",
"     Juan Carlos Garcia-Pagan, MD, PhD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?14/40/14985/contributors\">",
"     Jason Chang Pik Eu, MBBS, MRCP",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?14/40/14985/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?14/40/14985/contributors\">",
"     Sanjiv Chopra, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?14/40/14985/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?14/40/14985/contributors\">",
"     Anne C Travis, MD, MSc, FACG",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?14/40/14985/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Oct 5, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Portal hypertension is defined by a pathological increase in the pressure of the portal venous system. Cirrhosis is the most common cause of portal hypertension but it can also be present in the absence of cirrhosis, a condition referred to as \"noncirrhotic portal hypertension\". The causes of noncirrhotic portal hypertension can be divided into prehepatic, intrahepatic (presinusoidal, sinusoidal, and postsinusoidal), and posthepatic causes (",
"    <a class=\"graphic graphic_table graphicRef76516 \" href=\"UTD.htm?7/14/7404\">",
"     table 1",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    This topic review will focus on two of the major causes of presinusoidal noncirrhotic portal hypertension: idiopathic portal hypertension and schistosomiasis. A third major cause of presinusoidal noncirrhotic portal hypertension, portal vein thrombosis, is reviewed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?3/57/3993?source=see_link\">",
"     \"Extrahepatic portal vein obstruction (portal vein thrombosis)\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     IDIOPATHIC PORTAL HYPERTENSION (NONCIRRHOTIC PORTAL FIBROSIS, HEPATOPORTAL SCLEROSIS)",
"    </span>",
"    &nbsp;&mdash;&nbsp;In 1962, Indian scientists reported a syndrome of splenomegaly with noncirrhotic liver disease in autopsy specimens [",
"    <a class=\"abstract\" href=\"UTD.htm?14/40/14985/abstract/1\">",
"     1",
"    </a>",
"    ]. In the same year, Japanese researchers studied the hemodynamics of patients with portal hypertension during surgery and found that a third of the patients did not have cirrhosis, but had varying degrees of portal fibrosis [",
"    <a class=\"abstract\" href=\"UTD.htm?14/40/14985/abstract/2\">",
"     2",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    This distinct clinico-pathological entity was named \"noncirrhotic portal fibrosis (NCPF)\" in India and \"idiopathic portal hypertension (IPH)\" in Japan. A report from the United States described 36 patients with portal hypertension without cirrhosis who had phlebosclerosis of the intra- and extrahepatic portal veins, and introduced the term \"hepatoportal sclerosis (HPS)\" [",
"    <a class=\"abstract\" href=\"UTD.htm?14/40/14985/abstract/3\">",
"     3",
"    </a>",
"    ]. Similar reports of NCPF, IPH, and HPS have been described from different parts of the world with various names given to this condition, including obliterative portal venopathy, benign intrahepatic portal hypertension and idiopathic presinusoidal portal hypertension, among others [",
"    <a class=\"abstract\" href=\"UTD.htm?14/40/14985/abstract/4-11\">",
"     4-11",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Several differences in epidemiology, hepatic pressure gradients, and proposed etiology have been described in reports from different geographical areas but these probably reflect the varied spectrum of this disease. The clinico-pathological features are sufficiently similar that they are now considered to be the same disease, which we will refer to as idiopathic portal hypertension [",
"    <a class=\"abstract\" href=\"UTD.htm?14/40/14985/abstract/12\">",
"     12",
"    </a>",
"    ]. IPH is characterized by the presence of portal hypertension in the absence of liver cirrhosis, with histological features of dense portal fibrosis, marked phlebosclerosis, and dilated sinusoids.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Epidemiology",
"    </span>",
"    &nbsp;&mdash;&nbsp;IPH exists worldwide but is more common in developing countries. It is particularly common in Asia where it accounts for 15 to 25 percent of all causes of portal hypertension in India [",
"    <a class=\"abstract\" href=\"UTD.htm?14/40/14985/abstract/13,14\">",
"     13,14",
"    </a>",
"    ], and up to 30 percent in Japan [",
"    <a class=\"abstract\" href=\"UTD.htm?14/40/14985/abstract/12\">",
"     12",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The disease is often encountered in patients who are socioeconomically disadvantaged [",
"    <a class=\"abstract\" href=\"UTD.htm?14/40/14985/abstract/15\">",
"     15",
"    </a>",
"    ]. A distinct age or sex distribution is unclear, although slight differences in the sex and age distribution have been reported from different countries [",
"    <a class=\"abstract\" href=\"UTD.htm?14/40/14985/abstract/16,17\">",
"     16,17",
"    </a>",
"    ]. The reason for this is not clear, but differences in socioeconomic status, living conditions, average life span, and ethnicity may have a role. In Japan, the incidence of IPH has declined in recent decades, possibly because of improvements in hygiene and living standards [",
"    <a class=\"abstract\" href=\"UTD.htm?14/40/14985/abstract/17\">",
"     17",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     ETIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;The etiology of IPH is unknown. However, several pathophysiological mechanisms are believed to be involved.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Recurrent infections",
"    </span>",
"    &nbsp;&mdash;&nbsp;Repeated episodes of umbilical sepsis, bacterial infections, and diarrhea in early childhood (all relatively common in socioeconomically disadvantaged populations) are believed to lead to portal pyemia and pylephlebitis, which may subsequently cause vascular endothelial injury, microthrombosis, sclerosis, and obstruction of small and medium-sized portal vein radicals. This may subsequently lead to the development of IPH in early adulthood [",
"    <a class=\"abstract\" href=\"UTD.htm?14/40/14985/abstract/18\">",
"     18",
"    </a>",
"    ]. Supporting this hypothesis, animal studies involving repeated injections of Eschericia coli into the portal system of rabbits resulted in the development of noncirrhotic portal fibrosis [",
"    <a class=\"abstract\" href=\"UTD.htm?14/40/14985/abstract/19\">",
"     19",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Altered immune response",
"    </span>",
"    &nbsp;&mdash;&nbsp;Several alterations in the immunologic response have been described in patients with IPH [",
"    <a class=\"abstract\" href=\"UTD.htm?14/40/14985/abstract/20,21\">",
"     20,21",
"    </a>",
"    ]. In addition, different autoimmune diseases are frequently associated with IPH [",
"    <a class=\"abstract\" href=\"UTD.htm?14/40/14985/abstract/22-24\">",
"     22-24",
"    </a>",
"    ]. Anti-DNA antibodies are demonstrable in more than 65 percent of Japanese women with IPH [",
"    <a class=\"abstract\" href=\"UTD.htm?14/40/14985/abstract/22\">",
"     22",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Genetic predisposition",
"    </span>",
"    &nbsp;&mdash;&nbsp;A genetic basis for IPH has not been identified. However, familial aggregation of IPH and a high frequency of HLA-DR3 have been observed among Indian patients [",
"    <a class=\"abstract\" href=\"UTD.htm?14/40/14985/abstract/25\">",
"     25",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Hypercoagulability",
"    </span>",
"    &nbsp;&mdash;&nbsp;Some studies have suggested an association of IPH with a hypercoagulable state. A study of IPH in 28 Western patients found evidence of various prothrombotic disorders in 50 percent of patients [",
"    <a class=\"abstract\" href=\"UTD.htm?14/40/14985/abstract/26\">",
"     26",
"    </a>",
"    ]. Over the course of follow-up, 13 patients developed portal vein thrombosis within a median of 7.6 years (range 1 to 21). The authors advocated anticoagulant therapy in patients with IPH found to have a prothrombotic disorder. Similarly, a report from Turkey described extrahepatic portal vein thrombosis in 7 of 34 (20 percent) patients with HPS over a five-year follow-up period [",
"    <a class=\"abstract\" href=\"UTD.htm?14/40/14985/abstract/27\">",
"     27",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     HIV infection",
"    </span>",
"    &nbsp;&mdash;&nbsp;There have been consistent reports of patients with HIV infection who develop variceal bleeding due to underlying non-cirrhotic portal hypertension [",
"    <a class=\"abstract\" href=\"UTD.htm?14/40/14985/abstract/28-33\">",
"     28-33",
"    </a>",
"    ]. The pathogenesis has been shown to be related to the effect of highly active antiretroviral treatment (HAART), particularly long-term exposure to",
"    <a class=\"drug drug_general\" href=\"UTD.htm?14/38/14952?source=see_link\">",
"     didanosine",
"    </a>",
"    on the microvasculature of the liver or the direct effect of the HIV itself [",
"    <a class=\"abstract\" href=\"UTD.htm?14/40/14985/abstract/30,34\">",
"     30,34",
"    </a>",
"    ]. The discontinuation of didanosine has been reported in some studies to reduce the progression of IPH [",
"    <a class=\"abstract\" href=\"UTD.htm?14/40/14985/abstract/35,36\">",
"     35,36",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Patients present with variceal bleeding and splenomegaly, but without evidence of cirrhosis [",
"    <a class=\"abstract\" href=\"UTD.htm?14/40/14985/abstract/31-33\">",
"     31-33",
"    </a>",
"    ]. They appear to have pre-sinusoidal hypertension and an increased risk of portal vein thrombosis [",
"    <a class=\"abstract\" href=\"UTD.htm?14/40/14985/abstract/33\">",
"     33",
"    </a>",
"    ]. Individuals with underlying thrombophilic disorders may be at particularly increased risk [",
"    <a class=\"abstract\" href=\"UTD.htm?14/40/14985/abstract/29\">",
"     29",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Miscellaneous",
"    </span>",
"    &nbsp;&mdash;&nbsp;Preliminary observations have described a role for endothelin-1, nitric oxide, and connective tissue growth factor in development of IPH [",
"    <a class=\"abstract\" href=\"UTD.htm?14/40/14985/abstract/37-41\">",
"     37-41",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Chronic ingestion of arsenic, exposure to vinyl chloride monomers, copper sulphate, hypervitaminosis A, and several cytotoxic drugs are capable of producing a clinico-histological entity resembling IPH [",
"    <a class=\"abstract\" href=\"UTD.htm?14/40/14985/abstract/42-45\">",
"     42-45",
"    </a>",
"    ]. Thus, exposure to these agents should be considered in patients with IPH.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h1\">",
"     CLINICAL MANIFESTATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;IPH is typically characterized by portal hypertension with preserved liver function. The most common clinical presentation is variceal bleeding, which (in contrast to variceal bleeding in cirrhosis) is often relatively well tolerated due to the preserved liver function.",
"   </p>",
"   <p>",
"    Jaundice, ascites, and hepatic encephalopathy are uncommon, and are usually seen in the late stages of the disease or following an episode of gastrointestinal bleeding. Hepatopulmonary syndrome has been described in patients with IPH and reverses after liver transplantation [",
"    <a class=\"abstract\" href=\"UTD.htm?14/40/14985/abstract/46-48\">",
"     46-48",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    On clinical examination, massive splenomegaly (&gt;10 cm below the left subcostal margin) is present in &gt;95 percent of patients. Dilated superficial abdominal veins can be seen in 15 percent of patients and mild hepatomegaly (&lt;4 cm below the right subcostal margin) can be found in 50 percent of patients [",
"    <a class=\"abstract\" href=\"UTD.htm?14/40/14985/abstract/49\">",
"     49",
"    </a>",
"    ]. Other stigmata of chronic liver disease are usually absent.",
"   </p>",
"   <p>",
"    Liver biochemical tests are usually normal or nearly normal. Anemia, leucopenia, and thrombocytopenia as a result of hypersplenism are commonly present.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h1\">",
"     DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The diagnosis of IPH is based on the presence of unequivocal portal hypertension and a definite histological exclusion of cirrhosis and any other specific disorder that is able to cause portal hypertension [",
"    <a class=\"abstract\" href=\"UTD.htm?14/40/14985/abstract/50\">",
"     50",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Differential diagnosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;The differential diagnosis includes portal hypertension due to cirrhosis of any etiology and a variety of pre-, intra-, or postsinusoidal disorders associated with portal hypertension (",
"    <a class=\"graphic graphic_table graphicRef76516 \" href=\"UTD.htm?7/14/7404\">",
"     table 1",
"    </a>",
"    ). Thus, patients should be questioned about risk factors for liver disease, travel, a personal or family history of thrombosis, ingestion of vitamin A, or exposure to cytotoxic drugs or toxins including arsenic or vinyl chloride.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Imaging",
"    </span>",
"    &nbsp;&mdash;&nbsp;An imaging test is required to evaluate the liver parenchyma and circulation. By definition, the portal and hepatic veins in IPH are patent on imaging by ultrasound Doppler, CT angiography, or MRI angiography. However, patients with advanced disease may have secondary portal vein thrombosis, which may be misdiagnosed as primary extrahepatic portal vein thrombosis or thrombosis secondary to underlying cirrhosis. The clinical history and liver biopsy findings may help to differentiate between these entities. A finding of a liver stiffness value (FibroScan&reg;) far below what should be expected in patients with cirrhosis and portal hypertension can also help make the distinction [",
"    <a class=\"abstract\" href=\"UTD.htm?14/40/14985/abstract/33\">",
"     33",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Liver pathology",
"    </span>",
"    &nbsp;&mdash;&nbsp;Gross pathology of the liver surface is often normal, but can be markedly nodular in 10 to 15 percent of patients, with nodularity confined to the liver surface [",
"    <a class=\"abstract\" href=\"UTD.htm?14/40/14985/abstract/16\">",
"     16",
"    </a>",
"    ]. The portal vein and its branches are prominent with sclerosed walls. Autopsy specimens often demonstrate the presence of thrombosis in the small and medium portal vein branches [",
"    <a class=\"abstract\" href=\"UTD.htm?14/40/14985/abstract/51\">",
"     51",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    As noted above, a liver biopsy is required to exclude cirrhosis and other causes of portal hypertension in order to establish the diagnosis of IPH. The histological findings in IPH are variable, possibly because of heterogeneity in the disease and its severity, and because of sampling variability on liver biopsy specimens (",
"    <a class=\"graphic graphic_table graphicRef80624 \" href=\"UTD.htm?9/50/10028\">",
"     table 2",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?14/40/14985/abstract/16,26,52,53\">",
"     16,26,52,53",
"    </a>",
"    ]. From a clinical perspective, the most important role of a liver biopsy in the evaluation of IPH is to exclude the presence of cirrhosis and other specific disease entities (eg, nodular regenerative hyperplasia) that could account for the development of portal hypertension. IPH becomes a likely diagnosis when clinical portal hypertension occurs in association with a radiologically patent portal and splenic vein and an essentially normal liver biopsy specimen.",
"   </p>",
"   <p>",
"    A common denominator of the morphological alterations associated with IPH is obliteration of small portal venules (occlusive venopathy) that may lead to impairment in the intrahepatic portal perfusion and parenchymal atrophy. Other typical histological findings include an \"obliterative portal venopathy of liver\" characterized by irregular sclerosis of the portal vein wall, fibrosis of the portal tract, occlusive venopathy, dilatation of sinusoids due to increased portal pressure, and emergence of new aberrant portal channels (",
"    <a class=\"graphic graphic_picture graphicRef63404 graphicRef51618 \" href=\"UTD.htm?35/5/35930\">",
"     picture 1A-B",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?14/40/14985/abstract/54\">",
"     54",
"    </a>",
"    ]. In advanced cases, parenchymal atrophy in the subcapsular regions may lead to collapse [",
"    <a class=\"abstract\" href=\"UTD.htm?14/40/14985/abstract/52,53,55,56\">",
"     52,53,55,56",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Uncommon features include pseudonodules, piecemeal necrosis, and regenerative activity [",
"    <a class=\"abstract\" href=\"UTD.htm?14/40/14985/abstract/51\">",
"     51",
"    </a>",
"    ]. Regenerative nodules may develop near the hilum of atrophic livers in advanced cases. Electron microscopy has revealed widening of the space of Disse with fibrogenesis in the perisinusoidal space leading to capillarization of the sinusoids in some patients [",
"    <a class=\"abstract\" href=\"UTD.htm?14/40/14985/abstract/19\">",
"     19",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     Hemodynamics",
"    </span>",
"    &nbsp;&mdash;&nbsp;The intrasplenic and portal vein pressures are markedly elevated in patients with IPH [",
"    <a class=\"abstract\" href=\"UTD.htm?14/40/14985/abstract/57,58\">",
"     57,58",
"    </a>",
"    ]. The wedged hepatic vein pressure (WHVP) may be normal or slightly elevated in one-half of patients. However, the WHVP almost always underestimates the true portal pressure because communications between the hepatic veins often preclude correct positioning and occlusion of the balloon catheter [",
"    <a class=\"abstract\" href=\"UTD.htm?14/40/14985/abstract/59,60\">",
"     59,60",
"    </a>",
"    ]. Demonstration of such communication during hepatic venography is supportive of the presence of IPH.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h2\">",
"     Staging",
"    </span>",
"    &nbsp;&mdash;&nbsp;A four-stage classification system for IPH has been proposed based upon the evaluation of liver size (by imaging), subcapsular parenchymal atrophy (by portography) and presence of portal vein thrombosis (by Doppler ultrasound) [",
"    <a class=\"abstract\" href=\"UTD.htm?14/40/14985/abstract/55\">",
"     55",
"    </a>",
"    ]. Stage IV requires the presence of portal vein thrombosis, which has been associated with a poor prognosis. The clinical utility of this staging system needs to be validated in further studies.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h1\">",
"     MANAGEMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;The key issues in the management of patients with IPH are related mainly to management and prevention of variceal hemorrhage.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h2\">",
"     Acute bleeding",
"    </span>",
"    &nbsp;&mdash;&nbsp;There have been only a few studies involving a small number of patients to evaluate the efficacy of different approaches in the management of bleeding esophagogastric varices in IPH [",
"    <a class=\"abstract\" href=\"UTD.htm?14/40/14985/abstract/61-63\">",
"     61-63",
"    </a>",
"    ]. As a result, patients should be managed using the same general principles as management of variceal bleeding in patients with cirrhosis [",
"    <a class=\"abstract\" href=\"UTD.htm?14/40/14985/abstract/64\">",
"     64",
"    </a>",
"    ].These include early pharmacological treatment with vasoactive drugs, early endoscopic control of bleeding, careful blood product replacement, and prophylactic antibiotics. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?1/56/1928?source=see_link\">",
"     \"General principles of the management of variceal hemorrhage\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h2\">",
"     Primary and secondary prevention",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are few studies evaluating strategies to prevent variceal bleeding in patients with IPH. As a result, management is based upon strategies used for the prevention of first variceal bleeding and for prevention of variceal rebleeding in patients with cirrhosis [",
"    <a class=\"abstract\" href=\"UTD.htm?14/40/14985/abstract/64\">",
"     64",
"    </a>",
"    ]. One of the only controlled trials found that endoscopic band ligation was not more effective at preventing rebleeding than nonselective beta blockers in patients with noncirrhotic portal hypertension and a history of variceal bleeding [",
"    <a class=\"abstract\" href=\"UTD.htm?14/40/14985/abstract/65\">",
"     65",
"    </a>",
"    ]. Case reports of patients with IPH have described splenic embolization, percutaneous transhepatic obliteration and transjugular intrahepatic portosystemic shunt (TIPS) [",
"    <a class=\"abstract\" href=\"UTD.htm?14/40/14985/abstract/66,67\">",
"     66,67",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/49/27418?source=see_link\">",
"     \"Primary and pre-primary prophylaxis against variceal hemorrhage in patients with cirrhosis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?17/23/17786?source=see_link\">",
"     \"Prevention of recurrent variceal hemorrhage in patients with cirrhosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Shunt surgery is an effective alternative in patients who fail to respond to endoscopic therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?14/40/14985/abstract/68,69\">",
"     68,69",
"    </a>",
"    ]. However, the numbers of such procedures have been dramatically reduced since the introduction of TIPS using PTFE-covered stents. Splenectomy has been described in patients with symptomatic hypersplenism (spontaneous bleeding episodes, severe transfusion-dependent anemia or repeated splenic infarcts) [",
"    <a class=\"abstract\" href=\"UTD.htm?14/40/14985/abstract/16\">",
"     16",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h1\">",
"     PROGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Because of preserved liver function, the prognosis of patients with IPH is better than that of patients with cirrhosis who have a similar degree of portal hypertension. However, a subgroup of IPH patients progresses to develop advanced hepatic insufficiency, eventually requiring liver transplantation [",
"    <a class=\"abstract\" href=\"UTD.htm?14/40/14985/abstract/70,71\">",
"     70,71",
"    </a>",
"    ]. These patients generally have nodular transformation of the liver with extensive subhepatic and portal fibrosis. A few case reports have suggested an association between IPH and HCC, but whether other risk factors may have accounted for the observation is unclear [",
"    <a class=\"abstract\" href=\"UTD.htm?14/40/14985/abstract/72,73\">",
"     72,73",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A long-term cohort study of Western IPH patients suggested that overall survival in IPH was poorer compared with that of the general population [",
"    <a class=\"abstract\" href=\"UTD.htm?14/40/14985/abstract/74\">",
"     74",
"    </a>",
"    ]. However, the increased mortality was related to non-liver related conditions and not to complications of portal hypertension or liver failure. In this cohort study, only 4 of 62 patients (6.5 percent) died from liver-related conditions. The development of ascites was identified as a poor prognostic factor in patients with IPH.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h1\">",
"     SCHISTOSOMIASIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Schistosomiasis is one of the most common causes of noncirrhotic portal hypertension in the world [",
"    <a class=\"abstract\" href=\"UTD.htm?14/40/14985/abstract/75\">",
"     75",
"    </a>",
"    ]. Of the three main Schistosoma species, S. japonicum and S. mansoni are known to cause liver disease. S. hematobium affects mainly the urinary tract, although at advanced stages the liver can develop portal fibrosis.",
"   </p>",
"   <p>",
"    S. japonicum is distributed widely throughout the world, predominantly in Asia. S. mansoni is endemic in Egypt, Africa, Middle East, and South America. Two other species (S. mekongi and S. intercalatum) also cause hepatic infections in endemic areas in Southeast Asia and Western Africa, respectively. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?15/38/15977?source=see_link\">",
"     \"Epidemiology, pathogenesis, and clinical features of schistosomiasis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h2\">",
"     Pathophysiology",
"    </span>",
"    &nbsp;&mdash;&nbsp;The infection occurs when the schistosomal cercariae enter the body through the skin. Adult worms eventually find their way to inhabit tributaries of the inferior (S. mansoni) or superior (S. japonicum) mesenteric veins, respectively, where they produce several hundred to thousand eggs per day for several years before the end of their lifespan. Some of these eggs pass through the intestinal mucosa and are excreted in the urine or feces to continue their life cycle. Others flow into the portal vein tributaries and become trapped in the terminal portal venules, where they incite chronic inflammation which is subsequently followed by marked fibrosis. S. japonicum is capable of producing far more ova than S. mansoni and thus causes more severe liver disease [",
"    <a class=\"abstract\" href=\"UTD.htm?14/40/14985/abstract/76,77\">",
"     76,77",
"    </a>",
"    ]. The entrapped ova in the small portal venules elicit an immune response causing increased production of collagen, granuloma formation, and eventually lead to portal fibrosis over time. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?15/38/15977?source=see_link\">",
"     \"Epidemiology, pathogenesis, and clinical features of schistosomiasis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In the early stage the portal resistance is mainly presinusoidal. However, as the fibrotic changes in the portal tracts progress, lobular distortion at the sinusoidal level occurs. This results in an increase in resistance to portal venous flow, as evidenced by increased wedged hepatic venous pressure (WHVP) in advanced cases [",
"    <a class=\"abstract\" href=\"UTD.htm?14/40/14985/abstract/78\">",
"     78",
"    </a>",
"    ]. Hemodynamic studies in patients with hepatic schistosomiasis have demonstrated a hyperdynamic systemic and splanchnic circulation with normal hepatic venous pressure gradient (HVPG) and total hepatic blood flow [",
"    <a class=\"abstract\" href=\"UTD.htm?14/40/14985/abstract/76,79,80\">",
"     76,79,80",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h2\">",
"     Clinical features",
"    </span>",
"    &nbsp;&mdash;&nbsp;The acute stage of schistosomiasis mimics acute bacterial infection, and is accompanied by marked eosinophilia. Chronic schistosomiasis presents with predominantly hepatic or intestinal manifestations. Chronic hepatic schistosomiasis is characterized by features of portal hypertension: esophageal varices, hepatomegaly and splenomegaly with hypersplenism. In children, chronic infection is associated with growth retardation. Many patients with mild fibrosis remain asymptomatic throughout the earlier phases of their disease.",
"   </p>",
"   <p>",
"    Underlying hepatic function remains preserved, and hepatic encephalopathy, ascites, and liver failure are uncommon. Patients with hepatic schistosomiasis tolerate episodes of acute variceal bleeding well compared to patients with cirrhosis. In advanced cases, hepatic decompensation may develop with hypoalbuminemia and chronic ascites. However, this tends to occur in patients with coexisting liver disease such as chronic viral hepatitis B or C infection or alcoholism. These coexisting liver diseases have been found to aggravate the course of hepatic schistosomiasis, changing its natural history [",
"    <a class=\"abstract\" href=\"UTD.htm?14/40/14985/abstract/81-83\">",
"     81-83",
"    </a>",
"    ]. Extrahepatic manifestations such as pneumonia and pulmonary hypertension have been described in schistosomiasis mansoni infection [",
"    <a class=\"abstract\" href=\"UTD.htm?14/40/14985/abstract/84\">",
"     84",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25\">",
"    <span class=\"h2\">",
"     Diagnosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;The diagnosis of schistosomiasis can be made by the detection of schistosomal ova in the stool. As an alternative, it can be demonstrated in biopsies of the rectal mucosa or the liver. Because the worms concentrate more densely in the distal colon, rectal mucosa has a heavy load of schistosomal ova. The diagnosis can also be made using various immunologic assays [",
"    <a class=\"abstract\" href=\"UTD.htm?14/40/14985/abstract/85\">",
"     85",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?7/14/7398?source=see_link\">",
"     \"Diagnosis of schistosomiasis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26\">",
"    <span class=\"h2\">",
"     Treatment",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?25/16/25860?source=see_link\">",
"     Praziquantel",
"    </a>",
"    and oxamniquine are active against all forms of human schistosomiasis and are effective in eradicating the worms in the acute stage of the disease. Cure rates vary from 60 to 90 percent for S. mansoni and 60 to 80 percent for S. japonicum [",
"    <a class=\"abstract\" href=\"UTD.htm?14/40/14985/abstract/86,87\">",
"     86,87",
"    </a>",
"    ]. Even if treatment does not kill all the worms, it will result in a sharp reduction in egg laying. In patients with chronic schistosomiasis, the worms no longer lay eggs and the patient may not require any specific anthelminthic treatment.",
"   </p>",
"   <p>",
"    In addition to treating the underlying parasitic infection, treatment should be aimed at preventing or treating the consequences of portal hypertension. Only a few studies have described treatment options in these patients. As a result, patients should be managed using the same general principles as management of variceal bleeding in patients with cirrhosis [",
"    <a class=\"abstract\" href=\"UTD.htm?14/40/14985/abstract/64\">",
"     64",
"    </a>",
"    ]. These include early pharmacological treatment with vasoactive drugs, early endoscopic control of bleeding, careful blood product replacement, and prophylactic antibiotics. In the few studies that have been published, nonselective beta-blockers and endoscopic treatment were useful in preventing recurrent bleeding [",
"    <a class=\"abstract\" href=\"UTD.htm?14/40/14985/abstract/88,89\">",
"     88,89",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?1/56/1928?source=see_link\">",
"     \"General principles of the management of variceal hemorrhage\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Surgery has been described in patients with recurrent variceal bleeding despite medical and endoscopic treatment [",
"    <a class=\"abstract\" href=\"UTD.htm?14/40/14985/abstract/90\">",
"     90",
"    </a>",
"    ]. Nonselective shunts are not recommended because of the high rate of hepatic encephalopathy, hemolysis, and death [",
"    <a class=\"abstract\" href=\"UTD.htm?14/40/14985/abstract/91\">",
"     91",
"    </a>",
"    ]. Although there is no specific data available, TIPS may provide an alternative preferable to surgery.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H27\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Cirrhosis is the most common cause of portal hypertension, but portal hypertension can also be present in the absence of cirrhosis, a condition referred to as \"noncirrhotic portal hypertension\". The causes of noncirrhotic portal hypertension can be divided into prehepatic, intrahepatic (presinusoidal, sinusoidal and postsinusoidal) and posthepatic causes (",
"      <a class=\"graphic graphic_table graphicRef76516 \" href=\"UTD.htm?7/14/7404\">",
"       table 1",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      Idiopathic portal hypertension (IPH) is typically characterized by portal hypertension with preserved liver function. The most common clinical presentation is variceal bleeding, which (in contrast to variceal bleeding in cirrhosis) is often relatively well tolerated due to the preserved liver function. (See",
"      <a class=\"local\" href=\"#H11\">",
"       'Clinical manifestations'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      As the name implies, the etiology of IPH is unknown. However, several pathophysiological mechanisms are believed to be involved. (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Etiology'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The diagnosis of IPH is based on the presence of unequivocal portal hypertension and a definite histological exclusion of cirrhosis and any other specific disorder that is able to cause portal hypertension. The differential diagnosis includes portal hypertension due to cirrhosis of any etiology and a variety of pre-, intra-, or postsinusoidal disorders associated with portal hypertension (",
"      <a class=\"graphic graphic_table graphicRef76516 \" href=\"UTD.htm?7/14/7404\">",
"       table 1",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H12\">",
"       'Diagnosis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      There are no large studies to guide management of IPH. The key issues in the management of patients with IPH are related mainly to management and prevention of variceal hemorrhage. We suggest an approach similar to management of portal hypertension in patients with cirrhosis (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H18\">",
"       'Management'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Long-term prognosis is generally excellent for patients with IPH. However, in a small subgroup with histologically advanced disease, the disease may progress to liver failure, necessitating liver transplantation. The development of ascites has been shown to be a predictor of poor long-term outcome in IPH. (See",
"      <a class=\"local\" href=\"#H21\">",
"       'Prognosis'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Schistosomiasis is one of the most common causes of noncirrhotic portal hypertension in the world.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Chronic hepatic schistosomiasis is characterized by features of portal hypertension: esophageal varices, hepatomegaly and splenomegaly with hypersplenism. In children, chronic infection is associated with growth retardation. Many patients with mild fibrosis remain asymptomatic throughout the earlier phases of their disease. (See",
"      <a class=\"local\" href=\"#H24\">",
"       'Clinical features'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      In addition to treating the underlying parasitic infection, treatment should be aimed at preventing or treating the consequences of portal hypertension. (See",
"      <a class=\"local\" href=\"#H26\">",
"       'Treatment'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/40/14985/abstract/1\">",
"      RAMALINGASWAMI V, WIG KL, SAMA SK. Cirrhosis of the liver in northern India. A clinicopathologic study. Arch Intern Med 1962; 110:350.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/40/14985/abstract/2\">",
"      Imanaga H, Yamamoto S, Kuroyanagi Y. Surgical Treatment of Portal Hypertension According to State of Intrahepatic Circulation. Ann Surg 1962; 155:42.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/40/14985/abstract/3\">",
"      Mikkelsen WP, Edmondson HA, Peters RL, et al. Extra- and intrahepatic portal hypertension without cirrhosis (hepatoportal sclerosis). Ann Surg 1965; 162:602.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/40/14985/abstract/4\">",
"      Boyer JL, Sen Gupta KP, Biswas SK, et al. Idiopathic portal hypertension. Comparison with the portal hypertension of cirrhosis and extrahepatic portal vein obstruction. Ann Intern Med 1967; 66:41.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/40/14985/abstract/5\">",
"      HALLENBECK GA, ADSON MA. Esophagogastric varices without hepatic cirrhosis. A clinical study of treatment for their bleeding in 72 cases. Arch Surg 1961; 83:370.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/40/14985/abstract/6\">",
"      LEATHER HM. Portal hypertension and gross splenomegaly in Uganda. Br Med J 1961; 1:15.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/40/14985/abstract/7\">",
"      POLISH E, CHRISTIE J, COHEN A, SULLIVAN B Jr. Idiopathic presinusoidal portal hypertension (Banti's syndrome). Ann Intern Med 1962; 56:624.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/40/14985/abstract/8\">",
"      MILLER MC, BRANDT JL. Portal hypertension in the absence of both liver disease and vascular obstruction. Am J Dig Dis 1962; 7:442.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/40/14985/abstract/9\">",
"      COOK J, McFADZEAN AJ, TODD D. Splenectomy in cryptogenetic splenomegaly. Br Med J 1963; 2:337.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/40/14985/abstract/10\">",
"      SIDERYS H, VELLIOS F. PORTAL HYPERTENSION WITHOUT CIRRHOSIS OR EXTRAHEPATIC OBSTRUCTION. REPORT OF A CASE. Am J Surg 1964; 108:785.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/40/14985/abstract/11\">",
"      Sama SK, Bhargava S, Nath NG, et al. Noncirrhotic portal fibrosis. Am J Med 1971; 51:160.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/40/14985/abstract/12\">",
"      Okuda K, Nakashima T, Okudaira M, et al. Liver pathology of idiopathic portal hypertension. Comparison with non-cirrhotic portal fibrosis of India. The Japan idiopathic portal hypertension study. Liver 1982; 2:176.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/40/14985/abstract/13\">",
"      Basu AK, Boyer J, Bhattacharya R, et al. Non-cirrhotic portal fibrosis with portal hypertension: a new syndrome. I. Clinical and function studies and results of operations. Indian J Med Res 1967; 55:336.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/40/14985/abstract/14\">",
"      Datta DV. Non-cirrhotic portal fibrosis ('idiopathic' portal hypertension in India). J Assoc Physicians India 1976; 24:511.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/40/14985/abstract/15\">",
"      Vakili C, Farahvash MJ, Bynum TE. \"Endemic\" idiopathic portal hypertension: report on 32 patients with non-cirrhotic portal fibrosis. World J Surg 1992; 16:118.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/40/14985/abstract/16\">",
"      Sarin SK, Kapoor D. Non-cirrhotic portal fibrosis: current concepts and management. J Gastroenterol Hepatol 2002; 17:526.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/40/14985/abstract/17\">",
"      Okuda K. Non-cirrhotic portal hypertension versus idiopathic portal hypertension. J Gastroenterol Hepatol 2002; 17 Suppl 3:S204.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/40/14985/abstract/18\">",
"      Sarin SK, Aggarwal SR. Idiopathic portal hypertension. Digestion 1998; 59:420.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/40/14985/abstract/19\">",
"      Kono K, Ohnishi K, Omata M, et al. Experimental portal fibrosis produced by intraportal injection of killed nonpathogenic Escherichia coli in rabbits. Gastroenterology 1988; 94:787.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/40/14985/abstract/20\">",
"      Nayyar AK, Sharma BK, Sarin SK, et al. Characterization of peripheral blood lymphocytes in patients with non-cirrhotic portal fibrosis: a comparison with cirrhotics and healthy controls. J Gastroenterol Hepatol 1990; 5:554.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/40/14985/abstract/21\">",
"      Tokushige K, Komatsu T, Ohzu K, et al. A defective autologous mixed lymphocyte reaction in patients with idiopathic portal hypertension. J Gastroenterol Hepatol 1992; 7:270.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/40/14985/abstract/22\">",
"      Saito K, Nakanuma Y, Takegoshi K, et al. Non-specific immunological abnormalities and association of autoimmune diseases in idiopathic portal hypertension. A study by questionnaire. Hepatogastroenterology 1993; 40:163.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/40/14985/abstract/23\">",
"      Inagaki H, Nonami T, Kawagoe T, et al. Idiopathic portal hypertension associated with systemic lupus erythematosus. J Gastroenterol 2000; 35:235.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/40/14985/abstract/24\">",
"      Tsuneyama K, Harada K, Katayanagi K, et al. Overlap of idiopathic portal hypertension and scleroderma: report of two autopsy cases and a review of literature. J Gastroenterol Hepatol 2002; 17:217.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/40/14985/abstract/25\">",
"      Sarin SK, Mehra NK, Agarwal A, et al. Familial aggregation in noncirrhotic portal fibrosis: a report of four families. Am J Gastroenterol 1987; 82:1130.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/40/14985/abstract/26\">",
"      Hillaire S, Bonte E, Denninger MH, et al. Idiopathic non-cirrhotic intrahepatic portal hypertension in the West: a re-evaluation in 28 patients. Gut 2002; 51:275.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/40/14985/abstract/27\">",
"      K&ouml;ksal AS, K&ouml;kl&uuml; S, Ibi�� M, et al. Clinical features, serum interleukin-6, and interferon-gamma levels of 34 turkish patients with hepatoportal sclerosis. Dig Dis Sci 2007; 52:3493.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/40/14985/abstract/28\">",
"      Schiano TD, Kotler DP, Ferran E, Fiel MI. Hepatoportal sclerosis as a cause of noncirrhotic portal hypertension in patients with HIV. Am J Gastroenterol 2007; 102:2536.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/40/14985/abstract/29\">",
"      Mallet VO, Varthaman A, Lasne D, et al. Acquired protein S deficiency leads to obliterative portal venopathy and to compensatory nodular regenerative hyperplasia in HIV-infected patients. AIDS 2009; 23:1511.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/40/14985/abstract/30\">",
"      Kovari H, Ledergerber B, Peter U, et al. Association of noncirrhotic portal hypertension in HIV-infected persons and antiretroviral therapy with didanosine: a nested case-control study. Clin Infect Dis 2009; 49:626.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/40/14985/abstract/31\">",
"      Maida I, Garcia-Gasco P, Sotgiu G, et al. Antiretroviral-associated portal hypertension: a new clinical condition? Prevalence, predictors and outcome. Antivir Ther 2008; 13:103.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/40/14985/abstract/32\">",
"      Saifee S, Joelson D, Braude J, et al. Noncirrhotic portal hypertension in patients with human immunodeficiency virus-1 infection. Clin Gastroenterol Hepatol 2008; 6:1167.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/40/14985/abstract/33\">",
"      Chang PE, Miquel R, Blanco JL, et al. Idiopathic portal hypertension in patients with HIV infection treated with highly active antiretroviral therapy. Am J Gastroenterol 2009; 104:1707.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/40/14985/abstract/34\">",
"      Schouten JN, Van der Ende ME, Ko&euml;ter T, et al. Risk factors and outcome of HIV-associated idiopathic noncirrhotic portal hypertension. Aliment Pharmacol Ther 2012; 36:875.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/40/14985/abstract/35\">",
"      Cachay ER, Peterson MR, Goicoechea M, Mathews WC. Didanosine Exposure and Noncirrhotic Portal Hypertension in a HIV Clinic in North America: a Follow-up Study. Br J Med Med Res 2011; 1:346.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/40/14985/abstract/36\">",
"      Vispo E, Morello J, Rodriguez-Novoa S, Soriano V. Noncirrhotic portal hypertension in HIV infection. Curr Opin Infect Dis 2011; 24:12.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/40/14985/abstract/37\">",
"      Yamaguchi E, Yamanoi A, Ono T, Nagasue N. Experimental investigation of the role of endothelin-1 in idiopathic portal hypertension. J Gastroenterol Hepatol 2007; 22:1134.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/40/14985/abstract/38\">",
"      Kamath PS, Tyce GM, Miller VM, et al. Endothelin-1 modulates intrahepatic resistance in a rat model of noncirrhotic portal hypertension. Hepatology 1999; 30:401.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/40/14985/abstract/39\">",
"      Kamath PS, Carpenter HA, Lloyd RV, et al. Hepatic localization of endothelin-1 in patients with idiopathic portal hypertension and cirrhosis of the liver. Liver Transpl 2000; 6:596.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/40/14985/abstract/40\">",
"      Sato Y, Sawada S, Kozaka K, et al. Significance of enhanced expression of nitric oxide syntheses in splenic sinus lining cells in altered portal hemodynamics of idiopathic portal hypertension. Dig Dis Sci 2007; 52:1987.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/40/14985/abstract/41\">",
"      Morikawa H, Tamori A, Nishiguchi S, et al. Expression of connective tissue growth factor in the human liver with idiopathic portal hypertension. Mol Med 2007; 13:240.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/40/14985/abstract/42\">",
"      Morris JS, Schmid M, Newman S, et al. Arsenic and noncirrhotic portal hypertension. Gastroenterology 1974; 66:86.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/40/14985/abstract/43\">",
"      Datta DV, Mitra SK, Chhuttani PN, Chakravarti RN. Chronic oral arsenic intoxication as a possible aetiological factor in idiopathic portal hypertension (non-cirrhotic portal fibrosis) in India. Gut 1979; 20:378.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/40/14985/abstract/44\">",
"      Sarin SK, Sharma G, Banerjee S, et al. Hepatic fibrogenesis using chronic arsenic ingestion: studies in a murine model. Indian J Exp Biol 1999; 37:147.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/40/14985/abstract/45\">",
"      Smith PM, Crossley IR, Williams DM. Portal hypertension in vinyl-chloride production workers. Lancet 1976; 2:602.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/40/14985/abstract/46\">",
"      Babbs C, Warnes TW, Haboubi NY. Non-cirrhotic portal hypertension with hypoxaemia. Gut 1988; 29:129.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/40/14985/abstract/47\">",
"      Anand AC, Mukherjee D, Rao KS, Seth AK. Hepatopulmonary syndrome: prevalence and clinical profile. Indian J Gastroenterol 2001; 20:24.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/40/14985/abstract/48\">",
"      Martinez-Palli G, Drake BB, Garcia-Pagan JC, et al. Effect of transjugular intrahepatic portosystemic shunt on pulmonary gas exchange in patients with portal hypertension and hepatopulmonary syndrome. World J Gastroenterol 2005; 11:6858.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/40/14985/abstract/49\">",
"      Dhiman RK, Chawla Y, Vasishta RK, et al. Non-cirrhotic portal fibrosis (idiopathic portal hypertension): experience with 151 patients and a review of the literature. J Gastroenterol Hepatol 2002; 17:6.",
"     </a>",
"    </li>",
"    <li>",
"     Okuda K, Nakashima T, Kameda H, et al. Idiopathic portal hypertension: a national study. In: Hepatology: a Festschrift for Hans Popper, Brunner H, Thaler H (Eds), Raven Press, New York 1985. p.95.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/40/14985/abstract/51\">",
"      Okudaira M, Ohbu M, Okuda K. Idiopathic portal hypertension and its pathology. Semin Liver Dis 2002; 22:59.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/40/14985/abstract/52\">",
"      Ludwig J, Hashimoto E, Obata H, Baldus WP. Idiopathic portal hypertension; a histopathological study of 26 Japanese cases. Histopathology 1993; 22:227.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/40/14985/abstract/53\">",
"      Nakanuma Y, Hoso M, Sasaki M, et al. Histopathology of the liver in non-cirrhotic portal hypertension of unknown aetiology. Histopathology 1996; 28:195.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/40/14985/abstract/54\">",
"      Nayak NC, Ramalingaswami V. Obliterative portal venopathy of the liver. Associated with so-called idiopathic portal hypertension or tropical splenomegaly. Arch Pathol 1969; 87:359.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/40/14985/abstract/55\">",
"      Nakanuma Y, Tsuneyama K, Ohbu M, Katayanagi K. Pathology and pathogenesis of idiopathic portal hypertension with an emphasis on the liver. Pathol Res Pract 2001; 197:65.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/40/14985/abstract/56\">",
"      Aikat BK, Bhusnurmath SR, Chhuttani PN, et al. The pathology of noncirrhotic portal fibrosis: a review of 32 autopsy cases. Hum Pathol 1979; 10:405.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/40/14985/abstract/57\">",
"      Sarin SK, Sethi KK, Nanda R. Measurement and correlation of wedged hepatic, intrahepatic, intrasplenic and intravariceal pressures in patients with cirrhosis of liver and non-cirrhotic portal fibrosis. Gut 1987; 28:260.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/40/14985/abstract/58\">",
"      Ohnishi K, Sato S, Nomura F, Iida S. Splanchnic hemodynamics in idiopathic portal hypertension: comparison with chronic persistent hepatitis. Am J Gastroenterol 1989; 84:403.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/40/14985/abstract/59\">",
"      Okuda K, Kono K, Ohnishi K, et al. Clinical study of eighty-six cases of idiopathic portal hypertension and comparison with cirrhosis with splenomegaly. Gastroenterology 1984; 86:600.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/40/14985/abstract/60\">",
"      Futagawa S, Fukazawa M, Musha H, et al. Hepatic venography in noncirrhotic idiopathic portal hypertension. Comparison with cirrhosis of the liver. Radiology 1981; 141:303.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/40/14985/abstract/61\">",
"      Sarin SK, Govil A, Jain AK, et al. Prospective randomized trial of endoscopic sclerotherapy versus variceal band ligation for esophageal varices: influence on gastropathy, gastric varices and variceal recurrence. J Hepatol 1997; 26:826.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/40/14985/abstract/62\">",
"      Kochhar R, Goenka MK, Mehta SK. Outcome of injection sclerotherapy using absolute alcohol in patients with cirrhosis, non-cirrhotic portal fibrosis, and extrahepatic portal venous obstruction. Gastrointest Endosc 1991; 37:460.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/40/14985/abstract/63\">",
"      Kiire CF. Controlled trial of propranolol to prevent recurrent variceal bleeding in patients with non-cirrhotic portal fibrosis. BMJ 1989; 298:1363.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/40/14985/abstract/64\">",
"      de Franchis R, Baveno V Faculty. Revising consensus in portal hypertension: report of the Baveno V consensus workshop on methodology of diagnosis and therapy in portal hypertension. J Hepatol 2010; 53:762.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/40/14985/abstract/65\">",
"      Sarin SK, Gupta N, Jha SK, et al. Equal efficacy of endoscopic variceal ligation and propranolol in preventing variceal bleeding in patients with noncirrhotic portal hypertension. Gastroenterology 2010; 139:1238.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/40/14985/abstract/66\">",
"      Hirota S, Ichikawa S, Matsumoto S, et al. Interventional radiologic treatment for idiopathic portal hypertension. Cardiovasc Intervent Radiol 1999; 22:311.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/40/14985/abstract/67\">",
"      Doki N, Irisawa H, Takada S, et al. Transjugular intrahepatic portosystemic shunt for the treatment of portal hypertension due to idiopathic myelofibrosis. Intern Med 2007; 46:187.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/40/14985/abstract/68\">",
"      Mathur SK, Shah SR, Nagral SS, Soonawala ZF. Transabdominal extensive esophagogastric devascularization with gastroesophageal stapling for management of noncirrhotic portal hypertension: long-term results. World J Surg 1999; 23:1168.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/40/14985/abstract/69\">",
"      Pal S, Radhakrishna P, Sahni P, et al. Prophylactic surgery in non-cirrhotic portal fibrosis:is it worthwhile? Indian J Gastroenterol 2005; 24:239.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/40/14985/abstract/70\">",
"      Bernard PH, Le Bail B, Cransac M, et al. Progression from idiopathic portal hypertension to incomplete septal cirrhosis with liver failure requiring liver transplantation. J Hepatol 1995; 22:495.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/40/14985/abstract/71\">",
"      Isabel Fiel M, Thung SN, Hytiroglou P, et al. Liver failure and need for liver transplantation in patients with advanced hepatoportal sclerosis. Am J Surg Pathol 2007; 31:607.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/40/14985/abstract/72\">",
"      Isobe Y, Yamasaki T, Yokoyama Y, et al. Hepatocellular carcinoma developing six and a half years after a diagnosis of idiopathic portal hypertension. J Gastroenterol 2007; 42:407.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/40/14985/abstract/73\">",
"      Hidaka H, Ohbu M, Kokubu S, et al. Hepatocellular carcinoma associated with idiopathic portal hypertension: review of large nodules in seven non-cirrhotic portal hypertensive livers. J Gastroenterol Hepatol 2005; 20:493.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/40/14985/abstract/74\">",
"      Schouten JN, Nevens F, Hansen B, et al. Idiopathic noncirrhotic portal hypertension is associated with poor survival: results of a long-term cohort study. Aliment Pharmacol Ther 2012; 35:1424.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/40/14985/abstract/75\">",
"      Dunn MA, Kamel R. Hepatic schistosomiasis. Hepatology 1981; 1:653.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/40/14985/abstract/76\">",
"      El-Garem AA. Schistosomiasis. Digestion 1998; 59:589.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/40/14985/abstract/77\">",
"      Nakashima, T. Liver cirrhosis. Human cases. Acta Hepatol Jpn 1969; 10:485.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/40/14985/abstract/78\">",
"      Da Silva LC, Carrilho FJ. Hepatosplenic schistosomiasis. Pathophysiology and treatment. Gastroenterol Clin North Am 1992; 21:163.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/40/14985/abstract/79\">",
"      Deni&eacute; C, Vachiery F, Elman A, et al. Systemic and splanchnic hemodynamic changes in patients with hepatic schistosomiasis. Liver 1996; 16:309.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/40/14985/abstract/80\">",
"      Mies S, Neto OB, Beer A Jr, et al. Systemic and hepatic hemodynamics in hepatosplenic Manson's schistosomiasis with and without propranolol. Dig Dis Sci 1997; 42:751.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/40/14985/abstract/81\">",
"      Pereira LM, Melo MC, Saleh MG, et al. Hepatitis C virus infection in Schistosomiasis mansoni in Brazil. J Med Virol 1995; 45:423.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/40/14985/abstract/82\">",
"      Pereira LM, Melo MC, Lacerda C, et al. Hepatitis B virus infection in schistosomiasis mansoni. J Med Virol 1994; 42:203.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/40/14985/abstract/83\">",
"      Strickland GT, Elhefni H, Salman T, et al. Role of hepatitis C infection in chronic liver disease in Egypt. Am J Trop Med Hyg 2002; 67:436.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/40/14985/abstract/84\">",
"      de Cleva R, Herman P, Pugliese V, et al. Prevalence of pulmonary hypertension in patients with hepatosplenic Mansonic schistosomiasis--prospective study. Hepatogastroenterology 2003; 50:2028.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/40/14985/abstract/85\">",
"      Wynn TA, Thompson RW, Cheever AW, Mentink-Kane MM. Immunopathogenesis of schistosomiasis. Immunol Rev 2004; 201:156.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/40/14985/abstract/86\">",
"      Berhe N, Gundersen SG, Abebe F, et al. Praziquantel side effects and efficacy related to Schistosoma mansoni egg loads and morbidity in primary school children in north-east Ethiopia. Acta Trop 1999; 72:53.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/40/14985/abstract/87\">",
"      Davis A, Wegner DH. Multicentre trials of praziquantel in human schistosomiasis: design and techniques. Bull World Health Organ 1979; 57:767.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/40/14985/abstract/88\">",
"      el Tourabi H, el Amin AA, Shaheen M, et al. Propranolol reduces mortality in patients with portal hypertension secondary to schistosomiasis. Ann Trop Med Parasitol 1994; 88:493.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/40/14985/abstract/89\">",
"      Dowidar N, Hafez A, Abdel Baki M. Endoscopic sclerotherapy of oesophageal varices due to hepatosplenic schistosomiasis. A randomized controlled trial evaluating the effect of adjuvant propranolol therapy. J Egypt Soc Parasitol 2005; 35:773.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/40/14985/abstract/90\">",
"      da Silva LC, Strauss E, Gayotto LC, et al. A randomized trial for the study of the elective surgical treatment of portal hypertension in mansonic schistosomiasis. Ann Surg 1986; 204:148.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/40/14985/abstract/91\">",
"      Raia S, da Silva LC, Gayotto LC, et al. Portal hypertension in schistosomiasis: a long-term follow-up of a randomized trial comparing three types of surgery. Hepatology 1994; 20:398.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 3580 Version 9.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0605-2.133.93.82-ACA0B7D5D4-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f14_40_14985=[""].join("\n");
var outline_f14_40_14985=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H27\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      IDIOPATHIC PORTAL HYPERTENSION (NONCIRRHOTIC PORTAL FIBROSIS, HEPATOPORTAL SCLEROSIS)",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Epidemiology",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      ETIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Recurrent infections",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Altered immune response",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Genetic predisposition",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Hypercoagulability",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      HIV infection",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Miscellaneous",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      CLINICAL MANIFESTATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Differential diagnosis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Imaging",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Liver pathology",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      Hemodynamics",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      Staging",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      MANAGEMENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      Acute bleeding",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      Primary and secondary prevention",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      PROGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      SCHISTOSOMIASIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      Pathophysiology",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      Clinical features",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H25\">",
"      Diagnosis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H26\">",
"      Treatment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H27\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"GAST/3580\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"GAST/3580|PIC\">",
"      <a href=\"#\" title=\"PICTURES\">",
"       PICTURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?39/8/40072\" title=\"picture 1A\">",
"      IPH portal tract fibrosis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?27/36/28231\" title=\"picture 1B\">",
"      IPH dilatation portal vein",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"GAST/3580|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?7/14/7404\" title=\"table 1\">",
"      Classification NCPH",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?9/50/10028\" title=\"table 2\">",
"      Histologic idiopathic HTN",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?7/14/7398?source=related_link\">",
"      Diagnosis of schistosomiasis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?15/38/15977?source=related_link\">",
"      Epidemiology, pathogenesis, and clinical features of schistosomiasis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?3/57/3993?source=related_link\">",
"      Extrahepatic portal vein obstruction (portal vein thrombosis)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?1/56/1928?source=related_link\">",
"      General principles of the management of variceal hemorrhage",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?17/23/17786?source=related_link\">",
"      Prevention of recurrent variceal hemorrhage in patients with cirrhosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/49/27418?source=related_link\">",
"      Primary and pre-primary prophylaxis against variceal hemorrhage in patients with cirrhosis",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f14_40_14986="Management of thrombosis in the newborn";
var content_f14_40_14986=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"4\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Management of thrombosis in the newborn",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?14/40/14986/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?14/40/14986/contributors\">",
"     Anthony KC Chan, MBBS, FRCPC, FRCPath",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?14/40/14986/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?14/40/14986/contributors\">",
"     Donald H Mahoney, Jr, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?14/40/14986/contributors\">",
"     Joseph A Garcia-Prats, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?14/40/14986/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?14/40/14986/contributors\">",
"     Alison G Hoppin, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?14/40/14986/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jan 16, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Thrombotic disease is uncommon in newborns. However, this disorder can cause serious morbidity. The management of neonatal thrombosis excluding the central nervous system (CNS) is reviewed here. The pathogenesis, clinical features, and diagnosis of this disorder and CNS thromboembolic disease are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?14/16/14600?source=see_link\">",
"     \"Pathogenesis, clinical features, and diagnosis of thrombosis in the newborn\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/2/27690?source=see_link\">",
"     \"Stroke in the newborn\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     GENERAL APPROACH",
"    </span>",
"    &nbsp;&mdash;&nbsp;The management of neonatal thrombosis is extrapolated largely from data in adults. Little information is available on management strategies or the efficacy and safety of therapeutic agents.",
"   </p>",
"   <p>",
"    The approach to an individual infant must balance the risks and benefits.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      For",
"      <strong>",
"       asymptomatic",
"      </strong>",
"      thrombosis, we suggest supportive care and close monitoring of the size of the thrombus [",
"      <a class=\"abstract\" href=\"UTD.htm?14/40/14986/abstract/1\">",
"       1",
"      </a>",
"      ]. This approach avoids development of bleeding complications that may be associated with anticoagulant or fibrinolytic therapy. If the thrombus is associated with a central venous line or umbilical venous catheter, the catheter should be removed. If the thrombus extends, we suggest treatment [",
"      <a class=\"abstract\" href=\"UTD.htm?14/40/14986/abstract/1\">",
"       1",
"      </a>",
"      ]. Alternatively, initial treatment with anticoagulant is a reasonable option.",
"     </li>",
"     <li>",
"      For",
"      <strong>",
"       symptomatic",
"      </strong>",
"      thrombosis, we suggest treatment with anticoagulation",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      fibrinolytic agents. However, these strategies have not been studied in clinical trials, and data on outcome are sparse [",
"      <a class=\"abstract\" href=\"UTD.htm?14/40/14986/abstract/2,3\">",
"       2,3",
"      </a>",
"      ]. The management of less severe events also is uncertain. Central venous lines or umbilical venous catheters associated with thrombosis should be removed, if possible, after three to five days of anticoagulation [",
"      <a class=\"abstract\" href=\"UTD.htm?14/40/14986/abstract/1\">",
"       1",
"      </a>",
"      ]. If either type of catheter is still in place on completion of therapeutic anticoagulation, we suggest treatment with a prophylactic dose of low molecular weight",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?7/39/7801?source=see_link\">",
"       heparin",
"      </a>",
"      (LMWH) until the device is removed. (See",
"      <a class=\"local\" href=\"#H9\">",
"       'Dose'",
"      </a>",
"      below.)",
"     </li>",
"     <li>",
"      Peripheral arterial catheters associated with thrombosis should be removed promptly. If the thrombosis is symptomatic, anticoagulation therapy should be initiated [",
"      <a class=\"abstract\" href=\"UTD.htm?14/40/14986/abstract/1\">",
"       1",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      The optimal duration of therapy is uncertain. In general the duration of anticoagulation therapy would be from six weeks to three months.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Surgical thrombectomy rarely is performed in newborns [",
"    <a class=\"abstract\" href=\"UTD.htm?14/40/14986/abstract/4,5\">",
"     4,5",
"    </a>",
"    ]. In general, this procedure is limited by the small size of blood vessels and the clinical instability of newborns with thrombosis.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Baseline testing",
"    </span>",
"    &nbsp;&mdash;&nbsp;Before antithrombotic therapy is initiated, baseline coagulation testing should be performed. Tests should include:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Activated partial thromboplastin time (aPTT)",
"     </li>",
"     <li>",
"      Prothrombin time (PT) and international normalized ratio (INR)",
"     </li>",
"     <li>",
"      Plasma fibrinogen concentration",
"     </li>",
"     <li>",
"      Platelet count",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    A cranial ultrasound examination should be done to exclude bleeding. It is especially important for premature infants, who are at increased risk of developing an intracranial hemorrhage. During anticoagulant treatment, the platelet count should be maintained at",
"    <span class=\"nowrap\">",
"     &gt;50,000/microL,",
"    </span>",
"    and fibrinogen concentration should be &gt;1",
"    <span class=\"nowrap\">",
"     g/L.",
"    </span>",
"    (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/44/42697?source=see_link\">",
"     \"Clinical manifestations and diagnosis of intraventricular hemorrhage in the newborn\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/46/31465?source=see_link\">",
"     \"Management and complications of intraventricular hemorrhage in the newborn\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     ANTICOAGULANT THERAPY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Anticoagulant therapy in the newborn generally consists of administration of standard",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?7/39/7801?source=see_link\">",
"     heparin",
"    </a>",
"    or low-molecular-weight heparin (LMWH).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Heparin",
"    </span>",
"    &nbsp;&mdash;&nbsp;Standard",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?7/39/7801?source=see_link\">",
"     heparin",
"    </a>",
"    , also known as unfractionated heparin (UFH) is an indirect thrombin inhibitor that complexes with antithrombin (AT, formerly known as AT III) and converts it from a slow to a rapid inactivator of thrombin, factor Xa, and, to a lesser extent, factors XIIa, XIa, IXa, and VIIa [",
"    <a class=\"abstract\" href=\"UTD.htm?14/40/14986/abstract/6,7\">",
"     6,7",
"    </a>",
"    ]. The binding of AT to heparin is mediated by a unique pentasaccharide sequence that is distributed randomly along the heparin chains [",
"    <a class=\"abstract\" href=\"UTD.htm?14/40/14986/abstract/8\">",
"     8",
"    </a>",
"    ]. The inactivation of thrombin, but not factor Xa, requires the formation of a ternary complex in which heparin binds to both AT and thrombin (",
"    <a class=\"graphic graphic_figure graphicRef64839 \" href=\"UTD.htm?35/16/36110\">",
"     figure 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?14/40/14986/abstract/9\">",
"     9",
"    </a>",
"    ]. This ternary complex (containing heparin, AT, and thrombin) forms only on pentasaccharide-containing chains with at least 18 saccharide units, which is true of most chains of UFH but is less common in LMWH, which therefore have less antithrombin activity [",
"    <a class=\"abstract\" href=\"UTD.htm?14/40/14986/abstract/10\">",
"     10",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?33/8/33930?source=see_link\">",
"     \"Therapeutic use of heparin and low molecular weight heparin\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The advantages of UFH are its rapid reversibility and low cost. Disadvantages include its unpredictable pharmacokinetic response and resultant requirement for frequent monitoring.",
"   </p>",
"   <p>",
"    Infusion of UFH in newborns requires a dedicated intravenous catheter. This avoids interruption of anticoagulation therapy by infusion of other medications and minimizes the risk of inadvertent flushing of the catheter that may lead to excessive anticoagulation.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h3\">",
"     Dose",
"    </span>",
"    &nbsp;&mdash;&nbsp;The dose of",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?7/39/7801?source=see_link\">",
"     heparin",
"    </a>",
"    therapy in newborns is based upon a prospective cohort study of UFH treatment in 65 children with thrombosis, of whom 29 were less than one year of age, including 13 newborns [",
"    <a class=\"abstract\" href=\"UTD.htm?14/40/14986/abstract/11\">",
"     11",
"    </a>",
"    ]. Heparin is administered intravenously in a loading dose of 75 to 100",
"    <span class=\"nowrap\">",
"     units/kg",
"    </span>",
"    and an initial maintenance dose of 28",
"    <span class=\"nowrap\">",
"     units/kg",
"    </span>",
"    per hour. The loading dose of heparin should be withheld or reduced if there are significant bleeding risks (eg, in an extremely low birth weight infant with septicemia and associated disseminated intravascular coagulation [DIC]).",
"   </p>",
"   <p>",
"    UFH dosing in the neonate should be titrated to both aPTT and anti-factor Xa activity. Significance of the clot and the potential risk of bleeding should also be considered when adjusting the UFH dose [",
"    <a class=\"abstract\" href=\"UTD.htm?14/40/14986/abstract/1,12\">",
"     1,12",
"    </a>",
"    ]. We suggest titrating the dose of UFH to achieve an anti-factor Xa level of 0.35 to 0.7",
"    <span class=\"nowrap\">",
"     units/mL,",
"    </span>",
"    and also an activated partial thromboplastin time (aPTT) that is 1.5 to 2 times the upper limit of normal [",
"    <a class=\"abstract\" href=\"UTD.htm?14/40/14986/abstract/1\">",
"     1",
"    </a>",
"    ]. The results of aPTT testing can be used to facilitate dose adjustments, but only after establishing the aPTT range that corresponds to the target anti-factor Xa levels in an individual patient. This contrasts to the approach to dose adjustment in adults, in whom the aPTT range can be used alone because this generally corresponds to an anti-factor Xa activity of 0.35 to 0.7",
"    <span class=\"nowrap\">",
"     U/mL",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?14/40/14986/abstract/1\">",
"     1",
"    </a>",
"    ]. The additional monitoring is necessary for neonates because they have an increased clearance rate of",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?7/39/7801?source=see_link\">",
"     heparin",
"    </a>",
"    compared with older children or adults [",
"    <a class=\"abstract\" href=\"UTD.htm?14/40/14986/abstract/11\">",
"     11",
"    </a>",
"    ]. In addition, the efficacy of heparin may be reduced in newborns because the physiologic plasma concentration of antithrombin is low [",
"    <a class=\"abstract\" href=\"UTD.htm?14/40/14986/abstract/13,14\">",
"     13,14",
"    </a>",
"    ]. &nbsp;",
"   </p>",
"   <p>",
"    A series of 100 infants younger than six months of age who were treated with the",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?7/39/7801?source=see_link\">",
"     heparin",
"    </a>",
"    dosing and monitoring protocol outlined above illustrates the challenges of heparin therapy in young infants [",
"    <a class=\"abstract\" href=\"UTD.htm?14/40/14986/abstract/15\">",
"     15",
"    </a>",
"    ]. The median heparin dose needed to achieve target anti-factor Xa levels was 33",
"    <span class=\"nowrap\">",
"     units/kg",
"    </span>",
"    per hour, and two-thirds of infants had decreased thrombus size and no thrombus progression. However, nearly 17 percent of the infants never achieved target anti-factor Xa levels despite up to 60 days of therapy and up to triple the recommended dose. Moreover, 11 percent of the infants had a major bleeding episode.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13664577\">",
"    <span class=\"h3\">",
"     Duration of therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;The optimal duration of therapy is uncertain. Consensus guidelines recommend monitoring the thrombus with ultrasound and continuing therapy until the thrombus has resolved, with the usual duration of therapy being six weeks to three months [",
"    <a class=\"abstract\" href=\"UTD.htm?14/40/14986/abstract/1\">",
"     1",
"    </a>",
"    ]. If the thrombus does not resolve, the therapy should be continued for as long as three months after the anticoagulation is discontinued. In our practice, we generally switch to LMWH if treatment is needed for longer than two weeks. &nbsp;",
"   </p>",
"   <p>",
"    If the thrombus extends, the",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?7/39/7801?source=see_link\">",
"     heparin",
"    </a>",
"    therapy may not be optimal. In this case, the dose of UFH can be increased. Alternatively, LMWH, which has a more predictable anticoagulant response, can be used.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h3\">",
"     Adverse effects",
"    </span>",
"    &nbsp;&mdash;&nbsp;The major side effects of UFH are bleeding,",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?7/39/7801?source=see_link\">",
"     heparin",
"    </a>",
"    -induced thrombocytopenia (HIT), and osteoporosis [",
"    <a class=\"abstract\" href=\"UTD.htm?14/40/14986/abstract/10\">",
"     10",
"    </a>",
"    ]. The risk of bleeding in newborns is uncertain. As in adults, bleeding likely relates to the concentration of heparin as well as underlying disorders that would predispose to bleeding [",
"    <a class=\"abstract\" href=\"UTD.htm?14/40/14986/abstract/16\">",
"     16",
"    </a>",
"    ]. In one series, no bleeding occurred in 13 newborns given UFH for treatment of thromboembolic disease or prophylaxis [",
"    <a class=\"abstract\" href=\"UTD.htm?14/40/14986/abstract/11\">",
"     11",
"    </a>",
"    ]. However, aPTT levels were subtherapeutic in most of these patients.",
"   </p>",
"   <p>",
"    If bleeding occurs, UFH should be discontinued. If the bleeding is problematic, the effects of",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?7/39/7801?source=see_link\">",
"     heparin",
"    </a>",
"    can be reversed using",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?18/18/18724?source=see_link\">",
"     protamine sulfate",
"    </a>",
"    (1 mg of protamine sulfate can inactivate 100 units heparin). The dose of protamine depends upon the amount of heparin being given, and is calculated by assuming the half-life of heparin to be one hour.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22500112\">",
"    <span class=\"h4\">",
"     Heparin-induced thrombocytopenia",
"    </span>",
"    &nbsp;&mdash;&nbsp;HIT is a well-recognized complication of",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?7/39/7801?source=see_link\">",
"     heparin",
"    </a>",
"    therapy in adults [",
"    <a class=\"abstract\" href=\"UTD.htm?14/40/14986/abstract/17-20\">",
"     17-20",
"    </a>",
"    ]. Two major mechanisms cause this thrombocytopenia. One mechanism appears to be a direct effect of heparin on platelet activation. In most of these cases, the fall in platelet count occurs within the first two days after heparin initiation, often returns to normal with continued heparin administration, and is of no clinical consequence, at least in adults. The incidence of this type is estimated at 10 to 20 percent of adults receiving UFH. The second type is mediated by antibodies to a heparin-platelet factor 4 complex, which results in platelet activation and aggregation and enhanced generation of thrombin [",
"    <a class=\"abstract\" href=\"UTD.htm?14/40/14986/abstract/21,22\">",
"     21,22",
"    </a>",
"    ]. This occurs in 3 percent or less of adults receiving UFH for more than four days [",
"    <a class=\"abstract\" href=\"UTD.htm?14/40/14986/abstract/18-20\">",
"     18-20",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?39/59/40890?source=see_link&amp;anchor=H2#H2\">",
"     \"Heparin-induced thrombocytopenia\", section on 'Incidence and risk factors'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    HIT has been described in newborns [",
"    <a class=\"abstract\" href=\"UTD.htm?14/40/14986/abstract/23,24\">",
"     23,24",
"    </a>",
"    ]. However, it is difficult to evaluate the incidence because critically ill newborns have many reasons to have thrombocytopenia",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    thrombosis.",
"   </p>",
"   <p>",
"    One report described 34 newborns (mean gestational age 29 weeks) who developed thrombocytopenia (platelet count",
"    <span class=\"nowrap\">",
"     &lt;70,000/microL,",
"    </span>",
"    n = 23), a precipitous fall of 30 to 50 percent in the platelet count (n = 5), or thromboses (n = 6) while receiving",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?7/39/7801?source=see_link\">",
"     heparin",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?14/40/14986/abstract/23\">",
"     23",
"    </a>",
"    ]. Heparin-associated antiplatelet antibodies were found in 14 patients; these patients had clinical characteristics comparable to the 20 infants without antibodies, including the presence of an umbilical artery catheter in all but one patient in each group. Among those who had abdominal ultrasonography, aortic thrombosis occurred in 11 of 13 (84 percent) infants with and 5 of 20 (25 percent) without antibodies. Bleeding was not observed. However, the sensitivity of ultrasound to detect an asymptomatic thrombus in newborns is poor [",
"    <a class=\"abstract\" href=\"UTD.htm?14/40/14986/abstract/25\">",
"     25",
"    </a>",
"    ]. Thus, the relationship between antibody formation and thrombosis in this population remains uncertain.",
"   </p>",
"   <p>",
"    HIT should be considered in a newborn with thrombocytopenia of no apparent cause, although HIT is uncommon and other causes of thrombocytopenia occur frequently. In addition, experience with anticoagulants other than",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?7/39/7801?source=see_link\">",
"     heparin",
"    </a>",
"    is very limited in this age group. Thus, in most cases, heparin therapy should be continued, and the platelet count should be maintained by transfusion.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22500119\">",
"    <span class=\"h4\">",
"     Osteoporosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Osteoporosis has been reported in adult patients receiving UFH for more than six months [",
"    <a class=\"abstract\" href=\"UTD.htm?14/40/14986/abstract/6\">",
"     6",
"    </a>",
"    ]. Bone loss is thought to occur because of decreased bone formation, increased bone resorption, or both. Although cases of osteoporosis associated with",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?7/39/7801?source=see_link\">",
"     heparin",
"    </a>",
"    have been reported in children, there is no information on this complication in newborns [",
"    <a class=\"abstract\" href=\"UTD.htm?14/40/14986/abstract/26\">",
"     26",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Low molecular weight heparin",
"    </span>",
"    &nbsp;&mdash;&nbsp;Low molecular weight heparins (LMWHs) have many advantages over UFH [",
"    <a class=\"abstract\" href=\"UTD.htm?14/40/14986/abstract/10,27\">",
"     10,27",
"    </a>",
"    ]. These include greater bioavailability when given by subcutaneous injection, longer duration of anticoagulant effect, and clearance that is independent of dose, which results in a more predictable response. They can be administered subcutaneously and require minimal laboratory monitoring and dose adjustment; these are important for newborns with poor venous access. Potential advantages are the reduced risk of immune-mediated thrombocytopenia and osteoporosis.",
"   </p>",
"   <p>",
"    Because LMWH has a relatively predictable and stable anticoagulation response, we suggest using LMWH over UFH for treatment of neonatal thrombosis, provided that an assay of anti-factor Xa activity (required to monitor the anticoagulation effect of LMWH) is readily available. In clinical settings in which an assay of anti-factor Xa activity cannot be performed with results available within one to two days, UFH should be considered. The physicians' familiarity with the anticoagulant also is an important consideration in choosing LMWH versus UFH. &nbsp;",
"   </p>",
"   <p>",
"    LMWH is prepared from UFH by chemical or enzymatic methods. Like UFH, LMWH potentiates the inactivation of factor Xa by antithrombin (AT). However, the effect of LMWH on the AT inhibition of thrombin is decreased compared with UFH because most of the molecules in LMWH do not contain enough saccharide units to form the ternary complex in which thrombin and AT are bound simultaneously (",
"    <a class=\"graphic graphic_figure graphicRef64839 \" href=\"UTD.htm?35/16/36110\">",
"     figure 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?14/40/14986/abstract/10\">",
"     10",
"    </a>",
"    ]. As a result, LMWH in the usual therapeutic dose usually does not prolong the aPTT. The aPTT can be prolonged by higher doses of LMWH but not to the same extent as UFH. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?33/8/33930?source=see_link\">",
"     \"Therapeutic use of heparin and low molecular weight heparin\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Based on limited information, LMWH appears to be safe and effective in newborns. One prospective cohort study included 173 children who were treated with",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?41/55/42872?source=see_link\">",
"     enoxaparin",
"    </a>",
"    because they had or were at high risk for thromboembolic events [",
"    <a class=\"abstract\" href=\"UTD.htm?14/40/14986/abstract/3\">",
"     3",
"    </a>",
"    ]. Patients ranged in age from 1 day to 18 years; 21 (14.5 percent) were &lt;36 weeks gestational age and 48 (33.5 percent) were &lt;three months postnatal age when treatment was initiated. Thrombi resolved clinically in 94 percent of patients who received therapeutic doses. In those receiving prophylaxis, 96 percent had no symptoms of new or recurrent thromboembolic events. Major bleeding occurred in seven (4 percent) patients, of whom four were newborns.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h3\">",
"     Dose",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are several LMWH preparations and they should not be used interchangeably [",
"    <a class=\"abstract\" href=\"UTD.htm?14/40/14986/abstract/28\">",
"     28",
"    </a>",
"    ]. In the United States, four preparations (",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?41/55/42872?source=see_link\">",
"     enoxaparin",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/56/32648?source=see_link\">",
"     dalteparin",
"    </a>",
"    , ardeparin, and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?20/44/21191?source=see_link\">",
"     tinzaparin",
"    </a>",
"    ) are currently approved by the FDA for different clinical indications. Dosing in pediatric patients has been reported for enoxaparin [",
"    <a class=\"abstract\" href=\"UTD.htm?14/40/14986/abstract/29\">",
"     29",
"    </a>",
"    ], dalteparin [",
"    <a class=\"abstract\" href=\"UTD.htm?14/40/14986/abstract/30\">",
"     30",
"    </a>",
"    ], tinzaparin [",
"    <a class=\"abstract\" href=\"UTD.htm?14/40/14986/abstract/31\">",
"     31",
"    </a>",
"    ] and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?26/41/27286?source=see_link\">",
"     nadroparin",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?14/40/14986/abstract/32\">",
"     32",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      For",
"      <strong>",
"       treatment",
"      </strong>",
"      of thrombosis,",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?41/55/42872?source=see_link\">",
"       enoxaparin",
"      </a>",
"      is initiated in a dose of 1.7",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      per dose subcutaneously twice each day in term infants and 2.0",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      per dose twice each day in preterm neonates [",
"      <a class=\"abstract\" href=\"UTD.htm?14/40/14986/abstract/3,29,33\">",
"       3,29,33",
"      </a>",
"      ]. Doses are adjusted to maintain an anti-factor Xa concentration (measured four to six hours after the dose) of 0.5 to 1",
"      <span class=\"nowrap\">",
"       units/mL,",
"      </span>",
"      which is also the therapeutic range established in adults [",
"      <a class=\"abstract\" href=\"UTD.htm?14/40/14986/abstract/1,34\">",
"       1,34",
"      </a>",
"      ]. We do not recommend the use of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?31/56/32648?source=see_link\">",
"       dalteparin",
"      </a>",
"      and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?20/44/21191?source=see_link\">",
"       tinzaparin",
"      </a>",
"      in neonates because data on its use are still limited (",
"      <a class=\"graphic graphic_table graphicRef64075 \" href=\"UTD.htm?15/19/15677\">",
"       table 1",
"      </a>",
"      ). A nomogram has been developed for dose titration of LMWH in children. (See",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?41/55/42872?source=see_link\">",
"       \"Enoxaparin: Pediatric drug information\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      For",
"      <strong>",
"       prophylaxis",
"      </strong>",
"      ,",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?41/55/42872?source=see_link\">",
"       enoxaparin",
"      </a>",
"      is initiated at 0.75",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      per dose twice each day. The target concentration of anti-factor Xa for prophylaxis is 0.1 to 0.3",
"      <span class=\"nowrap\">",
"       U/mL,",
"      </span>",
"      which is lower than the target range for treatment [",
"      <a class=\"abstract\" href=\"UTD.htm?14/40/14986/abstract/3\">",
"       3",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    If bleeding occurs, LMWH should be discontinued and",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?18/18/18724?source=see_link\">",
"     protamine sulfate",
"    </a>",
"    administered to reverse the",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?7/39/7801?source=see_link\">",
"     heparin",
"    </a>",
"    effect. The dose of protamine sulfate depends upon the dose of LMWH and the time since LMWH was administered last. If LMWH was given within four hours, the maximum dose of protamine is 1 mg per 100 units LMWH, given by slow IV push. If LMWH was given more than four hours previously, a lower dose of protamine should be used. However, protamine only partially neutralizes the effects of LMWH [",
"    <a class=\"abstract\" href=\"UTD.htm?14/40/14986/abstract/35\">",
"     35",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13664593\">",
"    <span class=\"h3\">",
"     Duration of therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;The optimal duration of therapy is uncertain, although the usual duration is six weeks to three months. Our approach is to monitor the thrombus with ultrasound and continue therapy until the thrombus has resolved and the patient is entirely asymptomatic. If the thrombus was related to a CVL, then the CVL should also be removed before stopping therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?14/40/14986/abstract/1\">",
"     1",
"    </a>",
"    ]. If the thrombus does not resolve, the therapy should be continued for as long as three months, after which the anticoagulation is discontinued. &nbsp;",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Warfarin",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?21/4/21578?source=see_link\">",
"     Warfarin",
"    </a>",
"    is an oral anticoagulant that should not be used in newborns because of the potential risk of bleeding [",
"    <a class=\"abstract\" href=\"UTD.htm?14/40/14986/abstract/26\">",
"     26",
"    </a>",
"    ]. The effect of warfarin is caused by reduction of the functional plasma concentration of the vitamin-K dependent coagulation factors (factors II, VII, IX, and X). However, the concentration of these factors is physiologically reduced in newborns and often is similar to those of adults receiving warfarin therapy. Newborns also may have borderline levels of vitamin K, increasing the risk of warfarin-induced bleeding. Because human milk has low concentrations of vitamin K, breastfed newborns are especially sensitive to the effect of warfarin. On the other hand, infant formulas are supplemented with vitamin K, rendering formula fed newborns relatively resistant to treatment.",
"   </p>",
"   <p>",
"    Another problem with",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?21/4/21578?source=see_link\">",
"     warfarin",
"    </a>",
"    administration in newborns is its availability only in tablet form. Splitting or crushing the tablet into powder form may cause variability in the dose. In addition, treatment with warfarin requires frequent monitoring of INR.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Other agents",
"    </span>",
"    &nbsp;&mdash;&nbsp;Novel anticoagulants, including direct thrombin inhibitors such as",
"    <a class=\"drug drug_general\" href=\"UTD.htm?17/48/18184?source=see_link\">",
"     bivalirudin",
"    </a>",
"    and",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?14/13/14551?source=see_link\">",
"     argatroban",
"    </a>",
"    , are under investigation in children [",
"    <a class=\"abstract\" href=\"UTD.htm?14/40/14986/abstract/36-38\">",
"     36-38",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/59/37818?source=see_link\">",
"     \"Anticoagulants other than heparin and warfarin\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?14/13/14551?source=see_link\">",
"       Argatroban",
"      </a>",
"      &mdash;",
"      <strong>",
"      </strong>",
"      Argatroban is a direct thrombin inhibitor that is derived from L-Arginine [",
"      <a class=\"abstract\" href=\"UTD.htm?14/40/14986/abstract/37,39\">",
"       37,39",
"      </a>",
"      ]. This drug is the only agent approved in the United States and Canada for treatment of thrombosis in adult patients with",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?7/39/7801?source=see_link\">",
"       heparin",
"      </a>",
"      -induced thrombocytopenia (HIT). Argatroban is eliminated by the liver, and dose reduction should be considered in patients with hepatic dysfunction. There is no antidote available.",
"      <br/>",
"      <br/>",
"      There is only one prospective study of argatroban in children, which investigated its safety and efficacy for the indication of HIT [",
"      <a class=\"abstract\" href=\"UTD.htm?14/40/14986/abstract/38\">",
"       38",
"      </a>",
"      ]. The study enrolled a small number of infants (eight infants from a total 18 patients). Most of the subjects were suspected of having HIT, and required anticoagulation because of hemodialysis or continuous venovenous hemofiltration, recent cardiac surgery, or extracorporeal membrane oxygenation (ECMO). Among the eight infants, two patients (25 percent) had new thrombosis within the 30-day follow up period, and one patient had major bleeding (intracranial hemorrhage). Other available evidence is limited to case reports or case series involving fewer than 10 infants and children. Thus, there is insufficient evidence to determine the safety and efficacy of argatroban in infants. &nbsp;",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?17/48/18184?source=see_link\">",
"       Bivalirudin",
"      </a>",
"      <strong>",
"      </strong>",
"      &mdash;",
"      <strong>",
"      </strong>",
"      Bivalirudin is another direct thrombin inhibitor that is being studied in children. An initial study was designed to find appropriate doses and evaluate safety and efficacy in infants younger than six months of age with thrombosis [",
"      <a class=\"abstract\" href=\"UTD.htm?14/40/14986/abstract/36\">",
"       36",
"      </a>",
"      ]. The study enrolled 16 infants, with only four neonates. The four newborns suffered from common femoral vein thrombosis, inferior vena cava thrombosis, and right atrial thrombosis. Among the 16 subjects, 37.5 percent had complete or partial resolution of their thrombosis by 48 to 72 hours of treatment, but none of the four neonates had clot resolution. Only two patients had major bleeding, both with gross hematuria, and this resolved with the reduction of the infusion rate.",
"      <br/>",
"      <br/>",
"      A prophylactic use of bivalirudin was evaluated in another prospective study on pediatric patients undergoing cardiac catheterization. This study enrolled 110 children, including 11 neonates. This study demonstrated that the",
"      <span class=\"nowrap\">",
"       pharmacokinetic/pharmacodynamic",
"      </span>",
"      <span class=\"nowrap\">",
"       (PK/PD)",
"      </span>",
"      response of bivalirudin in this pediatric population was as predictable as in adult patients [",
"      <a class=\"abstract\" href=\"UTD.htm?14/40/14986/abstract/40\">",
"       40",
"      </a>",
"      ]. Further larger prospective studies to investigate the optimal dose in children are recommended.",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?39/35/40503?source=see_link\">",
"       Fondaparinux",
"      </a>",
"      <strong>",
"      </strong>",
"      &mdash;",
"      <strong>",
"      </strong>",
"      Fondaparinux is a synthetic antithrombin-dependent inhibitor of factor Xa. There is only one prospective study of fondaparinux in pediatric patients, which included 24 patients aged 1 to 18 years [",
"      <a class=\"abstract\" href=\"UTD.htm?14/40/14986/abstract/41\">",
"       41",
"      </a>",
"      ]. No patients younger than one year of age were enrolled. &nbsp;",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Given the current very limited evidence, we would not recommend the use of either",
"    <a class=\"drug drug_general\" href=\"UTD.htm?17/48/18184?source=see_link\">",
"     bivalirudin",
"    </a>",
"    or",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?14/13/14551?source=see_link\">",
"     argatroban",
"    </a>",
"    for management of acute thrombosis in newborn. The only rationale for use of argatroban in newborns would be in patients judged to be at high risk of HIT, who require cessation of UFH or LMWH and continuous anticoagulation with non-heparinoid agents [",
"    <a class=\"abstract\" href=\"UTD.htm?14/40/14986/abstract/39,42\">",
"     39,42",
"    </a>",
"    ]. However, the incidence of HIT in neonate is deemed to be very low, so the use of these agents should be very limited. &nbsp; &nbsp;",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h1\">",
"     THROMBOLYTIC AGENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Thrombolytic drugs currently used are intravenously infused plasminogen activators, which promote the conversion of plasminogen to plasmin, with subsequent cleavage of fibrin, fibrinogen, and factors V and VIII, resulting in clot breakdown (",
"    <a class=\"graphic graphic_figure graphicRef81428 \" href=\"UTD.htm?30/24/31118\">",
"     figure 2",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?14/40/14986/abstract/2,26\">",
"     2,26",
"    </a>",
"    ]. The thrombolytic activity of these agents may be reduced in newborns because their decreased plasminogen concentration compared with adults leads to decreased generation of plasmin [",
"    <a class=\"abstract\" href=\"UTD.htm?14/40/14986/abstract/43,44\">",
"     43,44",
"    </a>",
"    ]. Supplementation with plasminogen by administration of fresh frozen plasma may improve fibrinolytic activity [",
"    <a class=\"abstract\" href=\"UTD.htm?14/40/14986/abstract/2\">",
"     2",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Guidelines suggest AGAINST the use of thrombolytic therapy for neonatal thrombosis unless the thrombus occludes a major vessel causing critical compromise of organs or limbs [",
"    <a class=\"abstract\" href=\"UTD.htm?14/40/14986/abstract/1\">",
"     1",
"    </a>",
"    ]. Thrombocytopenia (platelet count",
"    <span class=\"nowrap\">",
"     &lt;100,000/microL),",
"    </span>",
"    low fibrinogen concentration (&lt;1",
"    <span class=\"nowrap\">",
"     g/dL),",
"    </span>",
"    and severe deficiency of coagulation factors should be corrected before initiating treatment. Contraindications to treatment include major surgery or hemorrhage within the previous 10 days, neurosurgery within three weeks, a severe asphyxial event within seven days, an invasive procedure within the previous three days, seizures within 48 hours, prematurity &lt;32 weeks gestation, systemic septicemia, active bleeding, or the inability to maintain platelets",
"    <span class=\"nowrap\">",
"     &gt;100,000/microL",
"    </span>",
"    or fibrinogen &gt;1",
"    <span class=\"nowrap\">",
"     g/dL",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?14/40/14986/abstract/45\">",
"     45",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Recombinant tissue-type plasminogen activator",
"    </span>",
"    &nbsp;&mdash;&nbsp;Recombinant tissue-type plasminogen activator (tPA) is the thrombolytic agent of choice. Streptokinase and urokinase also have been used in newborns. Compared to the others, tPA has improved clot lysis in vitro [",
"    <a class=\"abstract\" href=\"UTD.htm?14/40/14986/abstract/43\">",
"     43",
"    </a>",
"    ] and a lower risk of hypersensitivity [",
"    <a class=\"abstract\" href=\"UTD.htm?14/40/14986/abstract/46\">",
"     46",
"    </a>",
"    ]. Urokinase is not labeled for this indication in the United States, nor is it approved for use in children.",
"   </p>",
"   <p>",
"    No clinical trials have evaluated thrombolytic agents in newborns. Treatment of neonatal thrombosis with tPA is described in case reports and case series using a variety of doses and treatment regimens [",
"    <a class=\"abstract\" href=\"UTD.htm?14/40/14986/abstract/47-52\">",
"     47-52",
"    </a>",
"    ]. As an example, one report described the authors' experience with treatment of catheter-related thrombus in 14 patients and reviewed the literature [",
"    <a class=\"abstract\" href=\"UTD.htm?14/40/14986/abstract/47\">",
"     47",
"    </a>",
"    ]. Treatment with tPA resulted in complete dissolution of the clot in 11 of the 14 patients and partial lysis in two cases. No severe complications, including intracranial hemorrhage, occurred. Comparable results were found in a summary of 80 newborns treated with tPA for spontaneous and catheter-related thrombosis described in 29 reports [",
"    <a class=\"abstract\" href=\"UTD.htm?14/40/14986/abstract/47\">",
"     47",
"    </a>",
"    ]. Clot dissolution occurred completely or partially in 68 and 26 percent of cases, respectively.",
"   </p>",
"   <p>",
"    Bleeding complications varied widely among reports, with a range of major bleeding episodes of 0 to 57 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?14/40/14986/abstract/47-52\">",
"     47-52",
"    </a>",
"    ]. Because critically ill and preterm newborns are at risk for hemorrhage in the absence of thrombolytic therapy, information about the risk of bleeding complications with tPA awaits controlled trials.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h3\">",
"     Dose",
"    </span>",
"    &nbsp;&mdash;&nbsp;The dose of tPA in newborns is extrapolated from doses in older children and adults. For systemic therapy, tPA is given in a continuous infusion at a rate of 0.1 to 0.6",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    per hour for six hours, without a loading dose [",
"    <a class=\"abstract\" href=\"UTD.htm?14/40/14986/abstract/1\">",
"     1",
"    </a>",
"    ]. The drug can be given through a central or peripheral venous catheter.",
"   </p>",
"   <p>",
"    Fibrinogen concentration should be measured before and two hours after initiating therapy, and if bleeding occurs. Fresh frozen plasma",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    cryoprecipitate should be given to maintain the fibrinogen concentration above 1",
"    <span class=\"nowrap\">",
"     g/L",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?14/40/14986/abstract/1\">",
"     1",
"    </a>",
"    ]; some experts also recommend maintaining a platelet count",
"    <span class=\"nowrap\">",
"     &gt;100,000/microL.",
"    </span>",
"   </p>",
"   <p>",
"    Aside from resolution of the thrombus, there is no easy way to measure the effectiveness of the tPA infusion. The presence of d-dimers or",
"    <span class=\"nowrap\">",
"     fibrin/fibrinogen",
"    </span>",
"    degradation products indicates a fibrinolytic state. Measurement of aPTT may not be useful if",
"    <span class=\"nowrap\">",
"     fibrin/fibrinogen",
"    </span>",
"    degradation products are present, fibrinogen levels are low, or concurrent",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?7/39/7801?source=see_link\">",
"     heparin",
"    </a>",
"    therapy is given. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?9/33/9752?source=see_link&amp;anchor=H2#H2\">",
"     \"Clinical use of plasma components\", section on 'Fresh frozen plasma'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?9/33/9752?source=see_link&amp;anchor=H14#H14\">",
"     \"Clinical use of plasma components\", section on 'Cryoprecipitate'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Treatment of bleeding after use of tPA includes use of cryoprecipitate to increase the fibrinogen concentration, stopping the tPA infusion if possible, and administration of platelets if needed. Administration of epsilon",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?14/32/14854?source=see_link\">",
"     aminocaproic acid",
"    </a>",
"    (which inhibits activation of plasminogen to plasmin) is not needed because tPA has a very short half-life, and bleeding usually responds to these measures.",
"   </p>",
"   <p>",
"    Other fibrinolytic agents have been used in adults [",
"    <a class=\"abstract\" href=\"UTD.htm?14/40/14986/abstract/53\">",
"     53",
"    </a>",
"    ]. Data on their use are not available for children.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h1\">",
"     TREATMENT FOR THROMBOSIS IN DIFFERENT LOCATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;As discussed above, data are limited on the outcome of antithrombotic therapy in newborns. An approach is provided below for treatment of thromboembolic conditions in specific anatomic locations. &nbsp;",
"   </p>",
"   <p>",
"    Before initiating treatment, consultation should be obtained from a pediatric hematologist experienced in the management of these disorders. For additional consultation, a free service is provided by a group of physicians who have extensive experience in neonatal thrombosis (1-800-NOCLOTS) [",
"    <a class=\"abstract\" href=\"UTD.htm?14/40/14986/abstract/54\">",
"     54",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h2\">",
"     Renal vein thrombosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are no randomized trials in the treatment of neonatal renal vein thrombosis (RVT), and reported data are based upon retrospective case series. In a systematic review of the literature from 1992 to 2006 that identified 271 patients from 13 case series, the following treatment modalities were used in the 232 patients with available data on management [",
"    <a class=\"abstract\" href=\"UTD.htm?14/40/14986/abstract/55\">",
"     55",
"    </a>",
"    ]. The frequency of use is also included.",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Supportive care alone &ndash; 40 percent",
"     </li>",
"     <li>",
"      Unfractionated",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?7/39/7801?source=see_link\">",
"       heparin",
"      </a>",
"      (UFH) &ndash; 22 percent",
"     </li>",
"     <li>",
"      Low molecular weight",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?7/39/7801?source=see_link\">",
"       heparin",
"      </a>",
"      (LMWH) &ndash; 21 percent",
"     </li>",
"     <li>",
"      Fibrinolytic therapy &ndash; 11 percent",
"     </li>",
"     <li>",
"      Anti-thrombin therapy &ndash; 2 percent",
"     </li>",
"     <li>",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?21/4/21578?source=see_link\">",
"       Warfarin",
"      </a>",
"      &ndash; 1 percent",
"     </li>",
"     <li>",
"      Surgical intervention &ndash; &lt;1 percent",
"     </li>",
"     <li>",
"      Combination of treatment &ndash; 4 percent",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The renal outcome of the affected kidney did not differ in patients who were treated with supportive care or with",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?7/39/7801?source=see_link\">",
"     heparin",
"    </a>",
"    therapy (ie, UFH and LMWH) with atrophy of the affected kidney in 76 versus 73 percent of cases at last follow-up, respectively.",
"   </p>",
"   <p>",
"    Unilateral RVT without compromised renal function or extension into the inferior vena cava (IVC) can be managed initially with close observation and supportive care. This approach is supported by a comprehensive review of the literature [",
"    <a class=\"abstract\" href=\"UTD.htm?14/40/14986/abstract/55\">",
"     55",
"    </a>",
"    ] and by a small observational study that demonstrated anticoagulant treatment of unilateral renal thrombosis did not improve outcome of the affected kidney [",
"    <a class=\"abstract\" href=\"UTD.htm?14/40/14986/abstract/56\">",
"     56",
"    </a>",
"    ]. A central catheter in the IVC should be removed if present. Alternatively, the neonate can be started on anticoagulation therapy, which is advocated by some experts because renal vein thrombosis occasionally leads to serious complications including death [",
"    <a class=\"abstract\" href=\"UTD.htm?14/40/14986/abstract/57\">",
"     57",
"    </a>",
"    ]. Either anticoagulation therapy or supportive care with close monitoring is an acceptable approach [",
"    <a class=\"abstract\" href=\"UTD.htm?14/40/14986/abstract/1\">",
"     1",
"    </a>",
"    ]. If thrombosis progresses or there is extension into the IVC, UFH or LMWH is recommended. &nbsp;",
"   </p>",
"   <p>",
"    If RVT is bilateral, with or without compromised renal function, we begin heparinization, unless there are contraindications to its use. In this case, UFH should be used because LMWH accumulates with renal insufficiency [",
"    <a class=\"abstract\" href=\"UTD.htm?14/40/14986/abstract/1,58\">",
"     1,58",
"    </a>",
"    ]. Concomitant use of fibrinolytic therapy should also be considered [",
"    <a class=\"abstract\" href=\"UTD.htm?14/40/14986/abstract/1,56\">",
"     1,56",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H12\">",
"     'Thrombolytic agents'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    If LMWH is used in patients with renal insufficiency, the dose should be reduced. There are no data regarding dose adjustment of LMWH in neonatal renal failure. This author's approach is to decrease the dose in proportion to the degree of renal insufficiency (eg, 25 percent of the dose is used for infants estimated to have 25 percent of renal function), and make further adjustments according to the antifactor Xa level. Thrombolytic therapy should be considered for bilateral RVT and renal failure.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h2\">",
"     Right atrial thrombosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Right atrial thrombosis is usually associated with the use of central venous catheters and may compromise cardiac function or lead to pulmonary embolism. If possible, the catheter should be removed. We usually begin anticoagulation therapy with UFH or LMWH. If anticoagulation therapy is not begun, the thrombus should be monitored closely. UFH or LMWH should be started if the thrombus increases in size [",
"    <a class=\"abstract\" href=\"UTD.htm?14/40/14986/abstract/59\">",
"     59",
"    </a>",
"    ]. We begin thrombolytic therapy with tPA if cardiac function is compromised.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h2\">",
"     Arterial thrombosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Treatment should be initiated for arterial thrombosis that causes significant impairment of blood flow to an extremity or vital organ. An associated arterial catheter should be removed. If viability of the organ or limb is not immediately threatened, we usually begin anticoagulation therapy with LMWH or UFH [",
"    <a class=\"abstract\" href=\"UTD.htm?14/40/14986/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Thrombolytic therapy with tPA should be given in conditions that are life-threatening or if the viability of a limb or organ is jeopardized [",
"    <a class=\"abstract\" href=\"UTD.htm?14/40/14986/abstract/1\">",
"     1",
"    </a>",
"    ]. Anticoagulant treatment with UFH should be started (without a bolus) during the tPA infusion. The thrombus should be monitored by clinical examination and ultrasonography. (See",
"    <a class=\"local\" href=\"#H13\">",
"     'Recombinant tissue-type plasminogen activator'",
"    </a>",
"    above.) Surgical thrombectomy is an appropriate alternative in cases in which thrombolysis is contraindicated.",
"   </p>",
"   <p>",
"    The duration of anticoagulation therapy depends upon the clinical course. If the thrombus resolves, we use a short course (10 to 14 days). If the thrombus persists, we continue LMWH for three months.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h1\">",
"     NEONATAL PURPURA FULMINANS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Purpura fulminans in newborns is a rare life-threatening condition characterized by disseminated intravascular coagulation and hemorrhagic skin necrosis [",
"    <a class=\"abstract\" href=\"UTD.htm?14/40/14986/abstract/60\">",
"     60",
"    </a>",
"    ]. It usually is caused by homozygous or compound heterozygous deficiency in protein C or S, a mechanism that is consistent with the observation of consanguinity in some affected families [",
"    <a class=\"abstract\" href=\"UTD.htm?14/40/14986/abstract/60-66\">",
"     60-66",
"    </a>",
"    ]. The heterozygous parents of these infants have type 1 protein C deficiency but infrequently have a history of thrombosis. A similar consumptive coagulopathy occurs in mice in which inactivation of the protein C gene led to total protein C deficiency [",
"    <a class=\"abstract\" href=\"UTD.htm?14/40/14986/abstract/67\">",
"     67",
"    </a>",
"    ]. Purpura fulminans also can result from acquired protein C deficiency due to consumptive coagulopathy, as in meningococcemia [",
"    <a class=\"abstract\" href=\"UTD.htm?14/40/14986/abstract/60\">",
"     60",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?0/52/841?source=see_link&amp;anchor=H20#H20\">",
"     \"Protein C deficiency\", section on 'Acquired protein C deficiency'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22501024\">",
"    <span class=\"h2\">",
"     Clinical presentation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Neonatal purpura fulminans usually occurs on the first day of life. Affected infants present with ecchymoses, extensive venous and arterial thromboses (initially at sites of trauma), laboratory evidence of disseminated intravascular coagulation (thrombocytopenia, hypofibrinogenemia, and increased PT and aPTT times), and extremely low levels of protein C or protein S antigen (less than 1 percent of normal) [",
"    <a class=\"abstract\" href=\"UTD.htm?14/40/14986/abstract/61-63,68-72\">",
"     61-63,68-72",
"    </a>",
"    ]. Delayed presentation of the disorder (after six months of age) has been reported [",
"    <a class=\"abstract\" href=\"UTD.htm?14/40/14986/abstract/73\">",
"     73",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1364496\">",
"    <span class=\"h2\">",
"     Diagnosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;The diagnosis of protein C or S deficiency is made by testing a citrated plasma sample for protein C and S activity [",
"    <a class=\"abstract\" href=\"UTD.htm?14/40/14986/abstract/60\">",
"     60",
"    </a>",
"    ]. The sample must be collected prior to initiation of treatment, but treatment should not be delayed while awaiting the results. Results should be compared to age-specific reference ranges because protein C and S activity in healthy neonates is substantially lower than in older children or adults. Ideally, the diagnosis is confirmed with genetic testing; a list of clinical laboratories that perform genetic testing for this disorder is available at the",
"    <a class=\"external\" href=\"file://www.ncbi.nlm.nih.gov/sites/GeneTests/lab/clinical_disease_id/260112?db=genetests\">",
"     GeneTests website",
"    </a>",
"    .",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22501355\">",
"    <span class=\"h2\">",
"     Initial treatment",
"    </span>",
"    &nbsp;&mdash;&nbsp;Neonatal purpura fulminans is initially treated with a source of exogenous protein C;",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?7/39/7801?source=see_link\">",
"     heparin",
"    </a>",
"    and antiplatelet agents are ineffective [",
"    <a class=\"abstract\" href=\"UTD.htm?14/40/14986/abstract/62,68-72\">",
"     62,68-72",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    For infants with protein C deficiency, either fresh frozen plasma or",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?38/27/39349?source=see_link\">",
"     protein C concentrate",
"    </a>",
"    has been used with success:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Fresh frozen plasma (FFP) is given at a dose of 10 to 20",
"      <span class=\"nowrap\">",
"       mL/kg",
"      </span>",
"      every 12 hours [",
"      <a class=\"abstract\" href=\"UTD.htm?14/40/14986/abstract/1,74\">",
"       1,74",
"      </a>",
"      ]. Frequent dosing is necessary because the half-life of protein C in the circulation is only about 6 to 16 hours. However, administration of FFP on a frequent basis is limited by the development of hyperproteinemia, hypertension, loss of venous access, and the potential for exposure to infectious viral agents [",
"      <a class=\"abstract\" href=\"UTD.htm?14/40/14986/abstract/75,76\">",
"       75,76",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      A highly purified concentrate of protein C (Ceprotin, Baxter [",
"      <a class=\"abstract\" href=\"UTD.htm?14/40/14986/abstract/77\">",
"       77",
"      </a>",
"      ]) is given at a starting dose of 100",
"      <span class=\"nowrap\">",
"       units/kg",
"      </span>",
"      IV, followed by 50",
"      <span class=\"nowrap\">",
"       units/kg",
"      </span>",
"      IV every six hours [",
"      <a class=\"abstract\" href=\"UTD.htm?14/40/14986/abstract/60,78,79\">",
"       60,78,79",
"      </a>",
"      ].",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?38/27/39349?source=see_link\">",
"       Protein C concentrate",
"      </a>",
"      is available in the United States and Canada for compassionate use in this condition.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Subsequent dosing of FFP or",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?38/27/39349?source=see_link\">",
"     protein C concentrate",
"    </a>",
"    depends upon the patient's response because the half-life of protein C may be shortened considerably during acute thrombosis. The dose is titrated to achieve a trough level of protein C activity of 50 international",
"    <span class=\"nowrap\">",
"     units/dL",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?14/40/14986/abstract/60\">",
"     60",
"    </a>",
"    ]. Treatment is continued until the lesions resolve (typically within six to eight weeks) and the infant is transitioned onto other anticoagulants. &nbsp;",
"   </p>",
"   <p>",
"    For infants with protein S deficiency, FFP is used. The initial dose is 10 to 20",
"    <span class=\"nowrap\">",
"     mL/kg",
"    </span>",
"    every 12 hours (the same dose that is used for protein C deficiency). The half-life of protein S is about 36 hours (plasma levels of protein S are 23 percent at two hours, and 14 percent at 24 hours after an infusion of FFP 10",
"    <span class=\"nowrap\">",
"     mL/kg)",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?14/40/14986/abstract/65,80\">",
"     65,80",
"    </a>",
"    ]. The FFP dose titrated to a trough level of free protein S level of 30 international",
"    <span class=\"nowrap\">",
"     units/dL",
"    </span>",
"    should be more than adequate. &nbsp;",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22503029\">",
"    <span class=\"h2\">",
"     Long-term management",
"    </span>",
"    &nbsp;&mdash;&nbsp;Infants with purpura fulminans must be treated indefinitely with an anticoagulation regimen to prevent thrombosis [",
"    <a class=\"abstract\" href=\"UTD.htm?14/40/14986/abstract/63,68,81-83\">",
"     63,68,81-83",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Options for long-term management include LMWH (target anti-factor Xa concentration 0.5 to 1",
"    <span class=\"nowrap\">",
"     U/mL),",
"    </span>",
"    protein C supplementation (given subcutaneously), or oral",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?21/4/21578?source=see_link\">",
"     warfarin",
"    </a>",
"    therapy, or a combination of these drugs [",
"    <a class=\"abstract\" href=\"UTD.htm?14/40/14986/abstract/1\">",
"     1",
"    </a>",
"    ]. If warfarin therapy is used, the INR usually should be maintained between 2.5 to 3.5. A lower INR of 1.5 to 2.5 is appropriate if the patient is also treated with",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?38/27/39349?source=see_link\">",
"     protein C concentrate",
"    </a>",
"    ; a higher INR of 3 to 4.5 is appropriate if the patient has warfarin-induced skin necrosis [",
"    <a class=\"abstract\" href=\"UTD.htm?14/40/14986/abstract/84\">",
"     84",
"    </a>",
"    ]. Because LMWH has a predictable and stable anticoagulation response, we generally prefer it over warfarin for use in this age group, as discussed above. (See",
"    <a class=\"local\" href=\"#H4\">",
"     'Anticoagulant therapy'",
"    </a>",
"    above.) A subcutaneous preparation of protein C has been developed that requires administration every third day; this preparation avoids the potential hazards of long-term central venous access [",
"    <a class=\"abstract\" href=\"UTD.htm?14/40/14986/abstract/85-88\">",
"     85-88",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Liver transplantation can correct homozygous protein C deficiency and has been used for a patient for whom protein C replacement therapy was not available [",
"    <a class=\"abstract\" href=\"UTD.htm?14/40/14986/abstract/89\">",
"     89",
"    </a>",
"    ]. A combined liver and renal transplant was successfully used for a patient who developed renal failure due to renal vein thrombosis [",
"    <a class=\"abstract\" href=\"UTD.htm?14/40/14986/abstract/90\">",
"     90",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22502859\">",
"    <span class=\"h1\">",
"     PREVENTION OF THROMBOSIS",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22502884\">",
"    <span class=\"h2\">",
"     Arterial catheters",
"    </span>",
"    &nbsp;&mdash;&nbsp;To prevent thrombosis, fluid infused through an umbilical artery catheter should contain UFH in a concentration of 0.25 to 1.0",
"    <span class=\"nowrap\">",
"     units/mL",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?14/40/14986/abstract/1\">",
"     1",
"    </a>",
"    ]. In a systematic review of five trials by the Cochrane database, heparinization decreased the risk of catheter occlusion (relative risk 0.20, 95% CI: 0.11-0.35) [",
"    <a class=\"abstract\" href=\"UTD.htm?14/40/14986/abstract/91\">",
"     91",
"    </a>",
"    ]. The risk of aortic thrombosis, intraventricular hemorrhage, death, or clinical ischemic events did not appear to be affected, although the small sample size resulted in wide confidence intervals.",
"   </p>",
"   <p>",
"    Fluid infused through a peripheral artery catheter also should be heparinized, using a similar concentration. Use of UFH prolongs the patency of peripheral catheters, although data are limited in newborns [",
"    <a class=\"abstract\" href=\"UTD.htm?14/40/14986/abstract/92-94\">",
"     92-94",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22502891\">",
"    <span class=\"h2\">",
"     Central venous catheters",
"    </span>",
"    &nbsp;&mdash;&nbsp;Fluid infused through a central venous catheter should contain",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?7/39/7801?source=see_link\">",
"     heparin",
"    </a>",
"    in a concentration of 0.5",
"    <span class=\"nowrap\">",
"     units/mL",
"    </span>",
"    to prevent thrombosis and catheter occlusion [",
"    <a class=\"abstract\" href=\"UTD.htm?14/40/14986/abstract/1\">",
"     1",
"    </a>",
"    ]. However, heparinization of central venous catheters (umbilical or peripherally placed percutaneous) has not been studied in well designed trials [",
"    <a class=\"abstract\" href=\"UTD.htm?14/40/14986/abstract/95\">",
"     95",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Obstructed central venous catheters can be cleared with local instillation of tPA (0.25 to 0.50 mg) [",
"    <a class=\"abstract\" href=\"UTD.htm?14/40/14986/abstract/45\">",
"     45",
"    </a>",
"    ]. It is important to limit the volume infused to the dead space of the catheter to avoid systemic administration of tPA.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H27600983\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The management of neonatal thrombosis is extrapolated largely from data in adults. Little information is available on management strategies or the efficacy and safety of therapeutic agents. In general, asymptomatic thrombosis is managed by close monitoring of the size of the thrombus and by providing supportive care. Severe symptomatic thromboembolic events typically are treated with anticoagulation",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      fibrinolytic agents. Surgical thrombectomy rarely is performed in newborns. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'General approach'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Before antithrombotic therapy is initiated, baseline coagulation testing should be performed, including activated partial thromboplastin time (aPTT), prothrombin time (PT) and international normalized ratio (INR), plasma fibrinogen concentration, platelet count, and cranial ultrasound examination. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Baseline testing'",
"      </a>",
"      above.) &nbsp; &nbsp;",
"     </li>",
"     <li>",
"      Standard",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?7/39/7801?source=see_link\">",
"       heparin",
"      </a>",
"      , also known as unfractionated heparin (UFH), may be used in newborns. The advantages of UFH are its rapid reversibility and low cost. Disadvantages include its unpredictable pharmacokinetic response and resultant requirement for frequent monitoring and the need for a dedicated intravenous catheter to avoid interruption of anticoagulation therapy. The major side effects of UFH are bleeding, heparin-induced thrombocytopenia (HIT), and osteoporosis. UFH dosing in the neonate should be titrated to both aPTT and anti-factor Xa activity. (See",
"      <a class=\"local\" href=\"#H5\">",
"       'Heparin'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      We suggest that low molecular weight",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?7/39/7801?source=see_link\">",
"       heparin",
"      </a>",
"      (LMWH) be used rather than UFH for treatment of neonatal thrombosis, provided that an assay of anti-factor Xa activity (required to monitor the anticoagulation effect of LMWH) is readily available (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). LMWH is administered subcutaneously, requires less laboratory monitoring and dose adjustment, and probably has reduced risk of immune-mediated thrombocytopenia and osteoporosis as compared with UFH. There are several LMWH preparations and they should not be used interchangeably (",
"      <a class=\"graphic graphic_table graphicRef64075 \" href=\"UTD.htm?15/19/15677\">",
"       table 1",
"      </a>",
"      ). By contrast, UFH is preferred over LMWH in patients with renal insufficiency. (See",
"      <a class=\"local\" href=\"#H8\">",
"       'Low molecular weight heparin'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      We recommend AGAINST thrombolytic therapy for neonatal thrombosis unless major vessel occlusion is causing critical compromise of organs or limbs (",
"      <a class=\"grade\" href=\"._grade_2?title=Grade 1B\">",
"       Grade 1B",
"      </a>",
"      ). Fibrinolytic therapy should be undertaken with caution because of significant risks of major bleeding. In cases in which fibrinolytic therapy is indicated, because of critical compromise of organs or limbs, recombinant tissue-type plasminogen activator (tPA) is the thrombolytic agent of choice. Contraindications to fibrinolytic therapy include recent or expected surgery or by a variety of other conditions. (See",
"      <a class=\"local\" href=\"#H12\">",
"       'Thrombolytic agents'",
"      </a>",
"      above.) &nbsp; &nbsp;",
"     </li>",
"     <li>",
"      For neonates with unilateral renal vein thrombosis (RVT) without compromised renal function or extension into the inferior vena cava (IVC), either supportive care with close monitoring or anticoagulation therapy are acceptable alternatives. If thrombosis progresses or there is extension into the IVC, we suggest treatment with UFH or LMWH (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). We also suggest heparinization if RVT is bilateral and renal function is compromised (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ), unless there are contraindications to its use. In this case, UFH should be used because LMWH accumulates with renal insufficiency. (See",
"      <a class=\"local\" href=\"#H18\">",
"       'Renal vein thrombosis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Right atrial thrombosis usually is associated with the use of central venous catheters and may compromise cardiac function or lead to pulmonary embolism. If possible, the catheter should be removed. We usually begin anticoagulation therapy with UFH or LMWH. We begin thrombolytic therapy with tPA if cardiac function is compromised. (See",
"      <a class=\"local\" href=\"#H19\">",
"       'Right atrial thrombosis'",
"      </a>",
"      above.) &nbsp;",
"     </li>",
"     <li>",
"      Arterial thrombosis that causes significant impairment of blood flow to an extremity or vital organ should be treated with anticoagulation therapy with LMWH or UFH, and any associated arterial catheter should be removed. In conditions that are life-threatening or if the viability of a limb or organ is jeopardized, thrombolytic therapy with tPA should be given. (See",
"      <a class=\"local\" href=\"#H20\">",
"       'Arterial thrombosis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Neonatal purpura fulminans is a rare life-threatening condition characterized by disseminated intravascular coagulation and hemorrhagic skin necrosis. It usually is caused by homozygous or compound heterozygous deficiency in protein C or S. Early identification of the disorder and treatment with protein C replacement is essential to prevent serious morbidity and death. (See",
"      <a class=\"local\" href=\"#H21\">",
"       'Neonatal purpura fulminans'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/40/14986/abstract/1\">",
"      Monagle P, Chan AK, Goldenberg NA, et al. Antithrombotic therapy in neonates and children: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest 2012; 141:e737S.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/40/14986/abstract/2\">",
"      Edstrom CS, Christensen RD. Evaluation and treatment of thrombosis in the neonatal intensive care unit. Clin Perinatol 2000; 27:623.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/40/14986/abstract/3\">",
"      Dix D, Andrew M, Marzinotto V, et al. The use of low molecular weight heparin in pediatric patients: a prospective cohort study. J Pediatr 2000; 136:439.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/40/14986/abstract/4\">",
"      Lin PH, Dodson TF, Bush RL, et al. Surgical intervention for complications caused by femoral artery catheterization in pediatric patients. J Vasc Surg 2001; 34:1071.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/40/14986/abstract/5\">",
"      Hedrick M, Elkins RC, Knott-Craig CJ, Razook JD. Successful thrombectomy for thrombosis of the right side of the heart after the Fontan operation. Report of two cases and review of the literature. J Thorac Cardiovasc Surg 1993; 105:297.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/40/14986/abstract/6\">",
"      Hirsh J, Bauer KA, Donati MB, et al. Parenteral anticoagulants: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest 2008; 133:141S.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/40/14986/abstract/7\">",
"      Patel S, Berry LR, Chan AK. Analysis of inhibition rate enhancement by covalent linkage of antithrombin to heparin as a potential predictor of reaction mechanism. J Biochem 2007; 141:25.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/40/14986/abstract/8\">",
"      Choay J, Petitou M, Lormeau JC, et al. Structure-activity relationship in heparin: a synthetic pentasaccharide with high affinity for antithrombin III and eliciting high anti-factor Xa activity. Biochem Biophys Res Commun 1983; 116:492.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/40/14986/abstract/9\">",
"      Danielsson A, Raub E, Lindahl U, Bj&ouml;rk I. Role of ternary complexes, in which heparin binds both antithrombin and proteinase, in the acceleration of the reactions between antithrombin and thrombin or factor Xa. J Biol Chem 1986; 261:15467.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/40/14986/abstract/10\">",
"      Weitz JI. Low-molecular-weight heparins. N Engl J Med 1997; 337:688.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/40/14986/abstract/11\">",
"      Andrew M, Marzinotto V, Massicotte P, et al. Heparin therapy in pediatric patients: a prospective cohort study. Pediatr Res 1994; 35:78.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/40/14986/abstract/12\">",
"      Newall F, Johnston L, Ignjatovic V, Monagle P. Unfractionated heparin therapy in infants and children. Pediatrics 2009; 123:e510.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/40/14986/abstract/13\">",
"      Andrew M. Developmental hemostasis: relevance to thromboembolic complications in pediatric patients. Thromb Haemost 1995; 74:415.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/40/14986/abstract/14\">",
"      Schmidt B, Buchanan MR, Ofosu F, et al. Antithrombotic properties of heparin in a neonatal piglet model of thrombin-induced thrombosis. Thromb Haemost 1988; 60:289.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/40/14986/abstract/15\">",
"      Schechter T, Finkelstein Y, Ali M, et al. Unfractionated heparin dosing in young infants: clinical outcomes in a cohort monitored with anti-factor Xa levels. J Thromb Haemost 2012; 10:368.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/40/14986/abstract/16\">",
"      Juergens CP, Semsarian C, Keech AC, et al. Hemorrhagic complications of intravenous heparin use. Am J Cardiol 1997; 80:150.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/40/14986/abstract/17\">",
"      Warkentin TE, Chong BH, Greinacher A. Heparin-induced thrombocytopenia: towards consensus. Thromb Haemost 1998; 79:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/40/14986/abstract/18\">",
"      Warkentin TE, Levine MN, Hirsh J, et al. Heparin-induced thrombocytopenia in patients treated with low-molecular-weight heparin or unfractionated heparin. N Engl J Med 1995; 332:1330.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/40/14986/abstract/19\">",
"      Demasi R, Bode AP, Knupp C, et al. Heparin-induced thrombocytopenia. Am Surg 1994; 60:26.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/40/14986/abstract/20\">",
"      Schmitt BP, Adelman B. Heparin-associated thrombocytopenia: a critical review and pooled analysis. Am J Med Sci 1993; 305:208.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/40/14986/abstract/21\">",
"      Visentin GP, Ford SE, Scott JP, Aster RH. Antibodies from patients with heparin-induced thrombocytopenia/thrombosis are specific for platelet factor 4 complexed with heparin or bound to endothelial cells. J Clin Invest 1994; 93:81.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/40/14986/abstract/22\">",
"      Ziporen L, Li ZQ, Park KS, et al. Defining an antigenic epitope on platelet factor 4 associated with heparin-induced thrombocytopenia. Blood 1998; 92:3250.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/40/14986/abstract/23\">",
"      Spadone D, Clark F, James E, et al. Heparin-induced thrombocytopenia in the newborn. J Vasc Surg 1992; 15:306.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/40/14986/abstract/24\">",
"      Ranze O, Ranze P, Magnani HN, Greinacher A. Heparin-induced thrombocytopenia in paediatric patients--a review of the literature and a new case treated with danaparoid sodium. Eur J Pediatr 1999; 158 Suppl 3:S130.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/40/14986/abstract/25\">",
"      Roy M, Turner-Gomes S, Gill G, et al. Accuracy of Doppler echocardiography for the diagnosis of thrombosis associated with umbilical venous catheters. J Pediatr 2002; 140:131.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/40/14986/abstract/26\">",
"      Andrew ME, Monagle P, deVeber G, Chan AK. Thromboembolic disease and antithrombotic therapy in newborns. Hematology Am Soc Hematol Educ Program 2001; :358.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/40/14986/abstract/27\">",
"      Albisetti M, Andrew M. Low molecular weight heparin in children. Eur J Pediatr 2002; 161:71.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/40/14986/abstract/28\">",
"      van der Heijden JF, Prins MH, B&uuml;ller HR. For the initial treatment of venous thromboembolism: are all low-molecular-weight heparin compounds the same? Thromb Res 2000; 100:V121.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/40/14986/abstract/29\">",
"      Massicotte P, Adams M, Marzinotto V, et al. Low-molecular-weight heparin in pediatric patients with thrombotic disease: a dose finding study. J Pediatr 1996; 128:313.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/40/14986/abstract/30\">",
"      Nohe N, Flemmer A, R&uuml;mler R, et al. The low molecular weight heparin dalteparin for prophylaxis and therapy of thrombosis in childhood: a report on 48 cases. Eur J Pediatr 1999; 158 Suppl 3:S134.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/40/14986/abstract/31\">",
"      Kuhle S, Massicotte P, Dinyari M, et al. Dose-finding and pharmacokinetics of therapeutic doses of tinzaparin in pediatric patients with thromboembolic events. Thromb Haemost 2005; 94:1164.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/40/14986/abstract/32\">",
"      van Ommen CH, van den Dool EJ, Peters M. Nadroparin therapy in pediatric patients with venous thromboembolic disease. J Pediatr Hematol Oncol 2008; 30:230.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/40/14986/abstract/33\">",
"      Malowany JI, Monagle P, Knoppert DC, et al. Enoxaparin for neonatal thrombosis: a call for a higher dose for neonates. Thromb Res 2008; 122:826.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/40/14986/abstract/34\">",
"      Cruickshank MK, Levine MN, Hirsh J, et al. A standard heparin nomogram for the management of heparin therapy. Arch Intern Med 1991; 151:333.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/40/14986/abstract/35\">",
"      Crowther MA, Berry LR, Monagle PT, Chan AK. Mechanisms responsible for the failure of protamine to inactivate low-molecular-weight heparin. Br J Haematol 2002; 116:178.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/40/14986/abstract/36\">",
"      Young G, Tarantino MD, Wohrley J, et al. Pilot dose-finding and safety study of bivalirudin in infants &lt;6 months of age with thrombosis. J Thromb Haemost 2007; 5:1654.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/40/14986/abstract/37\">",
"      Chan VH, Monagle P, Massicotte P, Chan AK. Novel paediatric anticoagulants: a review of the current literature. Blood Coagul Fibrinolysis 2010; 21:144.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/40/14986/abstract/38\">",
"      Young G, Boshkov LK, Sullivan JE, et al. Argatroban therapy in pediatric patients requiring nonheparin anticoagulation: an open-label, safety, efficacy, and pharmacokinetic study. Pediatr Blood Cancer 2011; 56:1103.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/40/14986/abstract/39\">",
"      Risch L, Huber AR, Schmugge M. Diagnosis and treatment of heparin-induced thrombocytopenia in neonates and children. Thromb Res 2006; 118:123.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/40/14986/abstract/40\">",
"      Forbes TJ, Hijazi ZM, Young G, et al. Pediatric catheterization laboratory anticoagulation with bivalirudin. Catheter Cardiovasc Interv 2011; 77:671.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/40/14986/abstract/41\">",
"      Young G, Yee DL, O'Brien SH, et al. FondaKIDS: a prospective pharmacokinetic and safety study of fondaparinux in children between 1 and 18 years of age. Pediatr Blood Cancer 2011; 57:1049.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/40/14986/abstract/42\">",
"      Young G. Old and new antithrombotic drugs in neonates and infants. Semin Fetal Neonatal Med 2011; 16:349.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/40/14986/abstract/43\">",
"      Andrew M, Brooker L, Leaker M, et al. Fibrin clot lysis by thrombolytic agents is impaired in newborns due to a low plasminogen concentration. Thromb Haemost 1992; 68:325.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/40/14986/abstract/44\">",
"      Ries M, Easton RL, Longstaff C, et al. Differences between neonates and adults in tissue-type-plasminogen activator (t-PA)-catalyzed plasminogen activation with various effectors and in carbohydrate sequences of fibrinogen chains. Thromb Res 2001; 103:173.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/40/14986/abstract/45\">",
"      Manco-Johnson MJ, Grabowski EF, Hellgreen M, et al. Recommendations for tPA thrombolysis in children. On behalf of the Scientific Subcommittee on Perinatal and Pediatric Thrombosis of the Scientific and Standardization Committee of the International Society of Thrombosis and Haemostasis. Thromb Haemost 2002; 88:157.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/40/14986/abstract/46\">",
"      Stephens MB, Pepper PV. Streptokinase therapy. Recognizing and treating allergic reactions. Postgrad Med 1998; 103:89.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/40/14986/abstract/47\">",
"      Hartmann J, Hussein A, Trowitzsch E, et al. Treatment of neonatal thrombus formation with recombinant tissue plasminogen activator: six years experience and review of the literature. Arch Dis Child Fetal Neonatal Ed 2001; 85:F18.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/40/14986/abstract/48\">",
"      Farnoux C, Camard O, Pinquier D, et al. Recombinant tissue-type plasminogen activator therapy of thrombosis in 16 neonates. J Pediatr 1998; 133:137.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/40/14986/abstract/49\">",
"      Ferrari F, Vagnarelli F, Gargano G, et al. Early intracardiac thrombosis in preterm infants and thrombolysis with recombinant tissue type plasminogen activator. Arch Dis Child Fetal Neonatal Ed 2001; 85:F66.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/40/14986/abstract/50\">",
"      Gupta AA, Leaker M, Andrew M, et al. Safety and outcomes of thrombolysis with tissue plasminogen activator for treatment of intravascular thrombosis in children. J Pediatr 2001; 139:682.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/40/14986/abstract/51\">",
"      Nowak-G&ouml;ttl U, Auberger K, Halimeh S, et al. Thrombolysis in newborns and infants. Thromb Haemost 1999; 82 Suppl 1:112.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/40/14986/abstract/52\">",
"      Leaker M, Massicotte MP, Brooker LA, Andrew M. Thrombolytic therapy in pediatric patients: a comprehensive review of the literature. Thromb Haemost 1996; 76:132.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/40/14986/abstract/53\">",
"      Weitz JI, Stewart RJ, Fredenburgh JC. Mechanism of action of plasminogen activators. Thromb Haemost 1999; 82:974.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/40/14986/abstract/54\">",
"      Andrew M. Society for Pediatric Research Presidential Address 1998: the SPR and 1-800-NO-CLOTS: a common vision. Pediatr Res 1998; 44:964.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/40/14986/abstract/55\">",
"      Lau KK, Stoffman JM, Williams S, et al. Neonatal renal vein thrombosis: review of the English-language literature between 1992 and 2006. Pediatrics 2007; 120:e1278.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/40/14986/abstract/56\">",
"      Messinger Y, Sheaffer JW, Mrozek J, et al. Renal outcome of neonatal renal venous thrombosis: review of 28 patients and effectiveness of fibrinolytics and heparin in 10 patients. Pediatrics 2006; 118:e1478.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/40/14986/abstract/57\">",
"      Tuckuviene R, Christensen AL, Helgestad J, et al. Pediatric venous and arterial noncerebral thromboembolism in Denmark: a nationwide population-based study. J Pediatr 2011; 159:663.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/40/14986/abstract/58\">",
"      Samama MM, Gerotziafas GT. Comparative pharmacokinetics of LMWHs. Semin Thromb Hemost 2000; 26 Suppl 1:31.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/40/14986/abstract/59\">",
"      Yang JY, Williams S, Brand&atilde;o LR, Chan AK. Neonatal and childhood right atrial thrombosis: recognition and a risk-stratified treatment approach. Blood Coagul Fibrinolysis 2010; 21:301.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/40/14986/abstract/60\">",
"      Price VE, Ledingham DL, Kr&uuml;mpel A, Chan AK. Diagnosis and management of neonatal purpura fulminans. Semin Fetal Neonatal Med 2011; 16:318.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/40/14986/abstract/61\">",
"      Seligsohn U, Berger A, Abend M, et al. Homozygous protein C deficiency manifested by massive venous thrombosis in the newborn. N Engl J Med 1984; 310:559.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/40/14986/abstract/62\">",
"      Marciniak E, Wilson HD, Marlar RA. Neonatal purpura fulminans: a genetic disorder related to the absence of protein C in blood. Blood 1985; 65:15.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/40/14986/abstract/63\">",
"      Peters C, Casella JF, Marlar RA, et al. Homozygous protein C deficiency: observations on the nature of the molecular abnormality and the effectiveness of warfarin therapy. Pediatrics 1988; 81:272.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/40/14986/abstract/64\">",
"      Sugahara Y, Miura O, Yuen P, Aoki N. Protein C deficiency Hong Kong 1 and 2: hereditary protein C deficiency caused by two mutant alleles, a 5-nucleotide deletion and a missense mutation. Blood 1992; 80:126.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/40/14986/abstract/65\">",
"      Mahasandana C, Suvatte V, Marlar RA, et al. Neonatal purpura fulminans associated with homozygous protein S deficiency. Lancet 1990; 335:61.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/40/14986/abstract/66\">",
"      Pung-amritt P, Poort SR, Vos HL, et al. Compound heterozygosity for one novel and one recurrent mutation in a Thai patient with severe protein S deficiency. Thromb Haemost 1999; 81:189.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/40/14986/abstract/67\">",
"      Jalbert LR, Rosen ED, Moons L, et al. Inactivation of the gene for anticoagulant protein C causes lethal perinatal consumptive coagulopathy in mice. J Clin Invest 1998; 102:1481.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/40/14986/abstract/68\">",
"      Yuen P, Cheung A, Lin HJ, et al. Purpura fulminans in a Chinese boy with congenital protein C deficiency. Pediatrics 1986; 77:670.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/40/14986/abstract/69\">",
"      Branson HE, Katz J, Marble R, Griffin JH. Inherited protein C deficiency and coumarin-responsive chronic relapsing purpura fulminans in a newborn infant. Lancet 1983; 2:1165.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/40/14986/abstract/70\">",
"      Estell&eacute;s A, Garcia-Plaza I, Das&iacute; A, et al. Severe inherited \"homozygous\" protein C deficiency in a newborn infant. Thromb Haemost 1984; 52:53.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/40/14986/abstract/71\">",
"      Sills RH, Marlar RA, Montgomery RR, et al. Severe homozygous protein C deficiency. J Pediatr 1984; 105:409.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/40/14986/abstract/72\">",
"      Rappaport ES, Speights VO, Helbert B, et al. Protein C deficiency. South Med J 1987; 80:240.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/40/14986/abstract/73\">",
"      Tuddenham EG, Takase T, Thomas AE, et al. Homozygous protein C deficiency with delayed onset of symptoms at 7 to 10 months. Thromb Res 1989; 53:475.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/40/14986/abstract/74\">",
"      Marlar RA, Neumann A. Neonatal purpura fulminans due to homozygous protein C or protein S deficiencies. Semin Thromb Hemost 1990; 16:299.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/40/14986/abstract/75\">",
"      Vigano D'Angelo S, Comp PC, Esmon CT, D'Angelo A. Relationship between protein C antigen and anticoagulant activity during oral anticoagulation and in selected disease states. J Clin Invest 1986; 77:416.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/40/14986/abstract/76\">",
"      Vigan&ograve; S, Mannucci PM, Solinas S, et al. Decrease in protein C antigen and formation of an abnormal protein soon after starting oral anticoagulant therapy. Br J Haematol 1984; 57:213.",
"     </a>",
"    </li>",
"    <li>",
"     prescribing information for this product is available at the following website: file://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?id=22370 (Accessed on November 17, 2011).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/40/14986/abstract/78\">",
"      Dreyfus M, Magny JF, Bridey F, et al. Treatment of homozygous protein C deficiency and neonatal purpura fulminans with a purified protein C concentrate. N Engl J Med 1991; 325:1565.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/40/14986/abstract/79\">",
"      Conard J, Bauer KA, Gruber A, et al. Normalization of markers of coagulation activation with a purified protein C concentrate in adults with homozygous protein C deficiency. Blood 1993; 82:1159.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/40/14986/abstract/80\">",
"      Mahasandana C, Suvatte V, Chuansumrit A, et al. Homozygous protein S deficiency in an infant with purpura fulminans. J Pediatr 1990; 117:750.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/40/14986/abstract/81\">",
"      Martinelli I, Mannucci PM, De Stefano V, et al. Different risks of thrombosis in four coagulation defects associated with inherited thrombophilia: a study of 150 families. Blood 1998; 92:2353.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/40/14986/abstract/82\">",
"      Garcia-Plaza I, Jimenez-Astorga C, Borrego D, Marty ML. Coumarin prophylaxis for fulminant purpura syndrome due to homozygous protein C deficiency. Lancet 1985; 1:634.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/40/14986/abstract/83\">",
"      Hartman KR, Manco-Johnson M, Rawlings JS, et al. Homozygous protein C deficiency: early treatment with warfarin. Am J Pediatr Hematol Oncol 1989; 11:395.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/40/14986/abstract/84\">",
"      Monagle P, Andrew M, Halton J, et al. Homozygous protein C deficiency: description of a new mutation and successful treatment with low molecular weight heparin. Thromb Haemost 1998; 79:756.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/40/14986/abstract/85\">",
"      Minford AM, Parapia LA, Stainforth C, Lee D. Treatment of homozygous protein C deficiency with subcutaneous protein C concentrate. Br J Haematol 1996; 93:215.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/40/14986/abstract/86\">",
"      Sanz-Rodriguez C, Gil-Fern&aacute;ndez JJ, Zapater P, et al. Long-term management of homozygous protein C deficiency: replacement therapy with subcutaneous purified protein C concentrate. Thromb Haemost 1999; 81:887.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/40/14986/abstract/87\">",
"      de Kort EH, Vrancken SL, van Heijst AF, et al. Long-term subcutaneous protein C replacement in neonatal severe protein C deficiency. Pediatrics 2011; 127:e1338.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/40/14986/abstract/88\">",
"      Mathias M, Khair K, Burgess C, Liesner R. Subcutaneous administration of protein C concentrate. Pediatr Hematol Oncol 2004; 21:551.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/40/14986/abstract/89\">",
"      Lee MJ, Kim KM, Kim JS, et al. Long-term survival of a child with homozygous protein C deficiency successfully treated with living donor liver transplantation. Pediatr Transplant 2009; 13:251.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/40/14986/abstract/90\">",
"      Angelis M, Pegelow CH, Khan FA, et al. En bloc heterotopic auxiliary liver and bilateral renal transplant in a patient with homozygous protein C deficiency. J Pediatr 2001; 138:120.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/40/14986/abstract/91\">",
"      Barrington KJ. Umbilical artery catheters in the newborn: effects of heparin. Cochrane Database Syst Rev 2000; :CD000507.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/40/14986/abstract/92\">",
"      Rais-Bahrami K, Karna P, Dolanski EA. Effect of fluids on life span of peripheral arterial lines. Am J Perinatol 1990; 7:122.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/40/14986/abstract/93\">",
"      Butt W, Shann F, McDonnell G, Hudson I. Effect of heparin concentration and infusion rate on the patency of arterial catheters. Crit Care Med 1987; 15:230.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/40/14986/abstract/94\">",
"      Randolph AG, Cook DJ, Gonzales CA, Andrew M. Benefit of heparin in peripheral venous and arterial catheters: systematic review and meta-analysis of randomised controlled trials. BMJ 1998; 316:969.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/40/14986/abstract/95\">",
"      Shah P, Shah V. Continuous heparin infusion to prevent thrombosis and catheter occlusion in neonates with peripherally placed percutaneous central venous catheters. Cochrane Database Syst Rev 2001; :CD002772.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 5911 Version 5.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1105-83.177.194.223-D60132E406-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f14_40_14986=[""].join("\n");
var outline_f14_40_14986=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H27600983\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      GENERAL APPROACH",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Baseline testing",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      ANTICOAGULANT THERAPY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Heparin",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      - Dose",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H13664577\">",
"      - Duration of therapy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      - Adverse effects",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H22500112\">",
"      Heparin-induced thrombocytopenia",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H22500119\">",
"      Osteoporosis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Low molecular weight heparin",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      - Dose",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H13664593\">",
"      - Duration of therapy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Warfarin",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Other agents",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      THROMBOLYTIC AGENTS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Recombinant tissue-type plasminogen activator",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      - Dose",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      TREATMENT FOR THROMBOSIS IN DIFFERENT LOCATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      Renal vein thrombosis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      Right atrial thrombosis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      Arterial thrombosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      NEONATAL PURPURA FULMINANS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H22501024\">",
"      Clinical presentation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1364496\">",
"      Diagnosis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H22501355\">",
"      Initial treatment",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H22503029\">",
"      Long-term management",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H22502859\">",
"      PREVENTION OF THROMBOSIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H22502884\">",
"      Arterial catheters",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H22502891\">",
"      Central venous catheters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H27600983\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"PEDS/5911\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PEDS/5911|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?35/16/36110\" title=\"figure 1\">",
"      Mechanisms of action of heparin LMW heparin and fondaparinux",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?30/24/31118\" title=\"figure 2\">",
"      Regulation of fibrinolysis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PEDS/5911|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?15/19/15677\" title=\"table 1\">",
"      LMW heparin pediatric doses",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?36/59/37818?source=related_link\">",
"      Anticoagulants other than heparin and warfarin",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?41/44/42697?source=related_link\">",
"      Clinical manifestations and diagnosis of intraventricular hemorrhage in the newborn",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?9/33/9752?source=related_link\">",
"      Clinical use of plasma components",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?41/55/42872?source=related_link\">",
"      Enoxaparin: Pediatric drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?39/59/40890?source=related_link\">",
"      Heparin-induced thrombocytopenia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?30/46/31465?source=related_link\">",
"      Management and complications of intraventricular hemorrhage in the newborn",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?14/16/14600?source=related_link\">",
"      Pathogenesis, clinical features, and diagnosis of thrombosis in the newborn",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?0/52/841?source=related_link\">",
"      Protein C deficiency",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?27/2/27690?source=related_link\">",
"      Stroke in the newborn",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?33/8/33930?source=related_link\">",
"      Therapeutic use of heparin and low molecular weight heparin",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f14_40_14987="Agents that increase BP";
var content_f14_40_14987=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=NEPH%2F56767&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=NEPH%2F56767&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Agents that can interfere with blood pressure control",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td>",
"        Non-narcotic analgesics (non-steroidal anti-inflammatory agents, selective COX-2 inhibitors, aspirin)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Sympathomimetic agents (decongestants, diet pills, cocaine)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Stimulants (methylphenidate, dexmethylphenidate, dextroamphetamine, amphetamine, methamphetamine)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Alcohol",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Oral contraceptives",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Cyclosporine",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Erythropoietin",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Natural licorice",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Herbal compounds (ephedra or ma huang)",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reprinted with permission from: Calhoun DA, Jones D, Textor S, et al. Resistant Hypertension: Diagnosis, Evaluation, and Treatment: A Scientific Statement from the American Heart Association Professional Education Committee of the Council for High Blood Pressure Research. Hypertension 2008; 51:1403. Copyright &copy; 2008 Lippincott Williams &amp; Wilkins.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f14_40_14987=[""].join("\n");
var outline_f14_40_14987=null;
var title_f14_40_14988="IHC stain Merkel cell carcinoma";
var content_f14_40_14988=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ONC%2F54954&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ONC%2F54954&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Immunocytochemical differential diagnosis of Merkel cell carcinoma",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tr>",
"      <td class=\"subtitle1\">",
"       Tumour",
"      </td>",
"      <td class=\"subtitle1\">",
"       CK20",
"      </td>",
"      <td class=\"subtitle1\">",
"       CK7",
"      </td>",
"      <td class=\"subtitle1\">",
"       NSE",
"      </td>",
"      <td class=\"subtitle1\">",
"       NFP",
"      </td>",
"      <td class=\"subtitle1\">",
"       S100",
"      </td>",
"      <td class=\"subtitle1\">",
"       LCA",
"      </td>",
"      <td class=\"subtitle1\">",
"       CD99",
"      </td>",
"      <td class=\"subtitle1\">",
"       TTF1",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Merkel cell carcinoma",
"      </td>",
"      <td>",
"       +",
"      </td>",
"      <td>",
"       -",
"      </td>",
"      <td>",
"       +",
"      </td>",
"      <td>",
"       +",
"      </td>",
"      <td>",
"       -",
"      </td>",
"      <td>",
"       -",
"      </td>",
"      <td>",
"       Rarely + (cytoplasmic)",
"      </td>",
"      <td>",
"       _",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Small cell carcinoma",
"      </td>",
"      <td>",
"       -",
"      </td>",
"      <td>",
"       +",
"      </td>",
"      <td>",
"       +",
"      </td>",
"      <td>",
"       +/-",
"      </td>",
"      <td>",
"       -",
"      </td>",
"      <td>",
"       -",
"      </td>",
"      <td>",
"       Rarely + (cytoplasmic)",
"      </td>",
"      <td>",
"       +",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Lymphoma",
"      </td>",
"      <td>",
"       -",
"      </td>",
"      <td>",
"       -",
"      </td>",
"      <td>",
"       -",
"      </td>",
"      <td>",
"       -",
"      </td>",
"      <td>",
"       -",
"      </td>",
"      <td>",
"       +",
"      </td>",
"      <td>",
"       -",
"      </td>",
"      <td>",
"       -",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Primitive neuroectodermal tumour",
"      </td>",
"      <td>",
"       -",
"      </td>",
"      <td>",
"       -",
"      </td>",
"      <td>",
"       +",
"      </td>",
"      <td>",
"       Rarely +",
"      </td>",
"      <td>",
"       -",
"      </td>",
"      <td>",
"       -",
"      </td>",
"      <td>",
"       + (membranous)",
"      </td>",
"      <td>",
"       -",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Small-cell melanoma",
"      </td>",
"      <td>",
"       -",
"      </td>",
"      <td>",
"       -",
"      </td>",
"      <td>",
"       +",
"      </td>",
"      <td>",
"       -",
"      </td>",
"      <td>",
"       +",
"      </td>",
"      <td>",
"       -",
"      </td>",
"      <td>",
"       -",
"      </td>",
"      <td>",
"       -",
"      </td>",
"     </tr>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     CK20: cytokeratin 20; CK7: cytokeratin 7; NSE: neuron-specific enolase; NFP: neurofilament protein; S100: S100 protein; LCA: leucocyte common antigen; CD99: cluster-of-differentiation antigen 99; TTF1: thyroid transcription factor 1; +: positive stain; -: negative stain.",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Poulsen, M. Merkel-cell carcinoma of the skin. Lancet Oncol 2004; 5:593. Copyright&copy; 2004 The Lancet.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f14_40_14988=[""].join("\n");
var outline_f14_40_14988=null;
var title_f14_40_14989="Risk factors for abruption";
var content_f14_40_14989=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=OBGYN%2F75801&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=11\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=OBGYN%2F75801&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=11\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Major risk factors for placental abruption",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\" rowspan=\"2\">",
"        Risk factor",
"       </td>",
"       <td class=\"subtitle1\" colspan=\"2\">",
"        Singleton gestations",
"       </td>",
"       <td class=\"subtitle1\" colspan=\"2\">",
"        Twin gestations",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2\">",
"        Strength",
"       </td>",
"       <td class=\"subtitle2\">",
"        RR/OR",
"       </td>",
"       <td class=\"subtitle2\">",
"        Strength",
"       </td>",
"       <td class=\"subtitle2\">",
"        RR/OR",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"5\">",
"        Acute etiology",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Abdominal trauma/accidents",
"       </td>",
"       <td>",
"        +++",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Cocaine or other drug abuse",
"       </td>",
"       <td>",
"        +++",
"       </td>",
"       <td>",
"        5.0-10.0",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Polyhydramnios",
"       </td>",
"       <td>",
"        ++",
"       </td>",
"       <td>",
"        2.0-3.0",
"       </td>",
"       <td>",
"        ++",
"       </td>",
"       <td>",
"        1.7",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"5\">",
"        Obstetrical/medical risk factors",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Chronic hypertension",
"       </td>",
"       <td>",
"        ++",
"       </td>",
"       <td>",
"        1.8-5.1",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Preeclampsia/Pregnancy induced hypertension",
"       </td>",
"       <td>",
"        ++",
"       </td>",
"       <td>",
"        0.4-4.5",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Eclampsia",
"       </td>",
"       <td>",
"        +++",
"       </td>",
"       <td>",
"        3.0-5.5",
"       </td>",
"       <td>",
"        ++",
"       </td>",
"       <td>",
"        1.6-2.0",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Premature rupture of membranes",
"       </td>",
"       <td>",
"        ++",
"       </td>",
"       <td>",
"        1.8-5.1",
"       </td>",
"       <td>",
"        ++",
"       </td>",
"       <td>",
"        1.5-2.5",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Chorioamnionitis",
"       </td>",
"       <td>",
"        ++",
"       </td>",
"       <td>",
"        2.0-2.5",
"       </td>",
"       <td>",
"        ++",
"       </td>",
"       <td>",
"        1.7",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist2_start\" colspan=\"5\">",
"        Previous ischemic placental disease",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist2\">",
"        Preeclampsia",
"       </td>",
"       <td>",
"        ++",
"       </td>",
"       <td>",
"        1.5",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist2\">",
"        Fetal growth restriction/Small for gestation age infant",
"       </td>",
"       <td>",
"        ++",
"       </td>",
"       <td>",
"        1.4",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        &nbsp;&nbsp;&nbsp;&nbsp; Previous abruption",
"       </td>",
"       <td>",
"        ++++",
"       </td>",
"       <td>",
"        8.0-12.0",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"5\">",
"        Sociodemographic/behavioral",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Maternal age",
"       </td>",
"       <td>",
"        +",
"       </td>",
"       <td>",
"        1.1-1.3",
"       </td>",
"       <td>",
"        +",
"       </td>",
"       <td>",
"        1.1-1.4",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Parity",
"       </td>",
"       <td>",
"        +",
"       </td>",
"       <td>",
"        1.1-1.6",
"       </td>",
"       <td>",
"        +",
"       </td>",
"       <td>",
"        1.1-1.7",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Smoking during pregnancy",
"       </td>",
"       <td>",
"        ++",
"       </td>",
"       <td>",
"        1.4-2.5",
"       </td>",
"       <td>",
"        ++",
"       </td>",
"       <td>",
"        1.7",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Male infant sex",
"       </td>",
"       <td>",
"        +/-",
"       </td>",
"       <td>",
"        0.9-1.3",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     OR: odds ratio; RR: relative risk.",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f14_40_14989=[""].join("\n");
var outline_f14_40_14989=null;
var title_f14_40_14990="Smoking cessation in pregnancy";
var content_f14_40_14990=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=OBGYN%2F50450&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=5\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=OBGYN%2F50450&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=5\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Adaption of 5 A's for use during pregnancy",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\" class=\"container\">",
"     <tbody>",
"      <tr>",
"       <td class=\"container\">",
"        <table cellspacing=\"0\">",
"         <tbody>",
"          <tr>",
"           <td class=\"subtitle1_single\">",
"            STEP 1: Ask",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"subtitle2_single\">",
"            Recommendation:",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            ask the patient about her smoking status.",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"subtitle2_single\">",
"            Action:",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            Given high nondisclosure rates, identification of the pregnant smoker can be difficult. Specific strategies to identify smoking women include:",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"sublist2_start\">",
"            1) Use multiple choice questions when assessing whether a patient smokes[77]. The following multiple choice question is recommended in either oral or written form.",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"sublist2\">",
"            Which of the following describes you best?",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"sublist3\">",
"            A. I have",
"            <strong>",
"             NEVER",
"            </strong>",
"            smoked, or I have smoked less than 100 cigarettes in my lifetime.",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"sublist3\">",
"            B. I stopped smoking",
"            <strong>",
"             BEFORE",
"            </strong>",
"            I found out I was pregnant, and I am not smoking now.",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"sublist3\">",
"            C. I stopped smoking",
"            <strong>",
"             AFTER",
"            </strong>",
"            I found out I was pregnant, and I am not smoking now.",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"sublist3\">",
"            D. I smoke some now, but I cut down on the number of cigarettes I smoke",
"            <strong>",
"             SINCE",
"            </strong>",
"            I found out I was pregnant.",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"sublist3\">",
"            E. I smoke regularly now, about the same as",
"            <strong>",
"             BEFORE",
"            </strong>",
"            I found out I was pregnant.",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            2) Focus particular attention on women who report that they stopped smoking after conception. About half of non-disclosers in one series reported quiting after conception[7].",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            3) Consider using urinary cotinine measurements in women who report smoking as an objective measure of smoking exposure: set goals for lowering this level. The routine use of urinary cotinine to confirm non-smoking status is controversial given the ethical concerns and potential negative impact on the patient-doctor relationship. Until further guidelines and recommendations are available, it is not recommended.",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"subtitle1_single\">",
"            STEP 2: Advise (1 minute)",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"subtitle2_single\">",
"            Recommendation:",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            provide clear strong advice to quit with personalized messages about the impact of smoking and quitting on mother and fetus.",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"subtitle2_single\">",
"            Action:",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            1) Discuss the risks of smoking during pregnancy: low birth weight, placental abruption, placenta previa, premature delivery, stillbirth preterm premature rupture of membranes.",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            2) If the patient has had a history of a complicated pregnancy, discuss how smoking may have contributed to this complication.",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            3) Discuss risks of secondary smoke, particularly for patients with children at home; SIDS, upper respiratory infections, otitis media asthma, pneumonia.",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            4) Recommend that the patient quit as soon as possible for maximal benefit, however quitting at any time during pregnancy has some benefit.",
"           </td>",
"          </tr>",
"         </tbody>",
"        </table>",
"       </td>",
"       <td class=\"container\">",
"        <table cellspacing=\"0\">",
"         <tbody>",
"          <tr>",
"           <td class=\"subtitle1_single\">",
"            STEP 3: Assess (1 minute)",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"subtitle2_single\">",
"            Recommendation:",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            assess the willingness of the patient to make a quit attempt within the next month.",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"subtitle2_single\">",
"            Action:",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            Ask, \"Quitting smoking is one of the most important things you can do for your health and the health of your baby, If we help you, are you willing to try?[77]",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"subtitle1_single\">",
"            STEP 4: Assist (3 minutes)",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"subtitle2_single\">",
"            Recommendation:",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            assist smoker in quitting.",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"subtitle2_single\">",
"            Action:",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            1) Provide pregnancy specific, self-help smoking cessation materials; multi-lingual educational packets available on the web: file://chid.nih.gov. [77] file://www.modimes.org.",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"sublist2_start\">",
"            2) Encourage the use of problem solving methods and skills for cessation:",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"sublist2\">",
"            Review withdrawal symptoms.",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"sublist2\">",
"            Identify \"high risk situations\" where they are more likely to relapse and set up strategies for avoiding them.",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"sublist2\">",
"            Strongly consider referral to social worker who can help patient gain access to services available to minimize stressors at home.",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"sublist2\">",
"            Consider referral to coping and stress management program.",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"sublist2_start\">",
"            3) Encourage patient to seek family and social support:",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"sublist2\">",
"            Identify non-smoking individuals, particularly successful quitters that can be supportive.",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"sublist2\">",
"            Offer referral to smoking partner for smoking cessation.",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"sublist2\">",
"            Patient should inform family that they intend to quit smoking during the pregnancy and ask for their support (ie, not smoking in the same room).",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"sublist2_start\">",
"            4) Consider pharmacotherapy for patients who smoke 1O cigarettes or more and are unable to quit. Use lowest dose necessary (see next section for discussion).",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"sublist2\">",
"            Briproprion",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"sublist2\">",
"            Nicotine Replacement therapy",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"subtitle1_single\">",
"            STEP 5: Arrange (1 minute)",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"subtitle2_single\">",
"            Recommendation:",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            assess smoking status throughout pregnancy and encourage cessation for continuing smokers.",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"subtitle2_single\">",
"            Action:",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            1) Place a label on each chart that identifies the patient as a smoker.",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            2) Ask about smoking at each visit.",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            3) If still smoking, encourage cessation and consider adjunct pharmacotherapy as outlined in next section.",
"           </td>",
"          </tr>",
"         </tbody>",
"        </table>",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f14_40_14990=[""].join("\n");
var outline_f14_40_14990=null;
var title_f14_40_14991="FGS IF";
var content_f14_40_14991=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=NEPH%2F59969&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=NEPH%2F59969&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    IgM in focal glomerulosclerosis",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 394px; height: 255px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Immunofluorescence microscopy in focal segmental glomerulosclerosis is usually negative, except for probably nonspecific deposition of IgM in sclerotic area at the bottom of the glomerulus.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Helmut Rennke, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f14_40_14991=[""].join("\n");
var outline_f14_40_14991=null;
